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1.1 Defi nition
Osteoporosis is a leading public health problem in our rapidly growing, aging 
population. It is a systemic skeletal disease characterized by reduced bone mass 
and microarchitectural deterioration of bone tissue, with a consequent increase in 
bone fragility and susceptibility to fracture (1). Family and twin studies have shown 
that osteoporosis and its associated phenotypes are under strong genetic control 
(2). In addition, it has been shown than not one major locus is responsible of the 
susceptibility to develop osteoporosis; instead, diverse genetic and environmental 
factors involved with the disease have confi rmed its complex multifactorial nature 
(3). 
1.2 Bone physiology 
The skeleton is a highly organised and physiologically active system, continu-
ously remodelling through life in order to preserve skeletal integrity, while provid-
ing a reliable and constant source of calcium for the circulation and, thus, for all 
other tissues. There are two types of bone present in the human skeleton, namely 
cortical or compact bone and trabecular or spong y bone, the latter of which is the most 
metabolically active. The morphology of most human bones consists of an outer 
surface of cortical bone that surrounds the inner trabecular elements. It is known 
that both cortical and trabecular bone undergo remodelling, but the frequency of 
this process is much less in the cortex than in the trabecular components. Bone 
remodelling comprises the process of bone resorption, which is always followed 
by bone formation and provides a mechanism for bone self-repair. It represents 
simultaneous action of bone destroying (resorption) cells or osteoclasts, and bone 
forming cells or osteoblasts whose combined action on the specifi c bone surface 
is expressed in terms of bone remodelling units (BRU) (4). The bone-remodelling 
process includes fi ve stages: BRU activation, bone resorption, ‘coupling’ or reversal, 
bone formation and mineralization of newly formed bone matrix and the resting 
stage (Figure 1). 
The process of bone formation takes several months and is slow compared 
to the process of bone resorption which is completed within 7-14 days (5). The 
coupling between bone resorption and bone formation is age dependent. In young 
individuals (under age 25 years) bone formation normally exceeds bone resorption. 
During healthy mature adulthood (between 25–35 years of age) the net activity of 
osteoclasts equals the net activity of osteoblasts. In contrast, in elderly subjects bone 
resorption is higher than bone formation leading to overall bone loss with aging. 
The stages in the bone-remodelling process are well co-ordinated by many systemic 
and locally acting bone factors including numerous hormones, growth factors and 
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cytokines (6). The differences between subjects in bone growth, peak bone mass 
accrual, bone loss with aging and fracture risk could be due to differences in the 
action of individual factors but also to their interaction. That is the reason we focus 
on candidate gene polymorphisms and their interactions.
1.3 IGF-I and bone
IGF-I is a ubiquitous polypeptide that stimulates osteoblast activity, subsequently 
leading to bone matrix formation and inhibition of bone collagen degradation 
(7). IGF-I also stimulates osteoclast formation and action, although these effects 
are less clear (8).  It has been determined that skeletal IGF-I originates from two 
main sources: (a) de novo synthesis by bone forming cells (i.e. osteoblasts) where 
most of IGF-I in bone is derived from and (b) the circulation and/or bone mar-
row (9). During active bone resorption, as bone matrix is dissolved, signifi cant 
amounts of IGF-I are released from storage (i.e. bound to IGFBP-2 and IGFBP-5). 
Considering that IGF-I is stored within the skeletal matrix and is released dur-
ing bone resorption, IGF-I is one of the critical coupling proteins that keep bone 
resorption closely linked to formation (10). In addition, it has been determined that 
the major hormones regulating bone turnover in vivo also affect IGF-I expression 
in vitro (10). These include parathyroid hormone (PTH), estrogens, glucocorticoids 
Figure 1. Five stages of  the bone-remodeling process. 
                                  (Source http:\\www.medscape.com)
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and 1,25-dihydroxyvitamin D (9). An important role for IGF-I on bone growth, 
peak bone mass achievement and posterior bone loss (with aging) has been sug-
gested. IGF-I levels peak during puberty at or about the same time as acquisition 
of peak bone mass. In addition, serum IGF-I levels decline with ageing along a 
slope that is similar to that of age-related bone loss. Indeed, IGF-I plasma levels 
have been associated with low BMD (11-13), osteoporosis (14) and fractures (15), 
although it is not known if these systemic levels are representative of local (skeletal) 
concentrations (16-18).  Based on this, the IGF-I gene (map location 12q22-q24.1) 
arises as an obvious candidate gene to study in relation to osteoporosis.
1.4 Estrogen receptors and bone
Estrogens are sex hormones responsible for gender dimorphism and reproduc-
tion. They are also pleiotropic hormones with numerous biological actions extend-
ing beyond non-reproductive tissues, including bone. The biological actions of 
estrogens are mediated by binding to one of two specifi c estrogen receptors, ER 
α (ESR1 6q25.1) and ER ß (ESR2 14q22-24). Both estrogen receptor isoforms are 
expressed in osteoblasts, osteoclasts, and in several types of cells from the bone 
marrow the receptors co-localize in adult bone (19-22). When co-expressed, ESR2 
exhibits an inhibitory action on ESR1-mediated gene expression and in many 
instances opposes the actions of ERS1 (23). There is also evidence of gender- and 
age-specifi c expression of the ESR2 protein SR2, which can inhibit transcriptional 
activation by ESR1, perhaps through formation of ER α / ER ß heterodimers. In 
ESR2, alternative splicing that removes one or more exons has been observed in 
osteoblasts, and these alternative splice forms can eliminate or lower ligand bind-
ing affi nity (23). The characterization of mice lacking ESR1, or ESR2, or both 
has revealed that both receptor subtypes have overlapping but also unique roles in 
estrogen-dependent action in vivo. An ERS1 knockout mouse model has shown that 
these animals present with decreased bone mass in both genders (24). In contrast, 
ERS2 knockout models present with increased cortical bone mass suggesting that 
ESR2 is a  negative modulator of cortical but not cancellous bone modelling (25).
1.5 Bone Fracture: a Problem of  Biomechanics
As described above bone modelling and remodelling occur on the microstruc-
tural level, but net effects are evident in whole bone geometry. Previously, it has 
been shown that fractured individuals possess specifi c patterns of bone geometry 
which can signifi cantly discriminate them from non-fractured individuals (26-28). 
In order to conceptualize bone geometry some understanding of bioengineering 
is needed. To serve its different functions bone must have antagonist properties: it 
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must be stiff and able to resist bending forces due to load bearing and/or locomo-
tion, but it should also be fl exible enough to deform during impact loading without 
fracturing (29). With aging this ability to resist fracture is compromised, and is the 
reason for the prominent increase in the incidence of osteoporotic fracture with 
senescence (30). But, why do some elderly individuals fracture while others do not? 
It has been established that those elderly people who suffer osteoporotic fractures 
have lower bone mass and mechanically weaker bones which are more susceptible 
to fracture. This weakening can be the result of age-related changes in either tissue 
properties or in the structural dimensions. Even though tissue changes may not 
be ruled out, the most remarkable difference between fractured and non-fractured 
individuals relies on the amount and/or the distribution of bone mass. That is, 
osteoporotic fracture is structural in nature. BMD assessment using DXA is by far 
the most used method to assess the risk of osteoporotic fracture. The decline in 
BMD with aging arises from bone loss in the form of both cortical and trabecular 
thinning, but also, from an increase in total volume as the bone expands in width 
with age. Although it is clear that net bone loss within a fi xed diameter reduces 
mechanical strength, the effect on strength is less clear when accompanied by an 
expanding diameter (caused by periosteal apposition) (Figure 2). The presence of 
periosteal apposition with aging is the reason the interpretation of BMD should be 
complemented with indexes of bending strength, such as the section modulus. An 
important characteristic of the section modulus is that as the diameter of a hollow 
tube is increased, the same bending strength can be achieved with progressively 
less material and thus a lower volumetric density. Bones are not hollow tubes, but 
Implications of Homeostatic Expansion
20 40 60 80 100
Age
Density
Strength
Inner and Outer Bone Diameters expand with age
Instability Threshold
Cortex too thin for diameter
Figure 2.  Relation between bone expansion and aging and its consequences over 
bone density, strength and instability (contribution Thomas J. Beck).  
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the same biomechanical principles may apply. Although it is acknowledged that 
low BMD is predictive of fragility fracture, it is not obvious why compensatory 
expansion should lead to fragility unless expansion leads to cortical instability. If 
the process of bone expansion is carried too far, the section modulus no longer 
governs bending strength because the wall becomes unstable and prone to collapse 
(or buckle).  The “buckling ratio” is an index of bone instability which is estimated 
as (½) the ratio of outer radius to wall thickness. Higher buckling ratios represent 
higher bone instability and greater susceptibility to fracture. It has not been shown 
that fragility fractures are due to instability, nevertheless bones should become less 
stable as cortices thin, diameters increase and as internal support of trabeculae are 
lost (31). Based on these considerations several parameters of bone geometry can 
be measured by Hip Structural Analysis (HSA) software developed by Thomas J. 
Beck to measure hip bone geometry from DXA scans (32,33). 
1.6 Approaches in Genetic Studies 
In osteoporosis as in other complex diseases in humans, the strategies used 
to identify genes involved in disease have focused on two main approaches. One 
includes genome-wide screening using a linkage analysis approach and which is 
limited to family-based study designs. The other includes candidate gene studies 
which are commonly but not restricted to association analyses (since linkage strate-
gies may also be used) in population- or family-based studies (3). 
Genome-wide screening using linkage mapping is the fi rst step towards posi-
tional cloning. It is the process of systematically scanning the entire genomes of 
interrelated individuals who share a common trait or disease, using regularly spaced, 
highly variable (polymorphic) DNA segments whose exact position is known. The 
use of related individuals allows identifying genetic regions “in linkage” with the 
trait/disease, and to test if they share one or more chromosomal areas identical by 
descent in those regions more frequently than expected by chance alone. In this 
way, regions can then be further delineated for further analysis and characteriza-
tion of the responsible genes. The primary advantage of genome screening is that 
no prior knowledge of the physiology or biology underlying the disorder being 
studied is necessary, which may be an advantage when studying complex disorders, 
such as osteoporosis, with an etiology that is still largely not understood.
 
The candidate gene approach investigates whether a genetic variant in a par-
ticular already-known gene is involved with the trait or disease. A major advantage of 
this approach is that is based on known biology of the gene product.  This way, the 
choice of candidate genes in osteoporosis has been directed towards factors which 
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regulate bone turnover and proteins that make up normal bone matrix. Using this 
approach, many genes have been evaluated in osteoporosis, including vitamin D-, 
calcium-sensing-, calcitonin- and estrogen alpha-receptors, insulin growth factor 
I, collagen type I alpha 1 and others (2,3,34). In contrast with linkage mapping 
studies, association studies of candidate genes do not require (a large number of) 
interrelated individuals with both affected and unaffected members, which are 
very diffi cult to collect within the context of a late-onset disease like osteoporosis. 
Furthermore, it is now believed that association studies of candidate gene studies 
are better suited to study gene variants underlying common and more complex 
diseases, where the risk associated with any given candidate gene is relatively small. 
Nevertheless, a limitation of this approach is that in order to choose a potential 
candidate gene, some understanding of the mechanisms underlying the disease (i.e., 
pathophysiology) must already be present. 
The fi rst critical step in conducting candidate gene studies is the choice of a 
suitable candidate gene that may plausibly play a relevant role in the process or 
disease under investigation. The selection of candidate genes is usually based on 
knowledge of cellular signalling or metabolic pathways, its location or because it 
has been examined in previous association studies. Once a candidate gene has been 
selected, the genetic variants (DNA polymorphisms) within the gene that will be 
used for testing in an association study must be chosen. There are several types of 
polymorphisms which include: restriction fragment length (RFLP), minisatellite 
variable number of tandem repeats (VNTR), microsatellites (mostly CAn repeats) 
and single nucleotide (SNP). The SNP is the most suitable and frequently used type 
of polymorphism in association studies of candidate genes. In the past, the iden-
tifi cation of genetic variants in a gene was a laborious process that often involved 
sequencing the entire gene in 20-50 subjects. Nowadays, we have available databases 
with more than 5 million SNP’s (i.e. dbSNP and Celera) which facilitate the study 
of polymorphisms in candidate genes. Criteria to select a particular polymorphism 
for further studies includes determining whether the nucleotide variation is: 1) 
likely to have functional signifi cance, either because it actually results in amino acid 
changes in the resulting protein or because it occurs in regulatory regions; 2) with 
suffi cient frequency to allow detection of subtle differences between individuals 
with and without the trait or disease under investigation. However, variations in 
non-coding regions may be correlated with altered phenotype in two situations: 
one, when variations occur in regulatory regions, such as promoters or intron splice 
sites, or 3’UTR’s that could alter mRNA stability and routing; two, when variations 
are positioned close enough to a functional mutation (usually from 10-250 kb), and 
are therefore almost always inherited together, which is a phenomenon known as 
“linkage disequilibrium” (LD). This way, associations can arise due to a) direct 
effect of the polymorphism (i.e. functional variant), b) LD with a nearby truly 
functional variant. 
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One further question in the study of variation in candidate genes is if it is 
necessary to consider one-SNP-at-a-time or if they should be analyzed as phased 
haplotypes (35). The rationale behind this approach is that LD in genes appears 
to have a block-like structure and that a subset of SNP’s analyzed through phased 
haplotypes can identify most of the genetic variation in a genomic region (36).  In 
this way, a good representation of the genetic variation in a gene can be tested by 
choosing a number of polymorphisms similarly spaced through out the gene and 
analyzed in the form of haplotypes (35).
1.7 Study Population
1.7.1 Population-Based Setting
Association studies presented in this thesis are based on the Rotterdam Study 
(37), a prospective population-based cohort study, of determinants of chronic 
disabling diseases in Caucasian elderly men and women. The Rotterdam Study was 
approved by the medical ethics committee of the Erasmus Medical Center and 
written informed consent was obtained from all participants. At baseline, between 
1990 and 1993, all inhabitants aged 55 years and over (n=10,275) of the district of 
Ommoord in Rotterdam were invited to take part in the study. A total of 7,983 
subjects (response rate 78%), 4878 of whom were women, entered the study. At 
baseline, and again at the fi rst and second follow-up visits (1994-1995 and 1997-
1999, respectively), information was gathered concerning amongst others lifestyle 
habits, socio-economic status, medical history and pharmacotherapeutic history. 
In addition to an interview, all subjects were invited to visit the research center 
for physical examination and blood drawing. General practitioners (GPs) in the 
research area (who cover 80% of the cohort) reported all relevant fatal and non-
fatal events (such as fractures) through a computerized system. Research physicians 
verifi ed follow-up information by checking GPs’ patient records. This is possible 
because in The Netherlands the GPs have a gate-keeper function, which means 
that the only way to access specialist and hospital care is by consulting them. The 
GPs retain all medical information of his/her patients. For the remaining 20% of 
the cohort, research physicians regularly visited the GPs and collected data from 
their records. For hospitalized patients, discharge letters were additionally used for 
verifi cation. All events were coded independently by two research physicians ac-
cording to the International Classifi cation of Diseases, 10th revision (ICD-10) (38). 
If there was disagreement, consensus was reached in a separate session. A medical 
expert in the fi eld reviewed all coded events for fi nal classifi cation.
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1.7.2 Family-Based Setting
Heritability studies of this thesis are based on the Erasmus Rucphen Family 
(ERF) Study, an ongoing extended-pedigree study of genetic risk factors for neu-
ropsychiatric, cardiovascular, endocrinologic, ophthalmologic and musculoskeletal 
disorders. The ERF study is part of the Genetic Research in Isolated Populations 
(GRIP) program which aims to identify genetic risk factors in the development of 
complex disorders in an isolated community of about 20,000 inhabitants settled 
around eight adjacent villages in the southwest of The Netherlands. The ERF study 
population includes living descendants of 50 couples with at least six children and at 
least one baptized in the community church between 1890 and 1900. Descendants 
were invited to participate in the study (n=2500) independent of disease status. 
The Medical Ethics Committee of Erasmus Medical Center Rotterdam approved 
the ERF study and written informed consent was obtained from every participant. 
Phenotyping started in June 2002, is currently ongoing and includes a series of 
medical investigations assessed in a standardized manner (which are comparable to 
those used in the Rotterdam Study) by trained assistants and physicians during their 
visit to the research center located in Sprundel, The Netherlands. The assessment 
included total body, antero-posterior lumbar spine and dual femur DXA scans, 
anthropometrics, muscle strength and interview about physical activity, medical 
history and medication use. The current response rate is 78%. 
1.8 Aim and Description of  Chapters
In this thesis, a genetic epidemiology study of osteoporosis is presented. The 
objective was to identify genetic determinants of osteoporosis using a candidate 
gene approach framework. Chapter 2 presents a detailed epidemiological and bio-
mechanical description of longitudinal changes in BMD and bone geometry in the 
Rotterdam Study, the setting where the candidate gene studies are conducted. In 
Chapter 3 a comprehensive phenotypic analysis of DXA-based osteoporosis traits 
is performed by determining heritabilities and genetic correlations across BMD 
and bone geometry measurements. Chapter 4 focuses on the insulin-like growth 
factor I gene (IGF-I ); in Chapter 4.1 a promoter polymorphism is examined in 
relation to cross-sectional and longitudinal BMD measurements, and in Chapter 
4.2 the relationship with non-vertebral fractures is examined with respect to bone 
geometry measurements. In Chapter 5 polymorphisms in the estrogen receptor 
beta (ESR2) gene are examined in relation to BMD, bone geometry and the risk 
of osteoporotic fracture. In Chapter 6, the interaction between polymorphisms in 
the IGF-I, estrogen receptor alfa (ESR1) and ESR2 genes is examined in relation to 
osteoporotic fracture and bone parameters. Chapter 7 consists of a general discus-
sion of the general principles applied and the problems encountered in the process. 
Finally, the fi ndings of this thesis are placed in perspective of future research.        
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ABSTRACT
Introduction: Multiple factors are thought to contribute to age-related decline in 
bone mineral density (BMD). However, the underlying mechanisms are still incom-
pletely understood. For this reason we examined epidemiological and biomechani-
cal patterns of  longitudinal BMD changes in a large population-based cohort study 
of  elderly men and women age 55 and older.
Methods: Changes in BMD (mean  follow-up time 6.5 SD 0.6 years) were studied 
in 1166 men and 1548 women. Changes in bone geometry were determined by Hip 
Structural Analysis (HSA) of  DXA scans and were assessed in 865 men and 1052 
women (mean follow-up time 4.5 SD 0.6 years). 
Results: Approximately 45% of  the original study population at baseline was lost 
to follow-up, most likely due to morbidity. As expected, the decline of  BMD with 
age was higher in females and averaged about 0.8% and 0.3 % of  baseline BMD 
per year in females and males respectively. Advanced age (above 75 years), BMD at 
baseline and weight loss on follow-up were the most prominent factors infl uencing 
bone loss in both genders. HSA data showed that the decline of  BMD is caused 
by a combination of  bone loss at the cortices (resulting in cortical thinning) and 
periosteal bone apposition (resulting in an increase in neck width). This process of  
bone expansion was more pronounced in females. Also with aging, section modu-
lus (an index of  bone strength) decreased in both genders, possibly as an adaptive 
response to changes in body weight. In both genders the buckling ratio (an index 
of  bone instability) increased with age but it was much larger in females.
Conclusion:  BMD at baseline and weight loss with follow-up are the most signifi -
cant determinants of  BMD decline in both genders. Greater progression towards 
bone instability as a result of  cortical thinning and periosteal bone apposition 
might explain the higher susceptibility for hip fracture in elderly women. 
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INTRODUCTION
Femoral neck fragility in old age has usually been attributed to the “age-related 
bone loss” or involutional osteoporosis (1,2). Bone mineral density (BMD) mea-
surement by Dual-energy X-ray absorptiometry (DXA) is the most commonly used 
method to determine the risk of fragility fracture of an individual and to assess 
loss of BMD with age.  Even though the patterns of BMD decline with aging has 
been matter of intense study for decades now (3-6) the causes (7-11) and underlying 
mechanisms leading to BMD decline and bone fragility have not been completely 
elucidated. 
The decline in femoral neck BMD with time is not only due to bone loss, but 
also due to an increase in bone volume caused by bone expansion, the latter being 
less well studied (12-14). These two processes are interrelated and occur mainly 
due to cortical thinning and periosteal apposition (bone expansion) with a sexual 
dimorphism already present early in life (15). These two phenomena have opposing 
effects on bone strength with bone expansion allowing strength to be maintained 
with aging even in the presence of considerable bone loss (16). Nevertheless, if a 
threshold is reached where cortical thinning is excessive in relation to the already 
expanded femoral neck, cortices are thought to become unstable and prone to col-
lapse (buckle), facilitating the occurrence of fragility fracture(12).
   
Femoral neck BMD obtained from DXA provides no information regarding the 
relative contributions of periosteal apposition and endocortical resorption (result-
ing in cortical thinning) to net bone loss during aging. In this way, persons with 
similar BMD values may have important underlying differences in bone strength 
and bone stability and thus, in the risk of fracture. 
In this large population-based study we examined the underlying epidemiologi-
cal and biomechanical patterns of longitudinal BMD decline at the proximal femur, 
in elderly men and women aged 55 and older. We determined which factors at base-
line relate to longitudinal changes in BMD and studied the underlying structural 
changes in bone geometry with time. 
SUBJECTS AND METHODS
Subjects
The Rotterdam Study is a large prospective population-based cohort study of 
men and women aged 55 and over. The objective is to study the determinants of 
disease and disability in the elderly, with special focus on neurological, cardiovas-
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cular, ophthalmologic and locomotor diseases. The Medical Ethics Committee of 
the Erasmus Medical Centre has approved the Rotterdam Study. Both the rationale 
and the study design have been described previously (17). All 10,275 inhabitants of 
Ommoord, a district in Rotterdam, The Netherlands, were invited to participate. 
Of these, 7983 (4878 women) participated, resulting in a response rate of 78%.
Baseline data collection was conducted between July 1989 and June 1993 and 
included an initial home visit and interview by a trained research assistant and an 
extensive physical examination at the research center. First and second follow-up 
assessments were performed between July 1993 and January 1996 and between July 
1996 and December 1999, respectively, applying the same measurement protocols 
used at baseline. The third follow-up assessment is currently ongoing. 
The present study consists of two separate phases. In the fi rst phase changes 
in BMD with time were assessed between baseline and second follow-up (6.5 SD 
0.6 years) in 2714 individuals. In the second phase, the underlying biomechanical 
characteristics of BMD decline (changes in bone geometry) were assessed between 
fi rst and second follow-up (4.5 SD 0.6 years) in 1917 individuals.
BMD Measurements
In each assessment period bone mineral density measurements (g/cm2) of the 
proximal femur were performed by dual energy X-ray absorptiometry (DXA) using 
the same Lunar DPX-L densitometer (Lunar Radiation Corporation, Madison, WI, 
USA) and the same standard protocols. Methods, quality assurance, accuracy and 
precision issues of the DXA measurements have been described previously (3). 
In contrast to manufacturer recommendation and as reported earlier (18), DPX-L 
software upgrades did interfere with the serial BMD measurements during follow-
up. For this reason, we reanalyzed all existing scans (n=13,391) with the DPX-IQ 
v.4.7d software. To increase the accuracy in follow-up BMD measurements, the 
search and template tools in the compare mode of the DPX-IQ software were used 
to position the femoral neck region-of- interest in scans of the same individual. 
Additional retrospective calibrations using phantom measurements were performed 
to adjust for software changes not corrected by the DPX-IQ reanalysis (19). The 
change in BMD during follow-up was expressed in four different ways: 1) the ab-
solute BMD difference (mg/ cm2) between assessment periods; 2) the absolute rate 
of change in BMD (mg/cm2 per year), calculated as the BMD difference between 
assessment periods divided by the duration of follow-up in years; 3) percentage rate 
of change from previous BMD (% per year), calculated as the difference between 
two assessment periods divided by the earliest BMD measurement and divided by 
follow-up time in years and 4) the overall relative fraction of baseline BMD (%) 
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calculated as the BMD difference between two assessment periods divided by the 
earliest BMD measurement.
Hip Structural Analysis (HSA)
We have used the hip structural analysis (HSA) software developed by Thomas 
J. Beck to measure hip bone geometry from the DXA scans (12,20). The HSA 
program differs from the conventional density analyses in the sense that cross-sec-
tional dimensions are derived rather than averaged mass or density. The program 
uses the distribution of mineral mass in a line of pixels across the bone axis to 
measure geometric properties for cross-sections in cut planes traversing the bone at 
that location. Current versions average measurements for a series of 5 parallel “mass 
profi les” spaced ~1 mm apart along the bone axis. Analysis locations included the 
narrow-neck (NN) region across the narrowest point of the femoral neck. BMD, 
bone cross-sectional area (CSA), bone width (outer diameter) and cross-sectional 
moment of inertia (CSMI) were measured directly from mineral mass distribu-
tions using algorithms described previously (12). In addition, estimates of cortical 
thickness were obtained with simple models of the cross-sections which employ 
measured dimensions and assumptions of cross-section shape. The NN region is 
modeled as a circular annulus which assumes a proportion of cortical/trabecular 
bone of 60/40. For the current work, calculations of the section modulus (Z), an 
index of bending strength, and the buckling ratio (BR), an index of bone instability, 
were slightly modifi ed from those of previous reports (12) to account for shifts 
in the center-of-mass. Z was calculated as CSMI /ds, where ds is the maximum 
distance from the center of mass to the medial or lateral surface. Buckling ratios 
were computed as ds divided by estimated mean cortical thickness. In previous 
work (12), ½ the outer diameter was used instead of ds in calculations of Z and 
BR. As described previously in the section measurements, software updates, which 
altered scan image acquisition, made follow-up data from the HSA not compatible 
to baseline measurements. This is the reason why changes in geometry parameters 
in time were only analyzed between fi rst and second follow-up.
Clinical examination
Height (cm) and weight (kg) were measured in standing position wearing indoor 
clothes and without shoes. Body mass index or BMI (kg/m2), was calculated as 
weight divided by the square of height. Waist and hip circumferences (cm) were 
measured and waist to hip ratio calculated. 
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The diagnosis of diabetes was made in individuals with antidiabetic therapy 
(code A010 of the Anatomical Therapeutical Chemical classifi cation index, WHO 
1992) and/or a non-fasting serum glucose level equal to or higher than 11.1 
mmol/l.  The positive history of myocardial infarction was verifi ed in the EKG 
by a cardiologist or general practitioner.  Blood pressure was measured with the 
subject in the sitting position at the right upper arm with the use of a random zero 
sphygmomanometer. The average of 2 measurements was used for analysis and 
hypertension was defi ned as a diastolic blood pressure ≥ 100 mm Hg and/or a 
systolic blood pressure ≥ 160 mm Hg and/or use of antihypertensive medication 
indicated to treat high blood pressure (grades 2 and 3 of the 1999 World Health 
Organization criteria). In addition the presence of peripheral arterial disease was 
assessed as described previously (21,22). Total serum cholesterol was determined by 
an automated enzymatic procedure. 
Home interview
A trained interviewer performed an extensive home interview on medical his-
tory, risk factors for chronic disease and food intake. Calcium and vitamin intake 
was assessed together with total caloric intake as described previously (7,23). In 
this study, calcium intake was adjusted for total caloric intake. Smoking habits 
were assessed and categorized as current, former or never. Lower limb disability 
and use of walking aids was assessed using a modifi ed version of the Standford 
Health Assessment Questionnaire, as described previously (7,24), and disability 
was defi ned as an index of 0.5 or higher. The presence of intermittent claudication 
was diagnosed according to the criteria of WHO/Rose questionnaire. Age at and 
reason of menopause was assessed as defi ned previously (25). 
Statistical analysis
Data were analyzed stratifi ed by gender. Multiple linear regression was used to 
model the patterns of change in BMD and bone geometry across study groups, in-
cluding presence or absence of follow-up, age groups, tertiles of BMI and tertiles of 
weight change. Adjustments were done for age, weight, and height. Finally, model 
assumptions were verifi ed and model residuals were checked for goodness-of-fi t. If 
not stated otherwise, analyses were performed using the SPSS-package V.11 (SPSS 
Inc. Chicago, IL).  
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RESULTS
Table 1 compares baseline characteristics across the different assessments per-
formed in the Rotterdam Study, between all individuals with BMD measurements 
(reference) and those included in the BMD analysis (baseline to second follow-
up) and in the bone geometry analysis (fi rst to second-follow-up). The follow-up 
analyses are based on approximately 45% and 35% individuals, for BMD and bone 
geometry respectively. When the characteristics are compared at baseline, it be-
comes evident in both genders that individuals in the groups with follow-up are on 
average ~ 2 years younger, ~ 1 cm taller, ~1 kg heavier, and with 0.02 higher BMD 
levels than the overall population with BMD measurements.  
Figure 1 illustrates the patterns of BMD change with follow-up.  The longest 
follow-up was on average 6.5 years and was obtained between baseline and second 
follow-up (Figure 1A). The mean rate of change in BMD was -6.2 mg/cm2 per year 
in females and was -3.2 mg/cm2 per year in males. Figures 1B and 1C compare 
the two types of BMD measurements (the traditional femoral neck region and the 
hip structural analysis narrow-neck region, respectively) and were both obtained 
between fi rst and second follow-up periods on average 4.5 years apart. At the 
femoral neck region the mean rate of change in BMD was -3.1 mg/cm2 per year in 
males and -6.7 mg/cm2 per year in females. Similarly, at the femoral narrow-neck 
region the mean rate of change in BMD was -2.5 mg/cm2 per year in males and -5.1 
mg/cm2 per year in females. In all three analyses the overall trends and patterns are 
very similar.  In men, rates of BMD-loss are increasing with age, while in women, 
the rates are more stable across age groups and tend to be higher at the youngest (55 
to 60 years ) and oldest (above 75 years) age categories. 
In Table 2 health characteristics are compared between individuals lost to fol-
low-up and across tertiles of BMD change. In both genders approximately 45% of 
the individuals are lost to follow-up for the BMD measurements. These individuals 
lost to follow-up are 6.2 years older, 2.4 cm shorter, 2 kg lighter and have 0.04 
g/cm2 lower BMD, than individuals with follow-up BMD assessments. In addition, 
the presence of morbidity at baseline is higher, and manifested by the presence of 
disability, disorders of glucose metabolism, cardiovascular disease. Also, men have 
lower intake of vitamin intake and higher current smoking, but lower past history 
of smoking. Subjects with the higher rates of BMD loss (lowest tertile in BMD 
change) were on average 1.6 years older, had the greater weight loss (-0.8 kg per 
year) and 0.05 g/cm2 higher BMD levels at baseline. In addition, individuals with 
the highest rates of BMD decline appeared to have 2 mmHg higher systolic blood 
pressure (signifi cant in males only) and to be current smokers while they were less 
often former smokers and had lower intake of folic acid. Women with the highest 
bone loss appeared to have increased presence of diabetes, although the difference 
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Figure 1.  Absolute rates of BMD change in males (left)  and females 
(right)  A. Measured at femoral neck region between baseline and second 
follow-up assessment (mean duration 6.5 SD 0.6 years); B. measured at 
femoral neck region between fi rst and second follow-up assessment (mean 
duration 4.5 SD 0.6 years); C. Measured at narrow-neck region between 
fi rst and second follow-up assessment (mean duration 4.5 SD 0.6 years). 
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was not statistically signifi cant. Other parameters did not differ across tertiles of 
BMD change. 
The relation between rate of change in BMD, aging and rate of change in body 
weight between baseline and second follow-up period is shown in Figure 2. In 
males, weight loss is only signifi cantly higher and related to BMD loss in the older 
age group (p=0.05) while women in the lowest tertile of weight change (great-
est weight loss) have the highest rates of BMD loss in all age categories although 
signifi cantly higher only from age 65 years and older (p<0.03). 
A.
-0.012
-0.010
-0.008
-0.006
-0.004
-0.002
0.000
55-60 years
(n=263) 28.1%
60-65 years
(n=324) 27.8%
65-70 years
(n=283) 30.7%
70-75 years
(n=177) 41.2%
>75 years
(n=108) 56.5%
Lowest
Middle
Highest
Tertiles
weight change
B.
-0.012
-0.010
-0.008
-0.006
-0.004
-0.002
0.000
55-60 years
(n=343) 24.8%
60-65 years
(n=407) 28.3%
65-70 years
(n=362) 35.9%
70-75 years
(n=261) 35.6%
>75 years
(n=167) 53.3%
Lowest
Middle
Highest
Tertiles
weight change
Figure 2. Absolute rates 
of BMD change with age 
by  tertiles of weight change 
in: A. males and B. females. 
Under each age category 
group size and percent of 
individuals in the lowest 
tertile of weight change 
(greatest weight loss). 
The lowest and highest cut-
offs are at -2.0  and 0.7 
kg-per-year, respectively. 
Estimates are adjusted for 
baseline height and weight 
and assessed between base-
line and second  fol low-up 
period with a mean follow-
up duration of 6.5 (SD 0.6) 
years.
In Table 3 the patterns of BMD and bone geometry change are compared across 
genders between the fi rst and second follow-up periods. Overall, the rates of change 
are higher in women than in men. In women, NN BMD decreased 2,2% (relative 
fraction from baseline) while cortical thickness decreased by 2,2% and subperiostal 
width increased by 0.8%. Thus, BMD decreased most likely due to a combination of 
cortical thinning and bone expansion. These changes were less apparent in males. 
The buckling ratio increased by 7.5 % from baseline in females and by 3.9 % in 
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males, pointing towards greater progression towards bone instability in females.
In Table 4A the absolute rates of change in BMD and bone geometry are exam-
ined in males across age groups, tertiles of body mass index and by tertiles of rate of 
change in body weight. It is important to highlight for the tertile groups of weight 
change, that the highest tertile represents weight gain, the middle static weight 
and the lowest represents weight loss. As also seen in Figure 1, rates of BMD loss 
were higher in the older age groups. Consistently, the decrease in cortical thickness 
and increase in subperiostal width and in buckling ratio (bone instability) is also 
higher in the older age groups. A similar pattern is seen with bone strength, as 
section modulus decreases more at older age although not signifi cantly (p= 0.09). 
In contrast, no trend is seen across tertiles of baseline BMI though it appears that 
the individuals in the lowest BMI tertile have the lowest rates of BMD decrease. 
Additionally, no trends are seen across tertiles of rate of change in body weight , 
but consistently, individuals at the lowest tertile of weight change (greatest weight 
loss) had the highest rates of loss in BMD, cortical thickness and  section modulus 
(strength) and the highest increase in buckling ratio (bone instability).  Rates of 
change in subperiostal width are paradoxically negative but very small in all tertiles 
of weight change.
In Table 4B the same analysis across age groups, tertiles of baseline body mass 
index and by tertiles of rate of change in body weight is presented for women. In 
contrast to men, rates of BMD loss do not follow a linear trend through age groups. 
Even though the highest rates of BMD loss are seen in the oldest age group, the 
youngest age group also appears to have increased rates of BMD loss. The pattern 
of change in bone geometry suggests that cortical thinning is higher in the older 
age group, while increase in neck width is high in both the youngest and oldest age 
groups. The loss of bone strength (decrease in section modulus) and progression 
to instability (increase in buckling ratio) is faster in the older age group. No trends 
or mean differences in rates of BMD loss or change in geometry is seen across 
tertiles of baseline BMI.  The analysis across tertiles of rate of change in body 
weight shows that rates of BMD loss increase together with increasing rates of 
weight loss. Similarly this trend is evident with the parameters of bone geometry, 
where the rate of cortical thinning, loss of strength (decrease in section modulus) 
and progression towards bone instability (increase in buckling ratio) is higher with 
increasing weight loss. No such pattern is seen on changes in neck width. 
DISCUSSION
In this population-based study in a large group of elderly men and women aged 
55 and over, we examined the epidemiological and biomechanical aspects  underly-
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ing age-related changes in BMD in one of the longer periods of follow-up reported 
in the literature (6.5 and 4.5 years, respectively). We have shown that individuals for 
whom follow-up data are available were younger, taller (~ 2.4 cm), heavier and with 
higher BMD than those individuals lost to follow-up (~ 45% of all individuals), 
thus representing a selected and healthy cohort. Accordingly, morbidity was higher 
in the group lost to follow-up, with increased prevalence of disability, diabetes 
and cardiovascular disease. They also smoked more often and had lower intake 
of calcium and folic acid. We found that in both genders, individuals in the lowest 
tertile of BMD change (representing the highest rates of BMD loss), had higher 
BMD levels at baseline and greater weight loss with follow-up. In addition, men 
with greatest BMD loss were older and had higher systolic blood pressure. When 
examining the rates of change in BMD and bone geometry after 4.5 years of fol-
low-up we found that as compared to men, women have higher rates of BMD loss, 
with increased cortical thinning and bone expansion and increased loss of strength 
(decrease in section modulus), with faster progression towards bone instability as 
manifested by an increase in buckling ratio. In addition, we observed sex-specifi c 
patterns of change in bone geometry. In men, an age trend was present where the 
greatest rates of bone loss and change in geometry were observed in the group of 
the oldest men (> 75 years).  In contrast, rates of change in BMD and geometry 
were more prominent before age 65 years and after age 75 years, with an increasing 
linear relationship with increasing weight loss. In women, the rates of change in 
BMD and bone geometry are more stable across age groups and tend to be higher 
at the youngest (55 to 60 years ) and oldest (above 75years) age categories.
Patterns of BMD Decline and Health Characteristics
Previously, we have estimated rates of change in BMD in both genders, using 
both a cross-sectional analysis at baseline (3) and a longitudinal analysis with an 
average follow-up of only 2.0 years between baseline and fi rst follow-up (7). The 
results from our present study are consistent with these earlier observations in the 
Rotterdam Study and with those of others (4-6), and show that rates of BMD loss 
increase with advancing age in both men and women. Also the magnitude of the 
rates of change per year are comparable with those from previous reports, with 
rates of loss in women in the range of 1.0% of baseline BMD per year, being almost 
double that of men (0.5% of baseline BMD per year). Furthermore, we observed 
in women that rates of BMD loss tend to be higher before the age of 60 years 
and to rise again after age 75 years. Though this “U” shape pattern did not reach 
signifi cance, it is biologically plausible that at least some of the women younger 
than 60 years of age are early post menopausal, and therefore still in the phase of 
the rapid postmenopausal BMD loss (2,26).  
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An important observation is that approximately 45% of the individuals evaluated 
at baseline were lost to follow-up, and as shown by our analysis by health charac-
teristics, this was probably the consequence of increased morbidity, as represented 
by an increased prevalence of disability, type II diabetes, cardiovascular disease and 
current smoking.  Therefore, the rates of BMD and bone geometry change that 
we report in this study, although arising in a population-based setting, represent 
patterns found in a relatively healthy cohort of surviving men and women. This 
could also be the explanation for the fact that no strong associations were observed 
between rates of bone loss and morbid conditions. Nevertheless, some relation-
ships with morbidity were seen, although not consistently in both genders. That is, 
males with higher rates of BMD loss had also higher systolic blood pressure and 
in women the prevalence of diabetes mellitus was higher in the tertiles with higher 
BMD loss (although this was not statistically signifi cant). No specifi c conclusion 
may be drawn from these unspecifi c observations, yet these fi ndings are in line 
with the observation that increased rates of BMD loss are associated to increased 
risks of diabetes, hypertension, stroke and mortality (7,27,28). In contrast, some 
cross-sectional studies have shown that the presence of diabetes and hyperten-
sion are associated with higher BMD levels (8-11). Even though these results seem 
paradoxical, they are also in line with our fi ndings that higher rates of BMD loss 
occurred in individuals with higher BMD. Although regression to the mean could 
play a role, it is unlikely that it could explain alone the current fi ndings given the 
long follow-up (6.5 years).
Even though no associations were evident with weight or body mass index 
(BMI) at baseline, a strong association was seen between loss of body weight and 
decline in BMD in both genders. Further, our analysis across baseline age groups 
(Figure 2) showed that, even though the percentage of individuals with higher 
rates of weight loss increases with aging, higher weight loss in men appeared to be 
related to higher rates of BMD loss only in the older age groups, while in women 
this relationship was evident throughout all the age categories. These changes in 
body weight may be a consequence of underlying morbidity (29), but also they 
could represent expected decline in body weight with aging (i.e. in the form of 
sarcopenia) (16). 
Patterns of BMD Decline and Bone Geometry
Our fi ndings on bone geometry help to elucidate the way BMD declines with 
aging and to determine how the aging bone progresses towards fragility. In con-
cordance with previous reports we observe that women have comparatively higher 
rates of both cortical thinning and bone expansion (increase in femoral neck width) 
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(13), though the latter remains yet controversial in the light of measurement error 
(30). We also saw, that despite the presence of periosteal apposition, bone strength 
declined with time in both genders, with almost equivalent yearly rates in the age 
group 75 years and over. In contrast to previous reports (12,13), the rate of decline 
in strength was lower than that observed for BMD in women, but not in men (Table 
3).  When we examined the patterns of change in bone geometry across tertiles of 
BMI and weight change, we saw that there is no consistent relation of BMD with 
BMI categories in any gender. However, there was a clear relationship with weight 
change in females. Our fi ndings on weight-related decline in BMD are in line with 
a previous study which explored this relationship (29) and supports the hypothesis 
that one of the reasons for the BMD decline with aging is mechanical adaptation to 
changes in skeletal load.  When examining the progression towards bone instabil-
ity, we observed that the buckling ratio increased with aging in both genders. This 
was only linearly seen in men, while women after age 75 years showed the faster 
rates (about two times as those observed in men). This is in line with the fi nding 
that females had greater increase in neck width than men, and could explain the 
higher susceptibility for hip fracture in elderly women (31,32).   
To further explore the age-related changes in BMD and bone geometry, future 
studies might specifi cally look at relations with pharmacologic interventions (e.g. 
the use of thiaziades, statins), calcium intake and secondary hyperparathyroidism, 
vitamin supplementation and homocysteine metabolism (33), the growth hormone 
and insulin-like growth factor I axis (34,35), and sex-steroids (26,36,37).
In summary, this population-based study in elderly men and women age 55 and 
over, examined the longitudinal patterns of change in BMD and bone geometry. 
Since almost half of the original study population at baseline was lost to follow-up 
due to morbidity, the current fi ndings arise in a reasonable healthier cohort and 
need to be interpreted under the consideration of selection bias.  This way, few 
associations were found with health characteristics at baseline, with increasing 
age (age 75 years or older), BMD and weight loss with follow-up being the most 
signifi cant determinants of bone loss in both genders. Bone geometry data showed 
that BMD declines in the elderly due to bone loss (cortical thinning), but also due 
to increase in neck width (periosteal apposition), with both processes being more 
prominent in (postmenopausal) women than in men. Bone strength decreased in 
both genders possibly as an adaptative response to changes in body weight. Females 
had greater rates of increase in buckling ratio (index of bone instability) that could 
explain the higher susceptibility for hip fracture in elderly women. Specifi c research 
is needed to elucidate further these relationships between BMD decline, changes in 
bone geometry, morbidity and weight loss.
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ABSTRACT
In the present study (n=923) we estimated heritabilities (h2) and genetic cor-
relations of bone mineral density (BMD) and hip geometry measurements, within 
the Erasmus Rucphen Family study, an extended-pedigree study designed to map 
disease-related quantitative trait loci. Variance component methodology was used 
to study age and sex adjusted traits which included BMD of the hip, spine and 
total body (including body composition) and bone geometry measurements of 
the hip. An estimate of mechanosensitivity was calculated as the ratio of bone 
strength to lean mass. We found that heritability across skeletal sites is highest at 
the head/skull (h2 ~ 80%), and decreases from the axial towards the appendicular 
skeleton (h2 decreasing ~ from 70 to 26%). Consistently, genetic correlations (rho 
coeffi cient) of BMD across sites were high and decreased with increasing distance 
of the measurement sites (rho decreased from 1.00 to 0.50). BMD had signifi cant 
genetic correlation with height (rho ~ 0.20) and lean mass (rho ~ 0.30). Bone ge-
ometry had the highest heritabilities for parameters of size (h2 ranging ~ from 43 
to 75%), followed by cortical factors (h2  ~ 40%), and was lowest for strength (h2  
~ 25%). Mechanosensitivity indices were also heritable (h2 ~ 40%) and genetically 
correlated (rho ~ 0.40) with bone instability of the femoral neck and to spinal 
and head/skull BMD. These fi ndings suggest that the heritability of BMD is site-
specifi c and infl uenced by genes determining height and lean mass. Bone geometry 
parameters depicting strength and instability are also heritable. Finally, we propose 
that susceptibility to fragility fracture at older age is heritable partly because they 
refl ect genetically-determined differences in mechanosensitivity.
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INTRODUCTION
Osteoporosis is a systemic skeletal disease characterized by low bone mineral 
density (BMD) and microarchitectural deterioration of bone tissue, with a con-
sequent increase in bone fragility and susceptibility to fracture. The incidence of 
hip fracture is high in the elderly (1,2) and its associated morbidity and mortality 
(3,4) represents enormous costs for health systems (5). Since the completion of 
the human genome project the study of the genetic basis of complex diseases and 
hence osteoporosis has gained evolving importance. From the genetic perspective 
osteoporosis is a multifactorial disease resulting from multiple independent gene 
effects, and gene-gene and gene-environment interactions (6,7). 
The clinically relevant osteoporosis phenotype is the occurrence of low-trauma 
fracture but, osteoporotic fractures are also rare events that occur late in life. In 
addition, they are very complex in nature and evidence for their genetic determina-
tion is therefore scarce and confl icting (8-10). This diffi culty to use osteoporotic 
fractures as outcome in genetic studies has lead to the use of surrogate traits that 
assess characteristics of bone health. These include the determination of bone min-
eral density (BMD), quantitative ultrasound and the use of biochemical markers of 
bone metabolism.  
From these, BMD measured by dual energy X-ray densitometry (DXA) is the 
most commonly used trait in genetic studies of osteoporosis considering that it is a 
highly heritable trait with estimates of heritability ranging between 50-70 percent 
(7) and that is predictive of the risk of fracture (11,12). 
However, of the many genetic studies that have used BMD as a surrogate 
marker for osteoporotic fractures, only some have shown consistent and reproduc-
ible associations with candidate genes while few, if any, chromosomal regions have 
shown consistent linkage (13,14).   There are intrinsic limitations underlying the 
use of BMD as a trait. BMD traits are dynamic, they show gender- and age-specifi c 
patterns through life (15,16), and most important, the BMD measurement in itself 
does not represent invariably the underlying structural integrity of bone (17).  The 
latter also explains why BMD does not fully characterize the risk of fracture (2,12). 
Interpreting BMD in terms of mass distribution (bone geometry) beyond quantity 
alone can provide a better understanding of the relation between bone fragility and 
fracture. Up to now, genetic studies which have looked at bone geometry (18,19) 
have focused on size-related parameters like hip axis length (20) and neck-shaft 
angles, while few have looked at properties of mass distribution (21,22).  
Considering this, we have made a comprehensive dissection of the DXA-based 
osteoporosis phenotype to 1) explain what properties of the BMD measurement 
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makes it such a highly heritable trait, and 2) to identify the properties of BMD that 
could explain why the susceptibility to fragility fracture at older ages is heritable. 
To do this, we have studied a genetic isolated population with a broad age range 
in order to determine site-specifi c heritabilities and estimate the phenotypic and 
genetic correlations across BMD and hip bone geometry measurements. Further, 
we studied the relationship between bone strength and skeletal load by calculating 
an index of mechanosensitivity, and studied its heritability and genetic correlation 
with the BMD measurements and the other geometrical parameters.  
SUJECTS AND METHODS
Sample Composition and Evaluation of  Phenotypes
This study is part of the Erasmus Rucphen Family (ERF) Study, an ongoing ex-
tended-pedigree study of genetic risk factors for neuropsychiatric, cardiovascular, 
endocrinologic, ophthalmologic and musculoskeletal disorders. The ERF study is 
part of the Genetic Research in Isolated Populations (GRIP) program which aims 
to identify genetic risk factors in the development of complex disorders in an iso-
lated community of about 20,000 inhabitants settled around eight adjacent villages 
in the southwest of The Netherlands. The ERF study population includes all living 
descendants of  50 couples with at least six children and at least one baptized in the 
community church between 1890 and 1900, who were invited to participate in the 
study (n=2100) independent of disease status. The Medical Ethics Committee of 
Erasmus Medical Center Rotterdam approved the ERF study and written informed 
consent was obtained from every participant. Phenotyping started in June 2002, 
is currently ongoing and includes a series of medical investigations assessed in a 
standardized manner by trained assistants and physicians during their visit to the 
research center located in Sprundel, The Netherlands. The current response rate 
is 78%. This study is based on the fi rst 1064 participants evaluated until July 31, 
2003, who were ascertained independently of disease status. The mean inbreed-
ing coeffi cient is 0.008 (SD 0.007). The investigation protocols of the phenotypes 
considered in this study are described below.
Clinical examination
 
Trained physicians assessed the current use of bone active medication including 
Vitamin D, calcium, oral glucocorticoids, bisphosphonates and hormone replace-
ment therapy (in women). Further, for women, menopausal status and age at 
menopause was recorded. 
Phenotypic Dissection of DXA -based Traits
41
Height (cm) rounded to the closest 0.5 unit and weight (kg) were measured with 
participants in standing position, wearing light underclothing and without shoes. 
Body mass index or BMI (kg/m2), was calculated as weight (kg) divided by the 
square of height (meters).
Dual-energy x-ray absorptiometry measurements
DXA scans were performed using a Prodigy™ total body fan-beam densi-
tometer and analyzed with the enCORE™ 2002 software V. 6.70.021 (GE Lunar 
Corporation Madison, WI). Daily quality assurance tests were performed with a 
calibration block supplied by the manufacturer. Repeated measurements on the 
calibration block had coeffi cients of variation less than 1%. In addition a calibra-
tion aluminum phantom was measured weekly with coeffi cients of variation less 
than 1%. 
Dual-femur and antero-posterior lumbar spine scans were performed using 
standard specifi c positioning as suggested for DXA measurements. BMD (g/cm2), 
BMC (g) and area (cm2) were obtained from the femoral neck, upper femoral neck, 
trochanteric, Ward’s triangle and L1 to L4 regions of interest. Z-scores (differ-
ence in SD from the mean for individuals of same age and gender) and T-scores 
(difference in SD from the mean of a young adult of same gender) were obtained 
from the manufacturer database (reference German Caucasian population). In 
addition hip axis length was also measured by the manufacturer software. When 
bilateral measurements were available, mean values were computed. Total-body and 
regional BMD (g/cm2), fat mass (g), lean mass (g) and bone mineral content (g) 
were obtained from total body scans and were auto analyzed by the software which 
employs an algorithm that divides body measurements into areas corresponding 
to head, trunk, arms and legs. All analyzes were verifi ed by a trained technician 
who performed adjustments when necessary. Lean mass and fat mass indices were 
calculated as lean mass (in kg) and fat mass (in kg) divided respectively by the 
square of height (meters).
Hip Structural Analysis (HSA)
We have used the hip structural analysis (HSA) software developed by Thomas 
Beck to measure hip bone geometry from the DXA scans (17,23). The HSA 
program differs from the conventional density analyses in the sense that cross-
sectional dimensions are derived density, rather than averaged. Analysis locations 
included the narrow-neck (NN) region across the narrowest point of the femoral 
neck and the shaft region located 2 cm distal to the user-located midpoint of the 
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lesser trochanter. BMD, bone cross-sectional area, bone width (outer diameter) and 
cross-sectional moment of inertia (CSMI) were measured directly from mineral 
mass distributions using algorithms described previously (23). Section modulus 
was calculated as CSMI /ds, where ds is the maximum distance from the center of 
mass to the medial or lateral surface. Buckling ratios were computed as ds divided 
by estimated mean cortical thickness. 
Mechanosensitivity Indices
Evolutionary and biomechanical theory states that bone strength should scale 
to skeletal load (24,25), refl ecting the intrinsic mechanosensitivity of an individual. 
In this context, individuals with reduced mechanosensitivity will develop relatively 
weaker bones for equivalent skeletal loads and hence, show increased susceptibil-
ity to fracture. An approximated index of mechanosensitivity is the ratio of bone 
strength/moment arm to lean mass (used as a crude proxy of skeletal loading). We 
calculated the following mechanosensitivity indices (MSI):
Shaft MSI as:           
Femoral neck MSI as: 
where Z=section modulus (index of bending strength), LM=lean mass, NL= 
neck length and NSA= neck-shaft angle. Estimates were multiplied for a scaling 
factor of 10 for  convenience. 
Statistical Analysis
For the genetic modeling we have used the ASreml V.1.10 software (NSW 
Agriculture and IACR-Rothamsted Hertfordshire,U.K.). ASreml uses residual 
maximum likelihood methods for fi tting linear mixed models, handles large datas-
ets and supports loops. We performed a variance component analysis for quantita-
tive traits (26). This analysis allowed us to distinguish for each trait, the additive 
polygenic genetic component of the total phenotypic variance, apart from several 
of its other potential components (dominant polygenic effects, epistatic effects, 
shared environmental effects, measurement error and residual effects). Since both 
shared environmental and dominant effects may mask polygenic effects, we have 
LM
height
Zshaft
LM
NSASinNLZneck )180(( 
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included in the models a parameter which identifi ed siblings arising from the same 
mother in order to extract from the polygenic component those shared environ-
mental factors of early life.  The narrow-sense heritability (h2) was computed as the 
ratio of the additive polygenic genetic variance to the total variance. Each trait was 
considered in two different models: a crude one (Model 0) with adjustment for age, 
sex, and inbreeding coeffi cients; and a fully adjusted one (Model 1) including age, 
sex, inbreeding coeffi cients, height, FMI, LMI and bone active medication, which 
includes concomitant use of Vitamin D and/or calcium supplements, glucocorti-
coids, bisphosphonates and hormone replacement therapy (in women). 
Bivariate analyses were carried out to determine to what extent the aggregation 
and co-aggregation in families of a pair of traits may be attributed to shared genetic 
and environmental factors. Under the principle of Cholesky decomposition (27) 
genetic and phenotypic correlations were obtained from the formula:
where,  and are the heritabilities of the correlated traits, and  ρP, ρG and ρE  
refer to the phenotypic, genetic and environmental correlations, respectively.  This 
way, ρP < ρG, only when there is a negative rE. Estimates were considered signifi cant 
if twice the standard errors subtracted (or added) to the estimates did not cross the 
value of zero.
RESULTS
Of the 1064 participants who visited the research center 923 (87%) had com-
plete phenotypic information. Those with incomplete phenotypic information were 
signifi cantly older with mean age of 69.7 SD 13.4 years (p< 0.00001). Baseline 
characteristics of the study population are presented in Table 1. About 59% percent 
of participants are female with no signifi cant differences in mean age across gen-
ders. Of all women, approximately 66% were either peri or post menopausal. The 
average body mass index (BMI) in both men and women was 27 kg/m2 which cor-
responds to overweight (BMI>25). As observed from mean Z-scores, BMD is on 
average within the expected values for age with about 13% of the total population 
diagnosed with osteoporosis (T-score < -2.5). The use of bone active medication is 
relatively low in the elderly.
Skeletal BMD Measurements
Heritability (h2) estimates of BMD measured at the different skeletal sites are 
shown in Table 2 and Figure 1. Heritabilities of BMD from the total body scan 
EGP hhhh   )1()1(
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varied across skeletal sites, with appendicular segments showing lower h2 than the 
axial component, with a total body BMD averaging around 57%. Estimates fl uctu-
ated between 27% (ribs) and 81% (head/skull). BMD of the femoral neck and hip 
regions had an h2 of about 60% while the h2 of lumbar spine was approximately 
70%. The heritability of bone area at the lumbar spine was 75% while at the femoral 
neck it was less than 20%. An increase in heritability estimates in the fully adjusted 
models usually represented a decrease in total variance with a minor change on 
the genetic additive component. This reduction in total variance could represent 
either adjustment for environmental factors as well as for measurement error. Of 
those traits where heritability estimates decreased after adjustment, bone areas of 
the lumbar spines showed the highest reduction in the additive genetic component 
suggesting common underlying genetic factors with covariates. Several traits did 
not yield major changes after adjustment (in particular Z-scores which are BMD 
TOTAL MALES FEMALES
Assesed participants (n) 923 375 548
Age (years)* 52.2 (14.2) 53.9 (13.7) 51.1 (14.3)
Age at menarche (years)* - - 13.1 (1.7)
Age at menopause (years)* - - 47.1 (6.3)
Perimenopausal (%)** - - 30.1
Postmenopausal (%)** - - 35.9
Height (meters)* 1.65 (0.09) 1.72 (0.07) 1.60 (0.06)
Weight (kilograms)* 73.7 (14.5) 81.7 (13.4) 68.3 (12.6)
Body mass index (kg/m2)* 27.0 (4.5) 27.5 (4.1) 26.7 (4.8)
Lean mass index (kg/m2)* 17.0 (2.5) 19.2 (1.9) 15.4 (1.7)
Fat mass index (kg/m2)* 9.0 (3.6) 7.4 (2.8) 10.2 (3.6)
Fat tissue percent (%)* 33.8 (9.5) 26.9 (7.4) 38.6 (7.6)
Femoral Neck BMD (g/cm2)* 0.91 (0.14) 0.94 (0.14) 0.89 (0.13)
Z-score* -0.2 (0.9) -0.3 (0.9) -0.1 (0.9)
T-score* -0.9 (1.1) -1.0 (1.1) -0.8 (1.1)
L2-L4 Lumbar Spine BMD (g/cm2)* 1.15 (0.19) 1.20 (0.19) 1.12 (0.18)
Z-score* -0.1 (1.4) -0.2 (1.3) 0.0 (1.3)
T-score* -0.5 (1.5) -0.4 (1.5) -0.6 (1.5)
Osteopenia ** 44.2 47.8 41.7
Osteoporosis ** 12.8 13.2 12.6
Use of bone active medication (%)** 6.6 2.4 9.5
Vitamin D or calcium (%)** 2.7 0.3 4.4
HRT or estrogen (%)** - - 3.6
Bisphosphonates (%)** 2.1 0.5 3.1
Glucocorticoids (%)** 1.5 2.1 1.1
*   Data are unadjusted means (SD) ** Data are percent of participants
TABLE 1 CHARACTERISTICS OF THE STUDY POPULATION
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TABLE 2. HERITABILITIES OF DXA BMD-RELATED PHENOTYPES
Phenotype Additive genetic Total Additive genetic Total
FEMORAL NECK
BMD 0.09 (0.01) 0.15 (0.01) 59.4 (8.7) 0.07 (0.01) 0.12 (0.01) 56.2 (9.1)
BMC 0.25 (0.05) 0.52 (0.03) 47.7 (9.2) 0.14 (0.04) 0.40 (0.02) 34.2 (9.3)
Area 0.04 (0.02) 0.21 (0.01) 16.6 (9.4) 0.01 (0.02) 0.19 (0.01) 7.4 (8.8)
Z-score 0.52 (0.08) 0.83 (0.04) 62.5 (8.7) 0.48 (0.08) 0.80 (0.04) 59.5 (9.0)
T-score 0.58 (0.10) 0.95 (0.05) 61.6 (8.7) 0.47 (0.09) 0.82 (0.04) 57.7 (9.1)
Upper neck BMD 0.09 (0.02) 0.16 (0.01) 54.7 (8.9) 0.07 (0.02) 0.14 (0.01) 47.9 (9.4)
OTHER HIP REGIONS
Wards triangle BMD (g/cm2) 0.11 (0.02) 0.17 (0.01) 64.8 (7.2) 0.10 (0.02) 0.16 (0.01) 59.3 (8.5)
Throchanter BMD (g/cm2) 0.08 (0.01) 0.15 (0.01) 57.5 (8.5) 0.07 (0.01) 0.12 (0.01) 63.9 (8.4)
Total hip BMD (g/cm2) 0.10 (0.02) 0.17 (0.01) 58.0 (8.4) 0.09 (0.01) 0.13 (0.01) 66.5 (8.1)
LUMBAR SPINE
L2-L4 BMD (g/cm2) 0.23 (0.03) 0.31 (0.02) 71.7 (7.5) 0.21 (0.03) 0.30 (0.01) 70.3 (7.7)
L2-L4  BMC (g) 79.9 (10.2) 107.6 (4.4) 74.2 (7.3) 61.0 (8.6) 90.1 (4.3) 67.7 (7.7)
L2-L4 Area (cm2) 13.5 (1.71) 17.7 (0.6) 76.0 (7.5) 5.7 (1.1) 10.8 (0.5) 52.4 (9.2)
L2-L4 Z-score 1.51 (0.20) 2.05 (0.10) 73.5 (7.5) 1.52 (0.19) 2.04 (0.11) 74.4 (6.9)
L2-L4 T-score 1.62 (0.21) 2.20 (0.12) 73.6 (6.9) 1.51 (0.20) 2.11 (0.11) 71.8 (7.1)
L1-L4 BMD (g/cm2) 0.20 (0.03) 0.29 (0.01) 69.8 (7.8) 0.187 (0.027) 0.275 (0.013) 68.1 (8.0)
L1-L4  BMC (g) 123.7 (16.0) 166.0 (6.1) 74.5 (7.5) 96.5 (13.5) 139.1 (6.4) 69.4 (7.8)
L1-L4 Area (cm2) 20.9 (2.7) 28.0 (1.1) 74.7 (7.6) 8.9 (1.7) 16.7 (0.8) 53.2 (9.1)
TOTAL BODY
Total body BMD (g/cm2) 0.05 (0.01) 0.09 (0.00) 57.2 (8.3) 0.04 (0.01) 0.07 (0.00) 63.7 (8.0)
Total body BMC (kg) 0.08 (0.01) 0.13 (0.01) 60.4 (8.4) 0.05 (0.82) 8.3 (0.0) 57.3 (8.5)
Total body Z-Score 0.78 (0.10) 1.10 (0.06) 71.2 (7.0) 0.73 (0.10) 1.05 (0.06) 69.2 (7.1)
Total body T-Score 0.86 (0.14) 1.41 (0.07) 61.5 (8.1) 0.74 (0.10) 1.09 (0.06) 67.4 (7.2)
Head BMD (g/cm2) 0.06 (0.01) 0.07 (0.00) 79.3 (7.4) 0.05 (0.01) 0.07 (0.00) 80.4 (7.5)
Spine BMD (g/cm2) 0.10 (0.02) 0.16 (0.01) 60.6 (8.1) 0.09 (0.01) 0.15 (0.01) 61.2 (8.1)
Ribs BMD (g/cm2) 0.01 (0.00) 0.03 (0.00) 26.6 (9.2) 0.01 (0.00) 0.02 (0.00) 27.6 (8.0)
Arms BMD (g/cm2) 0.02 (0.01) 0.08 (0.00) 30.7 (8.4) 0.02 (0.01) 0.06 (0.00) 35.5 (8.4)
Legs BMD (g/cm2) 0.07 (0.01) 0.14 (0.01) 46.3 (8.9) 0.05 (0.01) 0.11 (0.01) 48.0 (9.0)
Pelvis BMD (g/cm2) 0.06 (0.01) 0.15 (0.01) 42.7 (8.4) 0.05 (0.01) 0.12 (0.01) 43.1 (7.7)
Data are estimates (SE)
 * Model 0 Adjustment for Sex, Age, Inbreeding coefficient
**Model 1 Adjustment for Sex, Age, Inbreeding coefficient, height, fat mass index, lean mass index and bone active medication (see text)
Variance component
% h 2
Model 0* Model 1**
Variance component
% h 2
measurements adjusted for age and sex).
 
The phenotypic and genetic correlations between all the BMD measurements 
and the three most frequent skeletal sites of measurement are shown in Table 3. In 
general, all genetic correlations are moderately high between sites, with highest cor-
relations occurring at adjacent sites, and decreasing with more distant sites. Overall 
head/skull BMD was the site observing the lowest genetic correlations with BMD 
measurement at other sites. Body height and lean mass index were signifi cantly 
correlated with femoral neck and total body BMD only, and not with L1-L4 lumbar 
spine BMD. No signifi cant genetic correlation was observed between BMD and fat 
mass index.   
Chapter 3
46
Figure 1.  BMD measurements and skeletal traits with heritabilities.  In 
shade the axial skeleton including the head/skull (light shade) and spinal 
column (dark shade). The square depicts total hip measurement and includes 
femoral  neck (59%), Wards triangle (65%) and trochanter (64%) regions.
Bone Geometry and Size Measurements
The heritability estimates of hip bone geometry and size are shown in Table 4 
and Figure 2. Size measurements (like hip axis and neck lengths) and bone diam-
eters (like neck and endocortical width) showed the highest heritability estimates. 
Hip axis length gave the highest reduction in the additive genetic component after 
adjustment. Overall, heritability estimates of the geometry parameters in the shaft 
were higher than at the narrow-neck region. Section modulus (index of bending 
strength) and cross-sectional moment of inertia (measurement of bending strength) 
of the femoral neck, had the lowest heritability estimates as compared to the other 
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parameters of bone geometry.
Table 5A presents the genetic correlations of the narrow-neck geometry param-
eters and   the most relevant variables used to interpret the risk of fracture: BMD, 
section modulus (index of bending strength) and the buckling ratio (index of bone 
instability). Narrow-neck BMD is totally phenotypic and genetically correlated with 
the average cortical thickness. In contrast, no phenotypic correlation is observed 
with neck width. In contrast  to the traditional femoral neck BMD, no signifi cant 
correlation is observed between narrow-neck BMD and body height or lean mass 
index. The section modulus, an index of bone strength, shows phenotypic and ge-
netic correlation with all bone geometry parameters and with body height. Similarly, 
A.
B.
Figure 2.  Bone geometry traits with  heritabilities.  A. Measurements 
of length axis and angles B. Bone diameters, cortical thickness, and bone 
indexes of strength (section modulus), instability (buckling ratio) and 
mechanosensitivity at the narrow-neck and shaft regions.
Phenotypic Dissection of DXA -based Traits
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the buckling ratio (index of bone stability) has a very high genetic and phenotypic 
correlation with all bone geometry parameters but not with body height.
 
In Table 5B the genetic correlations between the size measurements of the hip 
and the lumbar spine L1-L4 area are presented. In line with the observed reduction 
in the additive genetic component of the heritability after adjusting for covariates 
(including body height), all the size measurements possess high genetic correlation 
with body height, with the highest correlation observed with the lumbar spine L1-
L4 area.
Mechanosensitivity Indices
As shown in Table 6 after adjusting for covariates the mechanosensitivity indices 
of the femoral neck and shaft have signifi cant heritabilities of 35 and 46%, respec-
tively. When looking at the variance components after adjustment, total variances 
of both estimates decreased, but the additive genetic component increased in the 
narrow-neck index in contrast to a relative decrease in the additive component of 
the shaft index (suggesting common genetic factors with covariates).  
The phenotypic correlation between the two mechanosensitivity indices was 
0.45 (SE 0.04) while there was no signifi cant genetic correlation between them 0.24 
(SE 0.17).
Trait phenotypic and genetic correlations between both mechanosensitivity 
indices with BMD, bone geometry and covariates are also shown in Table 6. The 
narrow-neck mechanosensitivity index had signifi cant genetic correlation of 0.40 
with L1-L4 lumbar spine BMD but not with femoral neck BMD. Genetic correla-
tion was also signifi cant with total body and head/skull BMD. Similarly, there was 
signifi cant correlation with all components of bone geometry including bone size 
(hip axis length), strength (section modulus) and instability (buckling ratio). There 
was no signifi cation correlation with body height, lean and fat mass parameters.  In 
contrast, the mechanosensitivity index at the shaft had signifi cant correlations only 
with the bone instability parameter of the femoral neck (buckling ratio), and with 
body height and lean mass index.  
In Table 7A mean trait values are compared across tertiles of the narrow-neck 
mechanosensitivity index in men and women. As compared to men, women had 
higher mechanosensitivity index of the narrow neck (mean 8.9 SD 2.4  versus mean 
7.7 SD 2.3 p<0.00001) and of the shaft (mean 3.4 SD 0.5 versus mean 3.0 SD 0.5 
p<0.000001).Also, in contrast to all the other BMD measurements of the skeleton, 
Phenotypic Dissection of DXA -based Traits
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TABLE 6. HERITABILITIES AND TRAIT CORRELATIONS OF THE MECHANOSENSITIVITY INDEXES
Variance component Model 0* Model 1** Model 0* Model 1**
Additive genetic component 1.31 (0.50) 1.52 (0.04) 0.08 (0.017) 0.06 (0.013)
Total variance 5.46 (0.26) 4.30 (0.21) 0.18 (0.009) 0.13 (0.007)
% h
2
24.0 (8.9) 35.3 (9.5) 42.6 (8.3) 46.1 (8.4)
Phenotypic Genetic Phenotypic Genetic
Bone mineral density 
Femoral neck 0.15 (0.043) 0.23 (0.154) 0.04 (0.039) 0.18 (0.131)
L1-L4 lumbar spine 0.25 (0.046) 0.40 (0.138) 0.09 (0.041) 0.09 (0.124)
Total body 0.08 (0.041) 0.32 (0.150) -0.05 (0.038) 0.03 (0.133)
Head/Skull 0.19 (0.035) 0.33 (0.127) 0.04 (0.037) 0.02 (0.114)
Bone geometry 
Hip axis length -0.16 (0.036) -0.29 (0.124) 0.01 (0.037) -0.12 (0.115)
Section modulus narrow neck 0.66 (0.020) 0.36 (0.176) 0.37 (0.031) 0.19 (0.171)
Buckling ratio narrow neck -0.29 (0.050) -0.43 (0.172) -0.27 (0.042) -0.38 (0.142)
Height -0.07 (0.035) -0.21 (0.131) -0.19 (0.035) -0.25 (0.108)
Fat mass index -0.35 (0.030) -0.06 (0.189) -0.32 (0.032) -0.16 (0.169)
Lean mass index -0.41 (0.029) -0.09 (0.189) -0.41 (0.037) -0.33 (0.154)
  Data are estimates (SE)
 *      Model 0 Adjustment for Sex, Age, Inbreeding coefficient
**     Model 1 Adjustment for Sex, Age, Inbreeding coefficient, height, fat mass index, lean mass index and bone active medication (see text)
 *** Adjustment for Sex and Age
Narrow-neck mechanosensitivity index Shaft mechanosensitivity index
Heritabilities
Shaft mechanosensitivity indexNarrow-neck mechanosensitivity index
Trait correlations***
women had higher head/skull BMD than men (mean 2.07 SD 0.30 versus mean 
1.96 SD 0.26  g/cm2 p<0.00001). In males, there is no difference of mean age 
across tertiles while in women we see that mechanosensitivity decreases with age. 
In general height, weight and BMI are lower with increasing mechanosensitivity 
while BMD is higher at increasing mechanosensitivity. The latter relationship is 
especially evident when looking at BMD Z-scores.  In concordance, buckling ratios 
(indices of bone instability) are lower with increasing mechanosensitivity.     
Table 7B shows the same analysis across tertiles of femoral shaft mechanosensi-
tivity.  In both genders mean age is higher at increasing mechanosensitivity values 
while height, weight, BMI and BMD values decrease with increasing mechano-
sensitivity at the shaft. In contrast, BMD Z-scores do increase and buckling ratios 
(bone stability) are lower with increasing mechanosensitivity (signifi cantly only in 
males).     
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DISCUSSION
To our knowledge this is the fi rst study to make such a comprehensive dissec-
tion of the DXA-based osteoporosis phenotype. We have found that the heritabil-
ity across skeletal sites is highest at the head/skull (h2 ~ 80%), and decreases as 
it departs progressively from the axial skeleton to the appendicular skeleton (h2 
decreasing ~ from 70 to 26%). Consistently, genetic correlations of BMD across 
sites were high and also decreased with decreasing vicinity of the measurement 
sites (rho decreased from 1.00 to 0.50). BMD measurements at the femoral neck 
and total body observed signifi cant genetic correlation with height (rho ~ 0.20) and 
lean mass index (rho ~ 0.30) while lumbar spine BMD did not. The hip structural 
analysis showed that the parameters with highest heritability estimates were those 
of size and dimension (h2 ranging ~ from 48 to 26%), followed by factors related 
to cortical thickness (h2  ~ 40%), with the measures of bone strength showing the 
lowest yet signifi cant heritability estimates (h2  ~ 25%). BMD showed high genetic 
correlations with all the geometry parameters, being highest with cortical factors 
(rho between 0.88 and 1.00), followed by strength factors (rho between 0.40 and 
0.67) and least and inverse with size and dimension factors (rho between -0.25 and 
-0.45). The genetic correlation between size geometric parameters and body height 
ranged from 0.30 (hip axis length) to 0.75 (lumbar spine area). Mechanosensitivity 
indices determined at the femoral neck and shaft were found to be signifi cantly 
heritable (~ 35 and 46% respectively) with no signifi cant genetic correlation be-
tween them. Both were genetically correlated (rho ~ 0.40) with the index of bone 
instability (buckling ratio) of the femoral neck, suggesting this could be one of the 
properties explaining how susceptibility to fragility fracture at older age might be 
heritable.  
Why are Heritabilities Different at Skeletal Sites?
The strong differences in heritability estimates observed across the different 
BMD sites of measurement (Figure 1), are in line with the hypothesis that the 
genetic control of bone mass and morphology, even within a given bone, is highly 
site-specifi c (28). Considering the fact that head, spine and limbs arise from distinct 
embryological origins (29), the observed genetic correlations could probably be 
refl ecting differential genetic regulation across skeletal sites, but most probably, 
differences in heritability are a consequence of differential adaptation to different 
types of locomotive strains (environmental infl uences). In contrast to the previ-
ous suggestion that the use of BMD measured at multiple sites does not provide 
additional information for the clinic since they are highly correlated (30), we have 
shown that for genetic studies, multiple site measurements do refl ect different 
genetic backgrounds.
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What Properties of  BMD Refl ect Bone Fragility and Which Ones Are Heritable?
Equivalent BMD values may concur with different underlying structural 
confi gurations. For this reason, we have focused further on hip bone geometry 
parameters, which arise as interesting traits for genetic studies considering their 
varying biomechanical nature and that they are heritable (Figure 2). There use 
though, requires some understanding of bioengineering. BMD can decrease due to 
a reduction in mineralization, a reduction on bone mass and due to an increase in 
bone volume. Using DXA there is no way to distinguish between changes in bone 
mineralization and mass, yet osteoporosis by defi nition is a disorder of structure 
and not material. Some rare alterations in mineralization are heritable (i.e. heredi-
tary rickets or osteomalacia), predispose to fracture, but are not osteoporosis.  This 
way, osteoporosis and low BMD are mainly the result of a decrease in bone mass 
and/or an increase in bone volume, phenomena which have opposing effects on 
bone strength and consequently on the risk of fracture. That is, if two bones have 
equal diameters the one with less mass is weaker. In contrast, two bones with 
equal mass, the one with greater diameter is stronger but less dense. This way, 
bone expansion can improve bone strength and compensate for net bone loss. Yet, 
thinning of cortices with consequent expanding diameters will also progress with 
aging towards bone instability making bones prone to buckle and fracture. This 
gradual process towards instability with aging would also explain why fractures 
tend to occur at old age.    
Section modulus (index of bending strength) has lower heritability than the 
other geometrical parameters, a fi nding which is in line with the concept that bone 
strength is the consequence of dynamic and adaptative geometrical confi gurations 
which preserve bone strength through life. In addition, the buckling ratio (index 
of cortical instability) has a similar heritability (h2 ~ 40%) and a high genetic cor-
relation (rho ~ 0.94) with BMD measured at the same region, probably refl ecting 
a property (bone instability) included in the BMD measurement which predicts 
fracture and is heritable. 
Nevertheless, there are properties underlying the BMD measurement which 
may be heritable but may not infl uence the process towards bone fragility directly. 
The adjustments for and the analyses of genetic correlations we have done with 
body height, fat mass and lean mass indices provided some insight into interme-
diate pathways which can infl uence the heritabilities of our bone traits. In our 
variance component analysis we observed that the additive genetic component of 
BMD measurements decreased after adjustment for covariates (including height 
and lean mass index), suggesting possible common genetic factors. Genetic correla-
tions also suggested that most BMD measurements of the appendicular skeleton 
are to some extent infl uenced by genes acting infl uencing size (body height). This 
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is illustrated when the heritability of BMD measurements at the traditional femoral 
neck region (h2 ~ 60%) is compared to that observed in the narrow-neck (h2 
~ 40%). The standard BMD measurement of the femoral neck has greater bone 
area and comparatively higher heritability. However, it also has signifi cant genetic 
correlation with body height (rho ~ 0.20) which lacks in the narrow-neck BMD. 
These fi ndings suggest that a considerable proportion of the high heritability in 
BMD measurements could be explained by skeletal size. Similarly, we observed that 
lean mass is also signifi cantly correlated to BMD measurements at appendicular 
sites (rho between ~ 0.30 and 0.40), suggesting that genes related to muscle mass 
may indirectly be infl uencing the heritability of BMD. 
The concept of  mechanosensitivity
If we accept that bone strength is adaptative in response to the demands on 
skeletal loading (stress and strains), even in the presence of external and internal 
(hormonal) environmental regulation, the occurrence of weaker or stronger bones 
in presence of a given skeletal load would be refl ecting the genetically-determined 
mechanosensitivity of an individual. This is in essence, the degree of bone sensi-
tivity to mechanical stimuli (skeletal load) and has been proposed as a potential 
osteoporosis phenotype (31). The crude mechanosensitivity indices of the femoral 
neck and shaft proposed in this manuscript not only showed to be highly heritable 
(~40%) but were consistent with the fragility concept. Both indices had signifi cant 
genetic correlation with buckling ratios (index of bone instability) and as shown in 
the analyses by mechanosensitivity tertiles, decreased mechanosensitivity resulted 
in increased bone instability (buckling ratios) and lower BMD Z-scores. Mean 
BMD levels appear to decrease with higher mechanosensitivity of the shaft, but this 
is an artifact produced by the difference in mean age across tertiles. This bias is a 
result of the secular trend in height (older individuals are signifi cantly shorter, data 
not shown), which is part of the equation of the shaft mechanosensitivity index. 
Skull/head BMD useful in genetic studies of  osteoporosis?  
We have shown that head/skull BMD is the measurement with the highest heri-
tability and the lowest genetic correlation with BMD measurements at other skeletal 
sites. This is understandable considering that the skull is the skeletal site receiving 
the lowest strains (absence of mechanical loading) and thus less environmental in-
fl uences. It has been shown that the skull is responsive to low strains (32) and with 
greater sensitivity than in other skeletal sites in order to be strong enough to exert its 
protective function on the brain (33). Our study did not only show that head/skull 
BMD was genetically correlated to the narrow neck mechanosensitivity index but 
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also, head/skull BMD increased with mechanosensitivity. Further, in contrast to 
the other BMD measurements, head/skull BMD is higher in women than in men, 
which is in concordance with the observation that mechanosensitivity is also higher 
in women than in men. A possible explanation for this gender differences is that 
higher mechanosensitivity in women is a compensatory response to the estrogen-
mediated restrain on bone apposition which results in less biomechanical adapta-
tion (34,35). Alternatively, mechanosensitivity in women could be higher due to less 
strain (bodyweight and/or lean mass) over the skeleton as compared to men. In line 
with these hypotheses we observed that narrow-neck mechanosensitivity decreased 
with aging only in women. In addition, it is important to note that monogenic 
disorders with abnormal regulation of bone formation, such as sclerosteosis and 
van Buchem’s disease (36), have phenotypes which compromise the skull as well as 
other skeletal sites like clavicles, ribs, and diaphysis of the long bones. Considering 
this and our present fi ndings, more attention should be directed to the genetics of 
head/skull BMD where further insight into the pathophysiology of osteoporosis 
may be found. 
There are some limitations in our study. We have presented combined estimates 
for men and women, which is not an ideal analytical setting even after adjustment 
for gender differences. We acknowledge that in addition to differences in bone 
size, hormonal differences after menopause play a center role in the determination 
of bone phenotypes.  We have also done gender- and age-stratifi ed determination 
of trait heritabilities and correlations, but confi dence limits in our gender stratifi ed 
analysis became wider and always overlapped. In view of contradictory evidence for 
gender-specifi c effects (37), our future work will be focused on addressing gender-
specifi c effects over BMD, bone geometry and body composition.
Another issue to consider is the isolated nature of our population, which may 
compromise the extrapolation of our phenotypes to other populations, but baseline 
characteristics of our study population do not characterize a very distinct or special 
Caucasian population. One aspect in which our population differs is inbreeding, 
therefore, we have adjusted all our estimates for inbreeding coeffi cients. In ad-
dition since participants of our study were not ascertained through individuals 
with extreme osteoporosis phenotypes, inferences about the relevance of genetic 
factors can be made at the population level. Similarly, as compared to twin studies 
heritability estimates of our population are less prone to be infl uenced by shared 
environment given the wider spectrum of familial relationships (38,39). 
Previous studies have also used bivariate analysis as a tool to determine genetic 
correlations of BMD measurements across skeletal sites in different populations 
(40),  between BMD measurements and other osteoporosis traits including quan-
titative ultrasound (QUS) measurements (41) and also between BMD and the oc-
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currence of fracture (42). As shown in the study by Livshits et al. and in our study, 
the degree of genetic correlation is high across skeletal sites (ranging between 0.50 
to 0.80). Yet, the study by Knapp et al. suggests that the low genetic correlation 
between BMD measured by DXA and the QUS measurements could be explained 
by differences in bone composition (cortical versus trabecular), types which are not 
adequately discriminated by the DXA measurement. Even though our fi ndings on 
genetic correlations could suggest several degrees of pleiotropy and independence 
across traits, it is important to note that genetic correlation may also be caused by 
close linkage and linkage disequilibrium of genes with similar functions. Finally, as 
shown by Deng et al. there is low genetic correlation between fracture susceptibility 
and variations in BMD measurements, fi nding which supports our concept that 
bone geometry should be preferred over BMD in genetic studies.
In summary, we have made a comprehensive evaluation of DXA-based traits 
with implications for genetic studies of osteoporosis. Our analyses show different 
heritabilities through the skeleton, with higher heritabilities in the axial segment 
with progressively lower estimates towards the appendicular segment. Measurement 
of bone geometry parameters of the hip explain underlying biomechanical proper-
ties of BMD and showed diverse degrees of heritability. Genetic correlations of the 
studied traits provide further understanding of the traits, the intermediate pathways 
and their underlying genetic factors. Mechanosensitivity indices were shown to be 
heritable traits genetically independent of size and genetically correlated to bone 
instability and head/skull BMD which might be regarded as a possible indicator 
of mechanosensitivity. We propose that susceptibility to fragility fracture at older 
age is heritable partly because they refl ect genetically-determined differences in 
mechanosensitivity. Rather than using isolated BMD measurements, future genetic 
studies should target bone geometrical parameters and indices of mechanosensitiv-
ity. 
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ABSTRACT
Studies of the role of variants of the IGF-I gene in the regulation of bone mineral 
density (BMD) have yielded confl icting results. We examined the role of a micro-
satellite repeat polymorphism in one of the promoter regions of the IGF-I gene in 
relation to femoral BMD in elderly women and men from the Rotterdam Study. We 
studied 5648 and 4134 individuals at baseline and follow-up (approximately 2 years 
later), respectively. Femoral BMD measurements were performed using dual energy 
X-ray absorptiometry (DXA). In women, baseline BMD levels were on average 
0.02 g/cm2 lower (95%CI for difference -0.03, -0.00 g/cm2) without the 192-bp 
allele as compared with the homozygotes for the allele (p=0.03). The mean rate 
of BMD change from baseline to follow-up was -6.9 mg/cm2 (95%CI -10.8, -3.0), 
-4.5 mg/cm2 (95%CI -6.4, -2.5) and -2.3 mg/cm2 (95%CI -4.2, 0.3) in non-carriers, 
heterozygotes and homozygotes for the 192-bp allele, respectively (p trend=0.03). 
Adjustment for age and body mass index did not essentially change this relation. 
No such effects were observed in men. Our fi ndings suggest that this promoter 
polymorphism or another functional polymorphism in linkage disequilibrium may 
be a genetic determinant of BMD levels and rate of bone loss in postmenopausal 
women.
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INTRODUCTION
Osteoporosis has been defi ned as a systemic skeletal disease characterized by 
low bone mineral density (BMD) and microarchitectural deterioration of bone tis-
sue, with a consequent increase in bone fragility and susceptibility to fracture (1). 
From the genetic perspective, BMD is a complex trait determined by the peak bone 
mass achieved during adulthood and the subsequent rate of bone loss with age. 
Heritability estimates for BMD have been reported to be high, ranging between 
50-80% (2, 3). The contribution of genetic factors to the regulation of bone loss 
has been much less well studied and is yet confl icting (4). While Christian et al. 
(5) found no evidence of a genetic effect on radial (cortical) bone in aging male 
twins, Kelly et al. (6) reported a signifi cant genetic effect on changes in axial bone 
density in adult twins. It has become clear that there is not one major single gene 
responsible for the risk of osteoporosis (3). Rather, an individual’s susceptibility to 
develop osteoporosis is determined as in most common diseases, by several com-
mon gene variants with modest but real genetic effects (7). The regulation of bone 
mass depends on several factors, including the balance between the amount of 
bone resorbed by osteoclasts and the amount of bone formed by osteoblasts. Genes 
involved in the mechanisms that control the differentiation and the function of 
these cells may be determinants of BMD and osteoporosis. One approach to iden-
tify individual genetic factors is the so-called candidate gene approach. So far, several 
genes have been investigated including the VDR, COL1α1, IL-6, and TGF-β genes 
among others. Of these, only the COL1α1 gene has been found associated to BMD 
and fracture risk in a consistent way as illustrated by two meta-analyses (8, 9).  The 
insulin-like growth factor I (IGF-I) gene has also been considered a candidate gene 
based on its important role in bone metabolism.
IGF-I is a ubiquitous polypeptide that stimulates osteoblast activity, subsequently 
leading to bone matrix formation and inhibition of bone collagen degradation (10). 
IGF-I also stimulates osteoclast formation and action (11).  Plasma levels of IGF-I 
decrease with age both in males and females. Reduced plasma levels have been 
associated with low BMD (12-14), osteoporosis (15) and fractures (16), although it is 
not known if these systemic levels are representative of local skeletal concentrations 
(17-19). 
Several polymorphisms (20-22) have been identifi ed in the IGF-I gene (map 
location 12q22-q24.1) and in the 5’ fl anking promoter region extending up to 1630 
bp upstream of  the transcription initiation site of exon 1 (23-26). On position 
–684 of this promoter region lies a (CA)n microsatellite repeat polymorphism (27). 
Earlier, we have found that birth weight (28, 29), body height and serum levels 
of IGF-I after age 55 years (30) increased with the number of 192-bp alleles in the 
genotype for this polymorphism. Further, subjects without this “wild-type” allele 
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had increased risk for type 2 diabetes and myocardial infarction (30). 
Results of genetic studies regarding the relation of this polymorphism to os-
teoporosis and BMD have been controversial. Rosen et al. (31) reported that the 
192-bp/192-bp genotype was more prevalent in 25 Caucasian men with Idiopathic 
Osteoporosis than in controls. In the same study, healthy men with this genotype 
tended (p=0.15) to have lower BMD T scores. In 314 healthy postmenopausal 
Japanese women, Miyao et al. (32) found no association between BMD and the 
IGF-I promoter genotypes.  In contrast, Kim et al. (33) found that a genotype based 
on one of the major alleles of the polymorphism was related to spinal and femoral 
BMD in 300 postmenopausal Korean women. In a study in 542 female sib pairs 
and 363 pre-menopausal women, Takacs et al. (34) found no evidence for a relation 
between femoral or spinal BMD and the IGF-I gene locus or the (CA)n microsatel-
lite repeat polymorphism.
Given these inconsistent reports and our previous fi ndings on the relation of 
this IGF-I gene promoter polymorphism to serum IGF-I levels, height, type 2 dia-
betes mellitus (30) and birth weight (28), we examined the role of the 192-bp allele 
in relation to bone mineral density and rate of bone loss in a large population-based 
cohort.  
EXPERIMENTAL SUBJECTS
Subjects were derived from the Rotterdam Study, a single-center prospective 
population-based study of determinants of chronic disabling diseases in the elderly 
(age 55 years and over). Written informed consent was obtained from every partici-
pant. The design of the study has been described previously (35). In an attempt to 
evaluate all 7983 participants from the Rotterdam study, 7012 (87.9%) subjects were 
genotyped for the polymorphism (27) in the promoter region of the human IGF-I 
gene. From the 971 individuals not genotyped, 848 had no blood sample to isolate 
DNA for the analysis and in the remaining 123 we failed to obtain a genotype after 
multiple attempts. 
MATERIALS & METHODS
The analysis was performed in two phases. In the fi rst phase (baseline), all 
individuals with complete BMD and antropometric measurements (n=5648), were 
used for a cross sectional analysis of femoral BMD levels. In the second phase (fol-
low-up), subjects that had complete BMD measurements both at baseline and on 
the follow-up visit (n=4134), were used to study the yearly rate of change in BMD. 
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Measurements
Age was calculated for each individual from the date of birth and the date of 
BMD bone scan. Three 10-year strata were defi ned starting at age 55 years. Height 
(cm) and weight (kg) were measured in standing position wearing indoor clothes 
and without shoes. Body mass index or BMI (kg/m2), was calculated as weight 
divided by the square of height. Bone mineral density measurements (g/cm2) of the 
proximal femur were performed by dual energy X-ray absorptiometry (DXA) using 
a Lunar DPX-L densitometer (Lunar Radiation Corporation, Madison, WI, USA). 
Methods, quality assurance, accuracy and precision issues of the DXA measure-
ments have been described previously (36). 
Approximately two years (mean 23.8 months, SD 7.0) after the baseline scan, 
follow-up BMD measurements were performed using identical procedures. The 
rate of change in BMD (mg/cm2 per year) was calculated as the difference between 
baseline and follow-up BMD divided by the time (in years) elapsed between mea-
surements (and multiplied by a factor of 1000 for scale convenience). 
Genotyping
 Polymerase chain reaction (PCR) was performed using oligonucleotide primers 
designed to amplify the polymorphic (CA)n repeat 1 kb upstream of the human 
IGF-I gene. The reaction was carried out in a fi nal volume of 7.5 µl containing 25 
ng of genomic DNA obtained from peripheral white blood cells and extracted by 
standard proteinase K digestion and salting-out procedure (37), 5 pmol forward 
primer (5’-ACCACTCTGGGAGAAGGGTA-3’), 0.5 pmol reverse primer (5’-
GCTAGCCAGCTGGTGTTATT-3’), 25 mM dNTP, 2.2 mM MgCl2, 0.01% W1 
(Invitrogen), and 0.4 U Taq DNA Polymerase (Invitrogen). PCR was performed 
in 384 well plates (94°C 5 min; 35 PCR cycles of 30 sec at 94°C, 30 sec on 55°C, 
and 30 sec on 72°C; 72°C 7 min; 4°C hold). Forward primers were labeled with 
FAM, HEX, or NED to determine the size of PCR products by fragment analysis 
on an automated sequencing apparatus (ABI 377 Genescan Software V.3.1, 6.25% 
longranger gel, fi lter set D, predefi ned categories according to size and labeling 
of peak height between 100 and 2000 bp, each lane containing three samples). 
The size of the PCR products was determined in comparison with internal ROX 
500-size standard (Perkin Elmer). The two highest peaks were labeled (binned) 
with Genotyper Software V.2.5. The automatic binning was reviewed by two in-
dependent observers in separate fi les from the same gel, which were subsequently 
cross-checked. Discordant binned samples were genotyped again. From sequence 
analysis it is known that the allele with length 192-bp (“wild-type” in our popula-
tion) corresponds to 19 CA-repeats (CA(19)). Based on the relationship between 
the polymorphism and serum IGF-I levels, genotypes were assembled from two 
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allele categories as described by Vaessen et al. (30): the 192-bp allele and all other 
alleles pooled as “non-192-bp” alleles. This resulted in three groups of individuals: 
homozygotes for the 192-bp allele, heterozygotes for the 192-bp allele and non-car-
riers of the 192-bp allele.
Statistical analysis  
Genotype and allele frequencies of the IGF-I promoter polymorphism were 
determined, and the genotype frequencies were tested for Hardy-Weinberg equi-
librium proportions using the ARLEQUIN-package (38). Analyses specifying risk 
genotypes with other alleles showed no signifi cant associations, but were consistent 
with the 192-bp allele approach used.
In both the baseline and follow-up analyses, means and standard deviations 
were computed for all measurements, and compared with those of the same gender 
in the reference population using student T-tests. Subsequently, stratifi ed analyses 
by gender (and age groups) were performed. Multiple linear regression was used to 
model the relation with BMD and rate of BMD change adjusted for age, BMI, and 
baseline BMD (in the follow-up analysis). Possible interactions between genotypes 
and covariates were explored in plots and tested in the linear regression models 
including product terms. Trend analysis assuming an underlying additive genetic 
model (39) was done for the presence of zero, one or two copies of the associated 
allele, incorporating the genotype variable as a continuous term in the multiple 
linear regression models. Finally, model assumptions were verifi ed and model re-
siduals were checked for goodness-of-fi t. If not stated otherwise, all analyses were 
performed using the SPSS-package V.10 (SPSS Inc. Chicago, IL).  
RESULTS 
Allele and 192-bp genotype frequencies are shown in Table 1. No signifi cant de-
viations of the frequencies were observed among the baseline and follow-up groups. 
All genotype frequencies were in Hardy-Weinberg equilibrium proportions. In men 
and women, allele frequencies were stable over age categories (data not shown). 
Table 2 compares the characteristics of women and men of the two analyti-
cal phases with all women and men of the Rotterdam study (reference population 
n=7983). Overall, women showed lower BMD at baseline and a higher rate of BMD 
loss than men. The BMD levels of the group used for the baseline analysis were 
slightly lower than those observed in the group used for the follow-up analysis. 
The use of concurrent estrogen replacement therapy (HRT) or bone modulators in 
women is very low. 
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When analyzing cross-sectional baseline BMD measurements in females, the 
IGF-I polymorphism accounted for 0.2% of the variance (R2) in BMD levels. Mean 
femoral neck BMD adjusted for age and BMI (Figure 1) increased with the number 
of 192-bp alleles in the genotypes ( p for trend =0.02). BMD was on average 0.02 g/
cm2 (95%CI for difference –0.03, -0.00 g/cm2) lower in women without the 192-bp 
allele as compared to the homozygotes for the allele (p=0.03). This effect was also 
consistent at the other femoral sites (p for trend=0.01 and <0.01 for the trochanter 
and Ward’s triangle respectively). 
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No Allele
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Homozygous
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162 585 558 158 531 537 80 340 314
Figure 1.  Baseline mean* 
BMD of the femoral neck 
within 192-bp genotype 
groups in women *Data 
adjusted for age and BMI 
Figure 2.  Baseline mean* BMD of the femoral neck within 192-bp 
genotype groups and age categories in women. *Data adjusted for age 
and BMI  
When analyzing in age strata (Figure 2), this effect was only observed in women 
older than age 65 years: the differences between homozygous women and non-
carriers of the 192-bp allele was -0.02 g/cm2 (95%CI -0.04, -0.00 g/cm2) and -0.04 
g/cm2 (95%CI -0.07, 0.01 g/cm2), for the 65-75 years and 75 years-and-over age 
categories, respectively.  
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The interaction between IGF-I genotype and age was borderline signifi cant (p 
for interaction=0.06). There was no signifi cant interaction of IGF-I genotype and 
BMI (data not shown).  No such dose effect on baseline BMD was observed in 
males overall (Figure 3) or within age groups (data not shown). 
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Figure 3.  Baseline mean* 
BMD of the femoral neck 
within 192-bp genotype 
groups in men *Data ad-
justed for age and BMI 
At follow-up, the rate of change in mean BMD observed in the period between 
the baseline and follow-up measurements was analyzed. In women, the IGF-I 
promoter genotype accounted for 0.1% of the variance (R2) in BMD change. The 
mean rate of BMD change per year showed a signifi cant inverse trend (p=0.03) ac-
cording to the number of 192-bp alleles in the genotype, -6.9 mg/cm2 (95%CI  -10.8, 
-3.0) in women carrying zero, -4.5 mg/cm2 (95%CI  -6.4, -2.5) in women carrying 
one (heterozygotes) and -2.3 mg/cm2 (95%CI  -4.2, 0.3) in women carrying two 
copies (homozygotes) of the 192-bp allele, respectively (Figure 4). Also in women, 
this trend was consistent through all age strata (data not shown). Adjustment for 
baseline BMD did not essentially modify the results (data not shown). In males, 
no such trend effect was observed in the follow-up analysis, overall or within age 
groups (data not shown). 
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Figure 4.  Mean* femoral 
neck BMD change of the 
femoral neck within 192-bp 
genotype groups in women 
*Data adjusted for age, 
BMI and baseline BMD 
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DISCUSSION
This population based study in elderly individuals, showed that in women, 
the absence of the wild type (192-bp) allele in a (CA)n repeat polymorphism in the 
promoter region of the IGF-I gene is associated with lower BMD levels and higher 
rates of bone loss at the different femoral sites. No associations were observed in 
men at any femoral site of BMD measurement. 
Our fi ndings of decreased BMD levels and faster rate of bone loss in the ab-
sence of the 192-bp allele are in agreement with the association reported earlier, 
where the absence of the 192-bp allele was associated with lower total IGF-I serum 
levels (30). Results from that study may be extrapolated to our present study, since 
it was performed in a random subset of our current study population. Further, we 
have recently reported that  this promoter polymorphism infl uences the age-related 
decline in IGF-I levels (40).  
Strengths of our study design include its population-based nature, ethnic 
homogeneity, large sample size, gender-stratifi ed analysis and defi ned age range 
(elderly/postmenopausal). BMD characteristics in this study are similar to those 
reported previously in our population (36). Since individuals were selected on the 
basis of having complete BMD measurements either at baseline or at follow-up, 
we recognize the possibility of selection bias. Individuals whose BMD was not 
measured in the Rotterdam Study, were older and probably had higher morbid-
ity, and, if measured, would presumably have had lower BMD than those in the 
study. However, there is no evidence for genotype selection in our population as 
allele frequencies were virtually the same in the various study groups and in the 
genotypic reference population, and since they remained stable with age. Similarly, 
the bias arising from the individuals not genotyped for the polymorphism seems to 
be random from the genetic perspective, since our allele frequencies are similar to 
those reported in other Caucasian populations (27, 34). 
The short follow-up time (approximately 2 years) used to evaluate the rate of 
BMD change limits the power to assess differences among individuals. However, 
the 192-bp allele dose effect of our follow-up analysis is in agreement with our 
cross-sectional analysis in the sense that the presence of the 192-bp allele relates to 
higher BMD levels and lower rates of bone loss. 
The gender specifi city of our fi ndings is in concordance with the association 
between IGF-I levels and BMD reported earlier by Barrett-Connor et al. (14). It is 
not explained by differential survival between sexes in our population, since geno-
type and allele frequency distributions were similar in men and women in different 
age categories. Most likely, our fi ndings seem to identify differential responses of 
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the genotypes to the postmenopausal bone loss caused by estrogen defi ciency (41). 
Since differences in estrogen levels infl uence the IGF-I regulatory axis (42-45), the 
hypo-estrogenic state infl icted by the menopausal process in women, may be (in the 
absence of concurrent osteoporotic treatment i.e. hormone replacement therapy) 
modulating directly the observed IGF-I genotype effect on the rate of bone loss 
and BMD level. Anyway, it is unlikely that estrogen defi ciency explains most of the 
decline in IGF-I levels with age, since IGF-I levels begin to fall in both genders 
long before the age of menopause (14). Alternatively, genetic determined variations 
in body composition with aging could also be indirectly related to the observed 
genotype effect. Although the genotype-dependent differential rate of bone loss is 
observed from age 55 years, the genotype effect on BMD levels is only evident after 
age 65 years. This may refl ect the time it takes for these genotype effects (during 
post-menopausal estrogen defi ciency) to become detectable on BMD differences. 
Evaluation of possible biologic interactions of the IGF-I gene with genes and pro-
teins related to estrogen metabolism might provide further insight.
Not observing the 192-bp allele dose effect in males may be attributed to 
various mechanisms. In elderly men, estrogen levels are higher as compared to 
postmenopausal women (46), which might also affect the rate of bone loss, making 
age-related increases in bone turnover less pronounced in men (47).  Similarly, from 
the perspective of bone size and architecture (48), both genders have an age-related 
decline in bone material properties, but men exhibit greater compensating bone-
remodeling patterns (subperiosteal expansion and bone apposition at the femoral 
diaphysis). These differences in bone geometry are refl ected in BMD measurements, 
since DXA adjusts for the scanned area but does not correct for the fact that wider 
bones are also thicker, resulting in greater BMD even if the actual density of bone 
tissue is not different (49). This way, our analysis could not discriminate changes 
in BMD due to variations in bone mineral from those caused by changes in bone 
geometry.  Interestingly, Looker et al. postulated earlier that IGF-I could  be related 
to the  gender differences evidenced in bone geometry with aging (48).
 
Previous studies have either failed to identify associations between this polymor-
phism and BMD, or are confl icting. There are differences in study design that may 
explain this. Takacs et al. (34) included in their association analysis a population of 
pre-menopausal women, as compared to the post-menopausal population studied 
by us. Furthermore, the failure to identify linkage of this polymorphism to BMD 
in their sib-pair analysis may be explained by lack of power given the complexity of 
the trait and the relatively small effect size of the IGF-I polymorphism. Although 
Miyao et al. (32) and Kim et al. (33)  included postmenopausal women in their 
study, we face caveats to compare our fi ndings to theirs. Differences exist between 
the Dutch and both Japanese and Korean populations in allele and genotype fre-
quencies, in linkage disequilibrium (LD) and in racial phenotypes. In contrast to 
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our fi ndings, Rosen et al. (31) associated the presence of the 192-bp allele to lower 
total IGF-I serum levels and to male osteoporosis. Male patients with Idiopathic 
Osteoporosis represent a very distinct phenotypic trait compared to the estrogen-
defi cient osteopenia infl icted by menopause (41), which together with differences 
in power, might contribute to apparent contradictory results. 
Given the population-based approach of our study, we cannot distinguish if 
this polymorphism itself is involved in the regulation of IGF-I expression or merely 
fl ags another polymorphism in the promoter region functionally involved in IGF-I 
expression. If the latter is true, this may be an explanation for inconsistent fi nd-
ings in the association studies of this polymorphism with BMD (31-34) and other 
outcomes (50), since LD can differ between populations. 
In summary, we found in postmenopausal women a small, but signifi cant effect 
between an IGF-I gene promoter polymorphism, and both BMD and (short term) 
rates of bone loss.  The presence of the wild type (192-bp) allele in the genotype was 
associated with higher BMD and lower rate of bone loss. This genotypic effect on 
BMD in women may therefore suggest a relation between IGF-I activity and bone 
loss due to estrogen defi ciency. In men, no effect was observed probably due to 
gender differences in the age-related hormonal changes affecting bone turnover 
rates, bone size and architecture. This population-based study provides substantial 
evidence to implicate genetic determined levels of IGF-I to bone mineral density in 
Caucasian postmenopausal women.   
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ABSTRACT
Introduction: Previously, we found a CA-repeat promoter polymorphism in the 
IGF-I gene associated with IGF-I levels and BMD in post-menopausal women, 
but the relationship with fractures is unclear. In this large population-based study 
of elderly men and women we examined the association between this IGF-I pro-
moter polymorphism with parameters of bone geometry and the occurrence of 
fractures.
Material and methods: Within the Rotterdam Study, a prospective population-
based cohort, the IGF-I polymorphism was analyzed in relation to incident non-
vertebral fractures in 2799 men and 4212 women followed on average for 8.6 years. 
Further, we estimated structural parameters of hip bone geometry indirectly from 
DXA outputs of the femoral neck in 2372 men and 3114 women. We studied neck 
width, cortical thickness, and the cortical buckling ratio and the section modulus as indexes of 
bone stability and bending strength. 
Results:  Women heterozygotes and non-carriers of the allele had respectively 1.2 
(95%CI 1.0-1.5) and 1.5 (95%CI 1.1-2.0) increased risk of having a fragility fracture 
at older age as compared to homozygotes for the 192-bp allele (p trend=0.0007). 
In men fracture risk was not infl uenced by the polymorphism. As compared to 
homozygotes for the 192-bp allele, non-carrier males had ~1% narrower femoral 
necks and 2.2% lower section moduli (p-trend<0.05). Non-carrier females had 
1.7% thinner cortices, and 1.6% higher buckling ratios (p-trend<0.05) but no sig-
nifi cant differences in femoral neck widths and section moduli. In women with 
low BMI, genotype differences in bone strength (section modulus) and fracture 
risk were accentuated (p-interaction=0.05). The genotype dependent differences 
in hip bone geometry did not fully explain the genotype dependent differences in 
fracture risk.
Conclusions: The CA-repeat promoter polymorphism in the IGF-I gene is associ-
ated with the risk for fragility fracture at old age in women and with bone structure 
in both genders.
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INTRODUCTION
The ultimate clinical outcome of osteoporosis is fracture; its occurrence is 
mainly determined by the strength of bone and the risk of falling. While strength 
depends on bone geometry and bone material quality, the risk of falling determines 
the type of fall, the force of impact and the likelihood of fracture (1,2). In addi-
tion, the specifi c site of fracture follows specifi c epidemiological patterns which are 
infl uenced by different environmental factors (2). 
Family history of osteoporotic fracture is a risk factor for future fractures (3), 
indeed heritability of risk has been estimated to be between 25 and 35% (4,5). For 
these reasons, the search for genetic determinants of fracture risk has gained evolv-
ing importance, especially after the completion of the Human Genome Project 
(6-8). In the general population, an individual’s genetic susceptibility for fracture 
has been found to be associated with several common gene variants that have mod-
est but real genetic effects (9,10). Examples are polymorphisms in the COL1α1 
(11,12), VDR (13) and ERα (14) genes, all of which have been associated with the 
risk of fracture. The insulin-like growth factor I (IGF-I) has been shown to have an 
important role in bone metabolism (15). Plasma levels of IGF-I decrease with age 
both in males and females and reduced levels have been associated with low BMD 
(16-18), osteoporosis (19) and fractures (20,21). Consequently, the IGF-I gene has 
been considered a strong candidate to explain part of the genetic susceptibility to 
osteoporotic fracture. 
A (CA)n microsatellite repeat polymorphism located in the 5’ promoter region 
of the IGF-I gene has been described previously (22-24).  Earlier, we have studied 
this polymorphism in relation to several traits and diseases in the Rotterdam study. 
Birth weight (25,26), body height and serum levels of IGF-I after age 55 years (27) 
have been shown to increase with the number of 192-bp alleles in the genotype for 
this polymorphism. With regard to osteoporosis we found a small, but signifi cant 
gender-specifi c effect: the presence of the wild-type (192-bp) allele in the genotype 
was associated with higher BMD and lower rate of BMD decline in postmenopausal 
women (28). This genotypic effect on BMD suggested a relation between IGF-I 
activity and BMD decline due to menopausal estrogen defi ciency. Not observing 
this effect in men could be explained by gender differences in age-related hormonal 
changes affecting bone turnover rates, bone size and geometry. 
Given our previous fi ndings on the relation of this IGF-I gene promoter 
polymorphism to BMD, we analyzed the polymorphism in relation to the risk of 
non-vertebral fracture in elderly men and women. Further, we studied several pa-
rameters of hip bone geometry, in relation to the risk of hip fracture and in relation 
to the IGF-I promoter polymorphism. 
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MATERIAL AND METHODS
Subjects
Individuals were derived from the Rotterdam Study (n=7983), a single-center 
prospective population-based study of determinants of chronic disabling diseases 
in the elderly (age 55 years and over). Written informed consent was obtained from 
every participant. The design and rationale of the study has been described earlier 
(29). As described previously (28), we have genotyped 87.9% of the participants 
(n=7012) for the polymorphism in the promoter region of the human IGF-I gene. 
Genotyping was not possible in the remaining participants due for technical reasons 
(1.5%) or the absence of blood samples for DNA isolation (10.6%). 
The analysis was performed in two phases. In the fi rst phase, we analyzed IGF-I 
promoter genotypes (n=7012) in relation to non-vertebral fracture follow-up data 
in all genotyped individuals with complete fracture follow-up information (n=1219 
individuals with at least one fracture and 5793 individuals without fracture). In the 
second phase, we examined at baseline all genotyped individuals with complete 
BMD and anthropometric measurements for a cross-sectional analysis of hip bone 
geometry and fracture (n=5506).
Genotyping
Polymerase chain reaction (PCR) using genomic DNA obtained from peripheral 
white blood cells was performed using oligonucleotide primers designed to amplify 
the polymorphic (CA)n repeat, located 1 kb upstream of the human IGF-I gene. 
Specifi c genotyping methods and quality control procedures have been described 
earlier (28). From sequence analysis it is known that the allele with length 192-bp 
(“wild-type” in our population) corresponds to 19 CA-repeats (CA(19)) (22). Based 
on the relationship between the polymorphism and serum IGF-I levels, genotypes 
were assembled from two allele categories as fi rst described by Vaessen et al. (27): 
the 192-bp allele and all-other alleles pooled as “non-192-bp” alleles. Individuals were 
classifi ed in three genotypes groups: homozygotes for the 192-bp allele, heterozy-
gotes for the 192-bp allele and non-carriers of the allele (non-192-bp homozygotes).
Fracture Follow-up 
Information on incident non-vertebral fractures was collected from baseline 
(1990-1993) until December 31st 2002, comprising an average follow-up period of 
8.6 (SD 3.4) years.  Fracture events were retrieved from computerized records of 
the general practitioners (GP) in the research area (covering 80% of the cohort). 
Research physicians regularly followed participant information in GP’s records 
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outside the research area and made an independent review and encoding of all 
reported events. Subsequently, a medical expert in the fi eld reviewed all coded 
events for fi nal classifi cation.  Additional information on hip fractures was gathered 
through the Dutch National Hospital Registration.  We studied the relationship 
of the polymorphism to “all types” of fracture. Subsequently, we considered “all 
fragility” fractures including hip, pelvic, proximal humerus and wrist fractures. 
Further, since wrist fractures occur at a considerable younger age with specifi c 
falling patterns (2),  we excluded them to study the group with fragility fractures 
occurring at old age (mean age > 75 years). We also independently analyzed groups 
with fractures occurring at the hip, pelvis, proximal humerus or wrist.  Finally, we 
studied groups with “other” non-vertebral fractures including fractures of the rib 
(n=59), sternum (n=9), hand (n=120), lower leg (n=63), ankle (n=55), metatarsus 
(n=55) and foot (n=58). Vertebral fractures were not considered in this study.
Measurements
Between 1990 and 1993, participants were invited to come to the research centre 
for a baseline clinical examination. Height (cm) and weight (kg) were measured in 
standing position wearing indoor clothes and without shoes. Body mass index or 
BMI (kg/m2), was calculated as weight divided by the square of height. Bone min-
eral density measurements (g/cm2) of the proximal femur were performed by dual 
energy X-ray absorptiometry (DXA) using a Lunar DPX-L densitometer (Lunar 
Radiation Corporation, Madison, WI, USA). Methods, quality assurance, accuracy 
and precision issues of the DXA measurements have been described previously 
(30).
Bone geometry computational method  
Parameters of structural geometry of the hip were calculated indirectly from 
conventional DXA outputs obtained from the femoral neck region of interest (ROI) 
and are illustrated in Figure 1. Geometry parameters can be estimated from the 
BMD and the bone outer diameter using models of the cross-section represented 
by the ROI (31). The average diameter of the femoral neck was obtained by dividing 
the bone area by the width of the region of interest (usually 1.5 cm). To assess the 
reliability of this approximation of bone geometry, we compared the femoral neck 
diameter obtained from this calculation with that measured with the DXA ruler 
tool as recently described by Duan et al. (32), in 30 scans randomly selected from 
all 5674 available DXA scans. Femoral neck diameter approximated from bone 
area had a single measured percent coeffi cient of variation of 10.6 (n=30) and 10.8 
(n=5674), as compared to 9.6 obtained when measured directly (n=30) with the 
DXA ruler tool. 
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We used BMD and femoral neck diameter to approximate femoral neck geometry 
parameters that are conventionally extracted directly from the mass distribution 
using hip structural analysis (33). The mathematical calculation and the underlying 
assumptions regarding the geometry and structure of bone have been reported 
earlier (32,34,35). In summary, the approximation method assumes that the bone 
within the femoral neck region has the confi guration of a uniform right circular 
cylinder (tube), with a proportion of cortical mass of 60% and an effective density 
of hydroxyapatite in fully mineralized bone tissue of ~1.05 g/cm3(31). As shown in 
Figure 1, since the specifi c parameters considered in the analysis are obtained from 
a computational algorithm, by defi nition they are not independent from each other. 
In addition to BMD, we considered the neck width (cm) and the estimated cortical 
thickness (mm), the section modulus (cm3) an index of bending strength related to the 
radial distribution of the bone mass (computed as the ratio of the cross-sectional 
moment of inertia CSMI to the outer radius of the cross-section), and the cortical 
buckling ratio (BR) an index of bone geometrical instability (computed as the ratio of 
the radius of the cross-section to the cortical thickness).  In engineering this insta-
bility threshold is reached when buckling ratios exceed a factor of ~10 (36). Both 
geometry estimates and genotypes were obtained in a total of 5506 individuals. 
FIGURE 1. Graphical correspondence and correlations of the hip bone 
geometry parameters. All Pearson’s correlations are signifi cant (p<0.00001). 
CSMI=cross-sectional moment of inertia
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Statistical Analysis
Genotype and allele frequencies of the IGF-I promoter polymorphism were 
determined, and the genotype frequencies were tested for Hardy-Weinberg equilib-
rium proportions using the GENEPOP-package (37).  
In both phases we stratifi ed the analyses by gender. For the analysis of fracture 
follow-up data we estimated incident rates overall and by genotype.  For the time-
to-event or fracture-free survival analysis we specifi ed age (in years) as the underly-
ing time variable instead of follow-up time to analyze the effect of chronological 
age on fracture. To do this we took into account delayed entry (left truncation) by 
using the counting process notation of S-PLUS V.6.0. We estimated cumulative 
probabilities of fracture events after age 55 years using the Kaplan-Meier method. 
Crude and adjusted hazard ratios were estimated using COX proportional-hazards 
models. The assumption of proportionality of hazards was verifi ed for all covari-
ates. Interactions between genotype and covariates were examined. In addition, the 
risk of fracture was analyzed in BMI strata defi ned by tertiles and by the following 
BMI defi nition: low (or underweight with BMI less than 20 kg/m2), normal (with 
BMI between 20 and 25 kg/m2) and high (or overweight including obesity with 
BMI greater than 25 kg/m2).  For the analysis of hip bone geometry parameters, 
multiple linear regression was used to compare adjusted means between individuals 
with and without hip fracture, and to model the relation of genotype with bone 
geometry and anthropometric variables. Bone geometry parameters were also 
studied through cross-sectional strata across age decades starting at age 55 years 
and pooling together all individuals older than age 75 years to preserve suffi cient 
power for the analysis. The infl uence of BMI on the relation was analyzed in strata 
as described previously for the risk of fracture. Adjustments were done for age, 
weight, and height. Trend analysis assuming an underlying additive genetic model 
(38) was done for the presence of zero, one or two copies of the associated al-
lele, incorporating the genotype variable as a continuous term in a multiple linear 
regression model. Finally, model assumptions were verifi ed and model residuals 
were checked for goodness-of-fi t. If not stated otherwise, analyses were performed 
using the SPSS-package V.11 (SPSS Inc. Chicago, IL).  
RESULTS 
Genotype frequencies of women and men in the bone geometry study (n=5506) 
were very similar to those observed in all the 7012 genotyped individuals of the 
Rotterdam Study (44% in homozygotes, 44% in heterozygotes and 12% in non-
carriers of the 192-bp allele) and were in Hardy-Weinberg equilibrium (HWE) 
proportions. 
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Table 1 compares baseline characteristics and fracture incident rates observed 
during the follow-up period in women and men included in the IGF-I genotype 
analysis (n=7012), to those observed in the reference population (n=7983). On 
average, individuals included in the IGF-I genotype analyses are approximately two 
years younger. All other characteristics did not show signifi cant differences, includ-
ing BMD levels and use of concurrent estrogen replacement therapy (HRT) or 
bone active agents in women.  IGF-I genotypes were available for more than 92% 
and 88% of men and women with fracture. Fracture incident rates in individuals 
with genotypes are not signifi cantly different from those observed in the reference 
population.
 
IGF-I Genotype and Fracture Risk
The infl uence of genotype on fracture rates is shown in Table 2. In women, non-
carriers of the 192-bp allele have approximately 1.2 times increased risk of “all-type” 
and “fragility fracture” as compared to homozygotes for the 192-bp allele. When 
pooling hip, pelvic and proximal humerus fractures together as “fragility fractures 
occurring at older age”, non-carrier women have 1.5 times increased risk as com-
pared to homozygous for the 192-bp allele. In Figure 2 the fracture-free survival 
analysis shows that this higher proportion of non-carrier women with “fragility 
fracture at older age” is consistent through age with a signifi cant allele-dose effect 
(p=0.007). 
FIGURE 2. Proportion of fragility (hip, pelvis and proximal humerus) 
fractures with age according to IGF-I promoter genotypes in women
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FIGURE 3. Proportion of fragility (hip, pelvis and proximal humerus) frac-
tures with age according to IGF-I promoter genotypes in men
In these three types of fracture (hip, pelvis and proximal humerus), non-carri-
ers tend to have higher incidence rates than their heterozygous and homozygous 
counterparts, with a signifi cant allele dose effect at the proximal humerus (Table 
2A). In men, there were no signifi cant difference in fracture rates among IGF-I 
genotypes, as shown in Figure 3 for fragility fractures at older age, though the 
genotype coeffi cient was not signifi cantly different to that observed in women 
(p=0.80). In both genders, no consistent fracture rate differences were observed for 
wrist and other-type of fractures. Whether or not high impact fractures (i.e., skull 
fractures n=40) were included in the latter group did not modify the risk estimates. 
Adjustment for BMD, height and weight, BMI or hip geometry parameters did not 
essentially change the risk estimates (i.e. in women the risk of fragility fractures 
at older age was 1.45 (95%CI 0.9, 2.1) and 1.30 (95%CI 0.9, 1.7) for non-carriers 
and heterozygotes as compared to homozygotes for the 192-bp allele, respectively). 
When evaluating interactions between the IGF-I genotype and BMI in women 
(Table 3), the allele-dose effect for the risk of hip and fragility fracture at older age 
was accentuated in the lower tertile and “low” BMI strata. The interaction between 
“low” BMI (less than 20 kg/m2) and the non-carrier genotype was signifi cant both 
for hip (p=0.04) and fragility (p=0.05) fractures. This means that women with low 
BMI and who are non-carriers have an increased risk of hip and fragility fracture at 
older age, which is greater than that observed by the sum of having very low BMI 
or being non-carrier alone. In this BMI stratum (which represents only ~5% of the 
women), as compared to homozygote carriers, women who don’t carry any 192-bp 
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allele have 5.9 (95%CI 1.1-32.7) and 4.5 (95%CI 1.3-16.2) times greater increased 
risk of hip and fragility (at older age) fracture, respectively (table 3). In men, the 
evaluation of such interactions was limited by the small number of fractures.
Hip Bone Geometry and Fracture Risk 
When hip bone geometry was examined in relation to the occurrence of hip 
fracture (Table 4), in both genders, individuals with hip fracture had on average 
approximately 8 % signifi cantly lower BMD levels (p<0.00001), 6% lower section 
moduli (p=0.003), 9% thinner cortices (p<0.00001), and 10% higher buckling 
ratios (p<0.00001) as compared to non-fractured individuals. No differences 
were observed in neck width. When analyzing the overall effect of age on bone 
geometry (data not shown), there was no apparent change in femoral neck width 
across age strata, while there was a decrease in section modulus (p<0.00001), a 
decrease in cortical thickness (p<0.00001) and an increase in cortical buckling ratio 
(p<0.00001).  
Hip Bone Geometry by IGF-I Genotype
Anthropometric and bone geometry parameters were then evaluated across 
IGF-I promoter genotypes (Table 5). Men who do not carry the 192-bp allele had 
signifi cantly shorter femoral neck widths and lower section moduli with evidence 
for an allele dose effect. Non-carrier women had signifi cant lower height, BMD 
and cortical thickness, and increased buckling ratios, also with evidence for an 
allele dose effect. In both genders, section modulus was 2-3% lower in non-carriers 
as compared to homozygotes for the 192-bp allele, with mean differences that were 
borderline signifi cant (p<0.10). 
Bone geometry estimates across age strata and by IGF-I genotype are presented 
for men and women in Table 6. In men, the allele dose effects observed for femoral 
neck width and section modulus are driven by the group older than 75 years. In 
women, differences in cortical thickness and buckling ratio are suggested after age 
65 years, but signifi cant trends are present only in the group older than 75 years. 
When evaluating bone geometry parameters in relation to different BMI levels 
in women, a substantial genotype effect on bone strength was observed. Genotype 
differences in section modulus decreased with increasing BMI (data not shown) 
and are accentuated in the “low” BMI stratum (p-trend=0.0003). In this stratum 
(n=67), non-carriers and heterozygotes for the 192-bp allele had 30.7% (p=0.002) 
and 20.0% (p=0.02) lower section modulus as compared to homozygotes for the 
192-bp allele (mean±SEM = 0.93±0.05). Although not signifi cant, a similar pattern 
was observed in men (data not shown).
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DISCUSSION
This population based study in elderly individuals showed that the absence of 
the wild-type (192-bp) allele in a (CA)n repeat polymorphism in the promoter region 
of the IGF-I  gene is associated with increased risk of non-vertebral fracture in 
women, in particular with “fragility” fractures occurring at older age (hip, pelvis 
and proximal humerus). Although no evidence for an effect of the polymorphism 
on fracture risk was seen in men, an effect cannot be completely ruled out since risk 
effect sizes were not signifi cantly different between genders.  In addition, the IGF-I 
promoter polymorphism was associated with hip bone geometry in gender and age 
specifi c ways, but the genotype dependent differences in hip bone geometry did not 
fully explain the genotype dependent differences in fracture risk.
These results on fracture and bone geometry in women are in line with our 
previous fi ndings where the absence of the 192-bp allele was associated with lower 
BMD levels and greater rate of bone loss in women (28).  In the present study female 
non-carriers had thinner (estimated) cortices and higher buckling ratios especially 
in women older than 75 years. This pattern is consistent with the observation that 
non-carriers were more likely to suffer fragility. Nevertheless, the IGF-I genotype-
dependent fracture risk does not seem to be mediated by genotype-dependent dif-
ferences in hip bone geometry, considering that adjustment for either baseline BMD 
or bone geometry parameters did not essentially modify the genotype effect on the 
risk of fragility fracture. This could suggest that other IGF-dependent differences 
extrinsic to bone (i.e., effects on lean mass, cushion adiposity, neurological fi tness) 
may be involved in the complex pathway leading to fracture.  Differences in hip 
bone geometry are observed in men older than 75 years. Non-carriers of the 192-bp 
allele show wider femoral necks with higher section moduli, but consistent with 
the observation that buckling ratios were not higher in non-carriers, the genotype 
did not discriminate fragility fractures in men. This suggests that the presence of 
the 192-bp allele appears to cause men to have comparative wider and (resulting) 
stronger necks, but with no increase in cortical thickness and no (resulting) increase 
in stability. 
One important question deals with the mechanism for achieving these effects 
on bone geometry. Genetically determined differences in IGF-I levels could be an 
explanation. As shown previously, decreased IGF-I levels are associated with de-
creased BMD in both genders (16-18), with gender differences that could partially 
be explained by IGF-I mediated changes in sex steroid bioavailability (18,39,40). 
Similarly, it has been postulated that IGF-I levels could be involved in the sexual 
dimorphism observed for the changes in bone geometry with aging (41,42). In 
addition, we have reported earlier that this promoter polymorphism infl uences the 
age-related decline in IGF-I levels (43). Further, we have found that the presence 
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of the 192-bp allele was associated with increased total IGF-I serum levels and with 
body height in a random sample of the Rotterdam Study (27).  However, given 
the population-based approach of our association study, we cannot determine if 
the 192-bp promoter polymorphism is directly involved in the regulation of IGF-I 
expression, or if it is in linkage disequilibrium with another variant in the IGF-I 
gene locus that affects IGF-I gene function. Therefore, the specifi c mechanisms 
underlying the functionality of the polymorphism merit further research.
Even though we observe that height in women increases with the presence of 
the 192-bp allele as already reported (27), differences in bone strength and instabil-
ity are not attributable to differential body size since the IGF-I genotype-dependent 
differences in bone geometry remained after adjustment for height (in addition to 
age and weight).   
Our fi ndings in women with low BMI (less than 20 kg/m2), where differences 
in fracture risk and bone strength (section modulus) across genotypes become more 
evident, suggest that differences in body weight could infl uence the IGF-I mediated 
adaptation of bone to mechanical stimuli. This so-called “mechanosensitivity” has 
been thought to play a role in the development of postmenopausal osteoporosis 
(44,45) and is thought to be genetically determined (46). Further, this relationship of 
decrease loading affecting IGF-I action on bone formation is in concordance with 
fi ndings recently reported in mouse models where skeletal unloading was found 
to induce resistance to IGF-I on bone formation (47) by inhibiting the activation 
of the IGF-I signaling pathways (48).  In addition, differential production and/or 
activity of IGF-I will be more evident in this extreme stratum of frail women with 
expected low IGF-I , estrogen levels and/or increased morbidity. 
In a recent report (35), Ahlborg et al. found a relation between the extent of endo-
cortical resorption and periosteal apposition in the distal radius of postmenopausal 
women using a crude approximation of bone geometry similar to the one we have 
used. Interestingly, their results suggest that (postmenopausal) estrogen defi ciency 
removes a constraint on increasing periosteal apposition (i.e., bone expansion), a 
phenomenon which compensates for endocortical bone loss by maintaining the 
section modulus (41).  It could be hypothesized that if IGF-I mediates bone expan-
sion directly, differential IGF-I bioavailability across genotypes will infl uence bone 
instability and consequent fracture susceptibility in postmenopausal women. That 
is, after menopause, non-carriers of the 192-bp allele will reach instability faster as 
a consequence of rapidly expanding diameter in bones with already thin cortices. 
However, the structural data do not appear to support this hypothesis because 
femoral neck width was not detectably greater in women without the 192-bp allele, 
but this could be explained by measurement limitations as discussed below. 
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There are some limitations to our study. Although the approximation method 
for estimating femoral neck geometry has been used previously (32,35) it is crude 
and relies on several assumptions. Nevertheless, with the exception of neck width, 
our bone geometry estimations show expected patterns for sex, age and weight (41). 
We also show that differences in geometric parameters signifi cantly discriminate 
fractured individuals. Except for neck width, our fi ndings are consistent with previ-
ous reports using DXA (49),  fi lm radiography (50) and computed tomography (51) 
which show wider necks, thinner cortices, lower strength (section moduli or cross-
sectional moments of inertia) and increased instability (buckling ratios). Yet, it is 
important that our fi ndings on bone geometry using the approximation method are 
verifi ed by more direct measurements of geometry either by Hip Structure Analysis 
(33) or by a high-resolution 3-D method.
Another limitation of our study is that the analysis of bone geometry was 
cross-sectional. Thus, the relationship is weakened by the fact that most fracture 
events occurred on average 8.2 years later than baseline geometry measurements. 
Further, age-specifi c effects on bone geometry parameters should be interpreted 
cautiously since this type of analysis is prone to age cohort effects. Our inability to 
detect subtle increases in femoral neck width through age strata (widely observed 
elsewhere (32,35,49,52,53)) suggests lack of precision. This was also indicated by 
our sub-study on 30 random scans, where we found the femoral neck width derived 
from bone area to be less precise than the ruler method. This lack of precision may 
also be the reason why we were unable to observe a relationship between femoral 
neck width and the occurrence of hip fracture. Similarly, a direct measurement of 
bone geometry within a longitudinal study design should allow a better assessment 
of how changes in bone geometry relate to fracture incidence.
A further limitation might be information and selection biases. We expect the 
bias in fracture follow-up information to be small since fracture incidence rates 
of our study are similar to those reported earlier in our population within shorter 
follow-up periods (54). Moreover, genotypes were absent in only about 10% of 
all fracture cases. With regard to the BMD and geometry analysis there could be 
selection bias since individuals were selected on the basis of having complete BMD 
measurements and IGF-I genotypes.  However, as discussed earlier (28) the effect 
seems to be random, since  IGF-I allele frequencies were similar to those observed 
in other Caucasian populations (55).  
Considering than we have evaluated multiple endpoints in our study, multiple 
testing concerns could arise. Nevertheless a more stringent signifi cance threshold 
(p<0.01) in that respect, would not affect the interpretation of our fracture analysis. 
An argument against considering our fi ndings prone to a type I error is the fact that 
the direction of the effect seems invariably consistent, in that non-carriers of the 
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192-bp allele show unfavorable patterns of bone geometry as well as greater fracture 
risk as compared to homozygotes for the allele. As reported earlier for the IGF-I 
genotype effect on BMD (28) the relationship between the IGF-I genotype effect 
on bone geometry parameters is expected to be real, but modest as for most genetic 
effects in complex diseases (9). 
In summary, this population-based study provides evidence to implicate geneti-
cally determined levels of (local or systemic) IGF-I in the complex pathway leading 
to fragility fracture. We found an IGF-I gene promoter polymorphism associated 
with increased risk of “fragility” fractures occurring at older age (hip, pelvis and 
proximal humerus). Non-carriers of the 192-bp allele had 1.5 (95%CI 1.1-2.0) times 
increased risk of having this type of fragility fracture. In males, no association 
was observed with the risk of non-vertebral fracture. Hip bone geometry was as-
sociated to the polymorphism in gender-specifi c ways but does not explain the 
IGF-I genotype effect on fracture risk. Women non-carriers of the 192-bp allele 
had femoral necks with thinner cortices and higher instability (buckling ratios).  In 
men, femoral neck width and section modulus increased with the number of 192-bp 
(wild-type) alleles in the genotype, but no apparent differences in bone instability 
were observed. 
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ABSTRACT
Introduction: In this large population-based study we examined 
the role of  polymorphisms in the ESR2 gene in relation to chang-
es in BMD, hip bone geometry and the occurrence of  fractures.
Methods: Two polymorphisms of  the ERS2 gene were genotyped in 6417 Cau-
casian subjects of  the Rotterdam Study, a population based prospective cohort 
of  men and women aged 55 and over. One polymorphism located in the second 
intronic region, and the other in the 3’UTR. Four haplotypes were constructed 
from the two SNP’s and results are presented for haplotype 4, the most frequent 
haplotype. BMD was obtained by DXA and bone geometry parameters were 
measured by Hip Structural Analysis (HSA) in 4418 individuals at baseline. For 
follow-up (mean 4.5 ± 0.6 years), 1765 individuals with complete BMD and ge-
ometry measurements  were analyzed. Baseline parameters and change with fol-
low-up were compared across haplotype 4 genotypes, and adjusted for age, height 
and weight, using ANCOVA. The ESR2 genotypes were analyzed in relation to 
incident non-vertebral fractures (mean folllow-up 7.1 ± 3.4 years) in 2588 men and 
3829 women using Cox’s regression, and in relation to prevalent and incident ver-
tebral fractures in 1498 men and 1971 women usin (multiple) logistic regression.
Results:  At baseline, homozygous female carriers of  haplotype 4 had signifi cant 
wider femoral necks (p = 0.02), thinner cortices (p = 0.01), increased buckling ratios 
(p = 0.001) and lower vertebral area (p = 0.08) compared to non-carrier women. The 
follow-up analyses showed that women homozygous for haplotype 4 had signifi cantly 
lower rates of  BMD loss per year (p-trend = 0.01). Changes in HSA measurements 
were consistent with changes in BMD, where female non-carriers of  haplotype 4 had 
higher rates of  cortical thinning, increase in neck width (bone expansion) and buck-
ling ratios (bone instability), and decrease in section modulus (bone strength) than 
haplotype 4 homozygotes. In addition, women homozygous for haplotype 4 had 1.4 (95% 
CI, 1.0-1.8, p = 0.08) increased risk of  non-vertebral fragility fractures, and 1.8 (95 % 
CI, 1.2-2.6, p = 0.01) increased risk of  all types of  vertebral fractures, compared with 
non-carriers of  haplotype 4. In contrast, male homozygous carriers of  haplotype 4 had 
reduced risk for “other types” (not hip, pelvis, proximal humerus or wrist) fractures 
(HR 0.5, (95% CI, 0.3-1.0), p = 0.04). Also in men, a small effect on increased mor-
tality risk (HR 1.2,  (95% CI, 1.0-1.4) was seen in homozygous carriers of  haplotype 4.
Conclusion: Carriership of  haplotype 4 in the ESR2 gene is associated with in-
creased risk for both vertebral and fragility fracture in Caucasian postmeno-
pausal women.  In males, the decreased risk for “other types” of  non-vertebral 
fracture (oposing effect) can possibly be explained by selection on male survival.
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INTRODUCTION
Osteoporosis is characterized by low bone mass and structural deterioration 
of bone tissue, leading to increased bone fragility and susceptibility to fracture 
(1). A major predictor of this process is bone mineral density (BMD), which can 
be assessed by dual-energy X-ray absoptiometry (DXA) (2). Osteoporosis is con-
sidered to be a multifactorial disease with a strong genetic infl uence. Heritability 
estimates for BMD have been reported to be high, varying between 50 and 80% 
(3,4). Nevertheless, bone fracture risk will not only depend on BMD, but also on 
bone geometry and the risk of falling. 
Estrogens (and their receptors) play an important role in bone metabolism 
throughout life (5). Not only are they involved in adolescent growth and bone ac-
quisition in young adulthood, but also estrogen defi ciency (as seen after menopause) 
leads to bone loss and a subsequent increase in bone fragility (6). Genes from the 
estrogen endocrine pathway such as the estrogen receptors are therefore potential 
candidate genes for osteoporosis. Although two forms of estrogen receptors exist 
(ERS1 with chromosome map location on 6q25 and ERS2 on 14q22-24), most 
studies have focused on ERS1. Even though some studies have shown in women 
associations between polymorphisms in the ERS1 gene with BMD, vertebral bone 
area, and fracture risk (7-11), others have not (12-15). 
Until now, three association studies have been done on the ESR2 gene in relation 
to femoral neck or lumbar spine BMD (16-18). One of these studies showed sig-
nifi cant association in men with femoral neck BMD and a dinucleotide (CA) repeat 
polymorphism (D14S1026) (17). This study also showed an association with femoral 
neck BMD in men and two common SNP’s, rs1256031 (with allelic frequencies of: 
C = 52.2%, T = 47.8%) and rs1256059 (with allelic frequencies of C = 54.8 %, T 
= 45.2 %), which are located in intron 2 and intron 6, respectively (Figure 1) (17). 
No associations were seen with lumbar spine BMD or in women. In contrast with 
these results, Scariano et al. (16) found signifi cant associations in postmenopausal 
women with lumbar spine and femoral neck BMD and the dinucleotide (CA) repeat 
polymorphism. Accordingly, associations with BMD remain confl icting and the 
relationship with fractures has not yet been studied.
The aim of our study was to study genetic variants in the ERS2 gene suitable to 
examine in association with osteoporosis traits, including BMD, hip bone geometry 
and risk of fracture. We have done this in the Rotterdam Study, a large prospective 
population-based cohort study of diseases in elderly Caucasian men and women.
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MATERIAL AND METHODS
Study Population
Subjects were participants of the Rotterdam Study, a large prospective popula-
tion based cohort study of elderly men and women aged 55 years and over. The 
study was designed to investigate the occurrence of disease in the elderly in relation 
to several potential determinants. In summary, all 10275 inhabitants of Ommoord, 
a district in Rotterdam, the Netherlands, were invited to participate. Of those, 7983 
participated, bringing the overall response rate to 78 percent. Both the rationale 
and the design of the study have been described previously (19). The Medical Ethics 
Committee of Erasmus University Medical School has approved the Rotterdam 
Study and participants provided written informed consent. Baseline assessment 
took place between 1990 and 1993, while fi rst and second follow-up assessments 
were performed between July 1st 1993 and January 1st 1996, and between July 1st 1996 
and January 1st 2000, respectively. Baseline and follow-up examinations, including 
a home interview and an extensive physical examination at the research center was 
performed
We performed the analysis in two phases. In the fi rst phase we searched for 
single nucleotide polymorphisms (SNP’s) in the ESR2 gene and made a selection 
for the analysis. In the second phase, we determined haplotypes from the selected 
polymorphisms and analyzed them at baseline (n = 4418) and follow-up (n = 1765) 
in relation to BMD and bone geometry parameters. We also analyzed incident 
non-vertebral fractures (n = 1010 individuals with at least one fracture, and 5407 
individuals without fracture) and prevalent vertebral fractures (n = 381 screened in 
3469 individuals). 
Genotyping
Genomic DNA was isolated from peripheral leucocytes by using salting out 
methodology (20). For ESR2 we genotyped initially six SNP’s scattered across 
the gene. Taqman allelic discrimination assay was used, while primer and probe 
sequences were optimized using the SNP assay-by-design service of Applied 
Biosystems (Nieuwerkerk aan den IJssel, The Netherlands). For details see http://
store.appliedbiosystems.com. Reactions were performed on the Taqman Prism 
7900HT 384-well format. We determined linkage disequilibrium (LD) among
these six SNP’s using PHASE (v.2.0) software (University of Washington, 
Seattle, WA) (21,22). After selecting SNP’s for the analysis, PHASE was also used 
to construct haplotype alleles.
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Measurements
In each assessment period, height and weight were measured in standing 
position wearing indoor clothing without shoes. BMI was computed as weight in 
kilograms divided by height in meters squared (kg/m²). During the home interview 
female participants were asked to recall their age at menopause and responses were 
validated as described previously (23). Age was calculated from the date of birth 
and the date of the DXA-scan. 
BMD (g/cm²) of the femoral neck was measured by dual energy X-ray absorp-
tiometry (DXA, Lunar DPX-L densitometer, Madison, WI, USA) as described 
previously (24). Due to different software updates during the follow-up period all 
available scans were reanalyzed using the Lunar DPX-IQ V.4.4. software in order to 
allow comparison between longitudinal BMD measurements (25). Follow-up mea-
surements were done using identical procedures. The fi rst follow-up started after 
approximately 2 years (mean: 23.8 months; SD: 7.0), the second after approximately 
6.5 years (mean: 78.1 months; SD: 4.5). The rate of change in BMD was calculated 
as the difference between baseline and second follow-up (approximately 6.5 years) 
divided by the time elapsed between the measurements. The rate of change in bone 
geometry parameters was calculated as the difference between fi rst and second 
follow-up divided by the time elapsed between the measurements. The relative 
change from baseline (or fi rst follow-up) was estimated as the difference in BMD 
(or bone geometry parameters) between assessment periods divided by the BMD at 
baseline (or bone geometry parameters at 1st follow-up).
Hip Structural Analysis (HSA)
We have used the hip structural analysis (HSA) software developed by Thomas 
J. Beck (Johns Hopkins University, Baltimore, Maryland) to measure hip bone 
geometry from the DXA scans (26,27). The HSA program differs from the 
conventional density analyses in that cross-sectional dimensions are derived mass 
or density. The program uses the distribution of mineral mass in a line of pixels 
across the bone axis to measure geometric properties for cross-sections in cut 
planes traversing the bone at that location. Current versions average measurements 
for a series of 5 parallel mass profi les spaced ~1 mm apart along the bone axis. 
Analysis location included the narrow-neck (NN) region across the narrowest point 
of the femoral neck. BMD, bone cross-sectional area (CSA), bone width (outer 
diameter) and cross-sectional moment of inertia (CSMI) were measured directly 
from mineral mass distributions using algorithms described previously (26). In 
addition, estimates of cortical thickness are obtained with simple models of the 
cross-sections, which employ measured dimensions and assumptions of cross-sec-
tion shape. The NN region is modeled as a circular annulus, assuming a proportion 
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of cortical/trabecular bone of 60/40 percent. For the current work, calculations 
of section moduli (Z), an index of bending strength, and buckling ratios (BR), an 
index of bone instability, were slightly modifi ed from those of some early reports 
to account for shifts in the center-of-mass. Z was calculated as CSMI /ds, where ds 
is the maximum distance from the center of mass to the medial or lateral surface. 
Buckling ratios were computed as ds divided by estimated mean cortical thickness. 
In earlier work ½ the outer diameter was used instead of ds in calculations of Z and 
BR (28). As described previously in the measurements section, software updates, 
which altered scan image acquisition, made follow-up data from the HSA not 
comparable to baseline measurements. This is the reason why changes in geometry 
parameters over time were only analyzed between fi rst and second follow-up.
Non-vertebral Fracture Follow-up
The non-vertebral fracture analysis is based on follow-up data collected from 
baseline (1990-1993) until December 31, 2001, comprising a follow-up period of 7.1 
SD 3.4 years. Fracture events were reported either by general practitioners (GP’s) in 
the research area by means of a computerized system (covering 80% of the cohort) 
or through hospital records. Research physicians regularly checked participant 
information in GP’s records outside the research area and independently reviewed 
and coded the information. Subsequently, for fi nal classifi cation, a medical expert 
reviewed all coded events. Additional information on hip fractures was gathered 
through the Dutch National Hospital Registration. We studied the relationship of 
the polymorphism to “all types” of non-vertebral fracture. Subsequently, we con-
sidered “fragility” fractures, including hip, pelvic and proximal humerus fractures. 
We also independently analyzed groups with fractures occurring at the hip, pelvis, 
proximal humerus, or wrist. Finally, we studied groups with “other” non-vertebral 
fractures including fractures of the rib (n=53), sternum (n=8), hand (n=102), lower 
leg (n=57), ankle (n=53), metatarsus (n=51), and foot (n=53).
Vertebral Fracture Assessment 
Both at baseline and at follow-up visit, between 1997 and 1999, thoracolumbar 
radiographs of the spine were obtained. The follow-up radiographs were available 
for 3469 individuals, who survived on average 9.7 years after baseline center visit 
and who were still able to come to our research center. All follow-up radiographs 
were scored for presence of vertebral fracture using the McCloskey/ Kanis method, 
as described previously (29,30). If a vertebral fracture was detected, the baseline 
radiograph was evaluated as well. If the vertebral fracture was already present at 
baseline, it was considered a baseline prevalent fracture. If it was not present at 
baseline, the fracture was defi ned to be incident.
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Statistical Analysis
All analyses were performed for men and women separately. Genotype and 
haplotype frequencies were tested for Hardy-Weinberg equilibrium proportions 
using the GENEPOP-package (31).
For haplotypes constructed from the intron 2 and the ’3UTR polymorphisms, 
means and standard deviations were computed for all measurements and compared 
with those of the same gender in the complete Rotterdam Study using t-tests. To 
study the relation with bone geometry parameters and aging, three 10 year strata 
were defi ned for age at baseline, starting at age 55 years and pooling together all 
individuals older than 75 years (n = 816) to maintain suffi cient power for analysis.
Multiple linear regression was used to model the relation of haplotype carrier 
status with BMD and bone geometry parameters, adjusted for age, height and weight 
at baseline and in the follow-up analysis to test the relation with rate of change in 
BMD or geometry parameter, adjusted for age, height and weight at baseline or at 
fi rst follow-up. We analyzed the rate of change in mean BMD by haplotype 4 carrier 
ship between baseline and second follow-up and we measured geometry parameters 
in the period between the fi rst follow-up and the second follow-up. Trend analysis 
assuming an underlying additive genetic model (32) was done for the presence of 
zero, one or two copies of the associated haplotype, incorporating the haplotype 
variable as a continuous term in a multiple linear regression model. Finally, model 
assumptions were verifi ed and model residuals were checked for goodness-of-fi t. 
For the analysis of mortality and incident non-vertebral fractures, we estimated 
incident rates overall and by haplotype carrier status. For the time-to-event or 
fracture-free survival analysis, we specifi ed age (in years) as the underlying time 
variable instead of follow-up time to analyze the effect of chronological age on 
fracture. To do this we took into account delayed entry (left truncation) by using the 
counting process notation of S-PLUS V.6.0. We estimated cumulative probabilities 
of fracture events after age 55 years using the Kaplan-Meier method. Crude and ad-
justed hazard ratios were estimated using COX proportional-hazards models. The 
assumption of proportionality of hazards was verifi ed for all covariates. Interactions 
between haplotypes and covariates were examined. To estimate the risk of vertebral 
fractures, odds ratios with 95 % confi dence intervals (95% CI) were calculated using 
(multiple) logistic regression models. We performed all vertebral fracture analysis 
separately for both prevalent and incident fractures and combined for prevalent and 
incident vertebral fractures, called “all types” of vertebral fractures. Signifi cance of 
p-values was set at the 0.05 level. If not stated otherwise, SPSS 11.0 (SPSS, Chicago, 
IL, USA) was used for the statistical analyses. 
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Coding Region 3’ UTRPromoter
3
1
2 4 5 7 86 3’ UTR15’UTR
-9619
-12214 -299 -10550 + 984 +38
(rs 1271572)
(rs 1952586)
(rs 1256030) (rs 1256031) (rs 1256049) (rs 4986938)
Standardized Linkage Disequilibrium coefficients D’ between the studied ESR2 polymorphisms
rs 1271572 rs 1952586 rs 1256030 rs1256031 rs1256049 rs 4986938
rs 1271572 - 1.000 0.956 0.955 1.000 0.854
rs 1952586 1.000 - 0.742 0.618 1.000 1.000
rs 1256030 0.956 0.742 - 1.000 1.000 0.912
rs 1256031 0.955 0.618 1.000 - 1.000 0.913
rs 1256049 1.000 1.000 1.000 1.000 - 1.000
rs 4986938 0.854 1.000 0.912 0.913 1.000 -
Figure 1. Localization of  the analyzed polymorphisms within a schematic 
representation of  the ESR2 gene (top),  with LD map between polymor-
phisms (middle) and table of  LD coeffi cients (D’) estimated using the Phase 
v.2.0 software (bottom).
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RESULTS
Genotype and Linkage Disequilibrium Analysis
Genotype frequencies in men were out of Hardy Weinberg  equilibrium (HWE) 
proportions (p = 0.01). No signifi cant deviations of the frequencies were observed 
among any other baseline or follow-up groups (data not shown).
All of the available single nucleotide polymorphisms (SNP’s) were selected from 
the NCBI (http://www.ncbi.nlm.nih.gov/SNP) and Celera (http://www.celera.
com/) databases. We chose to genotype six validated SNP’s scattered over the gene 
according to previous publications and with allele frequencies (f) suffi ciently high 
to preserve power in an analysis (f > 0.10). Location, LD map and LD estimations 
for the six SNP’s are shown in Figure 1 (n = 90). The SNP rs1256031, located 10550 
basepairs upstream from the start of exon 2, was in strong LD (D’ of 1.00) with 
two other single nucleotide polymorphisms, scattered through the gene, namely 
rs1256030 and rs1256049. In addition, SNP rs4986938, located 38 basepairs down-
stream from the 3’UTR showed somewhat lower LD with the intron 2 SNP (D’= 
0.91). Therefore, we selected the intron 2 (rs1256031) and the 3’UTR (rs4986938) 
SNP’s for the fi nal analysis considering the previously reported associations (17) 
and the somewhat lower LD. Both SNPs are T/C substitutions with a frequency 
of the T allele of 54.3 and 37.9% for the intron 2 and the 3’UTR polymorphisms, 
respectively. Haplotype alleles were constructed from the two SNP’s  and coded 
as numbers 1 through 4 in order of increasing frequency in the population (1 
=CintCutr 2 = TintTutr, 3 = TintCutr, 4 =CintTutr  ). Table 1 shows the frequencies of 
the haplotypes. We focused our analysis on the presence of the risk haplotype 4, 
and classifi ed individuals into three genotype groups: non-carriers (with frequency 
of 31%), heterozygous carriers (with frequency of 49%) and homozygous carriers 
(with frequency of 20 %) of haplotype 4.
TABLE 1. ESR2 HAPLOTYPE FREQUENCIES
Subjects 1 2 3 4
All 0.7 17.1 37.1 45.1
Women 0.8 17.1 37.1 45.0
Men 0.4 17.3 37.2 45.1
Data are percent frequencies
Haplotype
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Baseline Characteristics 
Table 2 shows the baseline characteristics of the reference study population (n = 
7983) and of the four study populations (Table 2A of BMD and geometry analyses 
and Table 2B of the fracture analyses). As compared to the total study population 
individuals in the baseline group were on average 1.1 years younger, while individu-
als in the follow-up group were 4.9 years younger. At baseline, individuals of the 
follow-up group were 1.1 cm taller, 2.7 kg heavier, and had a 0,6 kg/m² higher BMI. 
BMD at baseline was on average ~ 0,025 g/cm² higher in the follow-up group. 
For fracture analysis we used all genotyped individuals. Compared to the total 
study population genotyped individuals followed for the presence of non-vertebral 
fracturtes were on average 1.1 years younger. Indicviduals who were screened for 
the presence of vertebral fractures were on average 4.8 years younger than the refer-
ence population. No signifi cant differences were observed in other chracteristics. 
Baseline Characteristics and Bone Geometry Parameters by Haplotype 4 Carrier Status
Table 3 shows age, anthropometric characteristics and bone geometry param-
eters for the Haplotype 4 carrier status at baseline. Women, who were homozygous 
carriers of haplotype 4 were the youngest with no differences in age at menarche or 
menopause. No differences were seen in body height, weight, BMI or (femoral neck 
or lumbar spine) BMD. Female homozygous carriers had 1.0 % higher femoral neck 
widths (p = 0.02), 3.8 % increased buckling ratios (p = 0.001) and 2.3 % thinner 
cortices (p = 0.01) as compared to non-carriers. A signifi cant trend was seen for 
increased buckling ratio in this group (p-trend = 0.01) and a borderline signifi cant 
trend was seen for higher femoral neck width (p-trend = 0.06) in homozygous 
carriers of haplotype 4.  Although not signifi cant, non-carrier males tended to have 
the thinnest cortices, lowest section modulus (strength) and highest buckling ratio 
(bone instability) as compared to the other genotype groups.
Longitudinal Changes in BMD and Bone Geometry Parameters by Haplotype 4 Carrier Status
Table 4 shows parameters of change in BMD and bone geometry with follow-
up by haplotype 4 carrier status. Overall, women show higher rates of bone loss 
than men (0.6-0.9 % versus 0.4 % respectively), after 6.6 years (SD = 0.4) of fol-
low-up. In female homozygous carriers lower rates of loss is seen for the absolute 
(g/cm²-yr) and relative (% of baseline) BMD (p = 0.04 and p = 0.02 respectively), 
with a signifi cant trend for both. Although not signifi cant, changes in geometry 
were consistent with the changes in BMD, where female non-carriers of haplotype 
4 had higher rates of cortical thinning, increase in neck width (bone expansion) 
and buckling ratios (bone instability), while section modulus (bone strength) was 
decreased more as compared to homozygous carriers of haplotype.
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In Figure 2, patterns of change in BMD, cortical thickness, neck width and 
buckling ratio with time are graphed for women (n = 949) across age strata and 
haplotype 4 carrier status. A similar pattern is seen in all bone geometry parameters, 
where differences are accentuated in the oldest age category (>75 yrs). Through 
age, for non-carriers, there is a higher decrease in BMD, higher increase in neck 
width, higher decrease in cortical thickness and higher increase in buckling ratio. A 
signifi cant trend was seen in the oldest age category.
Adjustment for baseline BMD (or fi rst follow-up BMD) did not essentially 
modify the results on changes in BMD or geometry (data not shown). In males, no 
(major or) signifi cant effects were observed in the follow-up analysis. 
ESR2 haplotype 4 and mortality risk
In men, a small effect of haplotype 4 was seen on survival (Figure 3). Male ho-
mozygous carriers had 1.2 (95%CI, 1.0-1.4) increased mortality risk as compared 
to non-carriers of haplotype 4, effect which is consistent through age. No such effect 
was seen in women.
Males HR 1.2 (95 % CI, 1.0-1.4) 
Females HR 1.1 (95 % CI, 0.9-1.3) 
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Figure 3. Overall mortality risk in males and females according to ESR2 
haplotype 4 carrier status
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ESR2 haplotype 4 and non-vertebral fracture risk
Tables 5 show the fracture incidence rates and fracture-free survival analysis by 
genotype in both genders. In general, males have lower incidence rates as compared 
to women. No increase in fracture risk was seen in men homozygous carriers of hap-
lotype 4 (Table 5A). Instead, this group of men have 0.5 (95% CI, 0.3-1.0) decreased 
risk for “other type” (not hip, pelvis, proximal humerus or wrist) of fractures as 
compared to non-carriers of haplotype 4. Figure 4 shows that this protective effect for 
suffering  “other type” of fractures is driven by the abscense of fracture events after 
the age of 80 years, while the other two groups (heterozygotes and non-carriers of 
haplotype 4) undergo an increase in the number of event with a signifi  cant allele-
55 60 65 70 75 80 85 90 95 100
Age (years)
0.
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8
1.
0
Fr
ac
tu
re
-fr
ee
 S
u
rv
iv
al
Non-carriers
Heterozygotes
Homozygotes
p-trend = 0.04 
Figure 4. Proportion of  other types (not hip, pelvis, proximal humerus or 
wrist) of  non-vertebral fractures with age according to ESR2 haplotype 4 carrier 
status in men. 
dose effect (p = 0.04). 
Female homozygous carriers of haplotype 4 have 1.4 (95% CI, 1.0-1.8) increased 
risk for fragility fractures (hip, pelvis and proximal humerus) as compared to non-
carriers Table 5B). As shown in Figure 5, the higher rate of fragility fracture in 
women homozygous for haplotype 4 is consistent throughout all ages (p-trend = 
0.08). Adjustment for BMD, height and weight did not essentially change these risk 
estimates.
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Figure 5. Proportion of  fragility ( hip, pelvis, proximal humerus) fractures 
with age according to ESR2 haplotype 4 carrier status in women. 
ESR2 haplotype 4 and vertebral fracture risk
Table 6 shows the risk of vertebral fracture by carrier status. Women homozygous 
carriers of haplotype 4 have 2.4 (95%CI 1.5-3.8) increased risk for prevalent vertebral 
fractures at baseline and 1.8 (95% CI 1.2-2.6) increased risk for having any type 
of vertebral fractureas compared to non-carriers of the haplotype. Both showed 
evidence for an allele dose effect (p-trend < 0.01 and p-trend 0.01 for  prevalent and 
all type of vertebral fractures, respectively).  Further adjustment for the presence or 
absence of baseline prevalent vertebral fracture or for baseline lumbar spine BMD 
did not essentially change these results (data not shown). In men no such effect on 
vertebral fractures was seen.
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DISCUSSION
This population-based study showed that female homozygous carriers for hap-
lotype 4, of the ESR2 gene, have increased risk of fragility (HR 1.4 95%CI 1.0-1.8) 
and vertebral fracture (OR 1.8 95%CI 1.2-2.6). Consistently, hip structural analysis 
showed that, as compared to non-carriers of haplotype 4, homozygous women had 
wider femoral necks (p = 0.02), thinner cortices ( p = 0.01) and higher buckling ratios 
( p = 0.001) at baseline, while BMD was not signifi cantly different. The patterns of 
change in BMD and bone geometry with follow-up showed that homozygous carriers 
of haplotype 4 have lower rates of BMD loss compared to non-carriers. Consistently, 
female non-carriers of haplotype 4 have higher rates of cortical thinning, increase in 
neck width (bone expansion) and buckling ratios (bone instability), while section 
modulus (bone strength) is decreased more as compared to homozygous carriers 
of haplotype 4. In contrast, male homozygous carriers of haplotype 4, had a protective 
effect for suffering other types of non-vertebral fractures (not hip, pelvis, proximal 
humerus or wrist). Further, a small effect on overall mortality risk was seen in male 
homozygous carriers of haplotype 4 (OR 1.2 95 % CI 1.0-1.4). No other effects were 
observed in males for vertebral fracture, BMD or bone geometry. 
To our knowledge, this is the fi rst study that investigated the relationship be-
tween variations in the ESR2 gene and the risk of fracture. Our results on the 
risk for non-vertebral fracture are in line with our fi ndings on bone geometry at 
baseline. Women who were homozygous carriers of haplotype 4 had thinner cortices 
in wider femoral necks, consequently presenting higher buckling ratios (bone in-
stability). This is consistent with the observation that homozygous female carriers 
were more likely to suffer fragility fractures (26,33). Adjustment for BMD or bone 
geometry parameters at baseline did not modify the genotype effect on risk of 
fracture, suggesting that the haplotype dependent fracture risk does not seem to be 
entirely mediated by differences in BMD or hip bone geometry at baseline. When 
we looked at the patterns of change in bone geometry with follow-up, we observed 
that non-carriers of haplotype 4 had higher rates of BMD decline than homozygous 
carriers of haplotype 4. On fi rst sight this may appear contradictory, however this may 
be explained by the structural changes shown in the analysis of bone geometry with 
time. We know that expansion of the femoral neck is a compensatory mechanism in 
bone which preserves bending strength in the presence of thinning cortices. Both 
cortical thinning and bone expansion result in decreased bone mineral density and 
consequently in a relative higher rate of decline in BMD over time. Considering 
that homozygous carriers of haplotype 4 had thinner cortices and wider necks than 
non-carriers at baseline, it is plausible that the processes of cortical thinning and 
compensatory bone expansion may occur earlier in postmenopausal life in carriers 
of haplotype 4 than in non-carriers. Similarly, it has been proposed that women with 
hip fracture have wider necks than controls, not only due to the occurrence of 
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periosteal apposition (bone expansion) after menopause but also for differences in 
bone growth during early life (34). Although we did not observe genotype–medi-
ated differences in body height, the latter can be still an explanation for our fi ndings 
considering that there is an effect on vertebral area.
Consistent with the fi nding on fragility fractures, women homozygous for 
haplotype 4 also had increased risk of suffering vertebral fractures. It has been previ-
ously shown that women with vertebral fractures have less vertebral bone mass and 
bone size than women without fractures (35). From a biomechanical perspective, 
less vertebral size provides less resistance to axial compressive forces, which are 
the main determinant of vertebral (crush) fracture. In line with this, our results 
show that women who are homozygous carriers of haplotype 4 have lower vertebral 
area than non-carrier women, with no observed differences in lumbar spine BMD. 
This way, it is likely that variations in the ESR2 gene in women are infl uencing the 
structural adaptation with aging of the femoral neck and of the vertebral bodies in a 
similar way. Considering that previously we have also found variations in the ESR1 
gene associated with vertebral fracture in women (8), possible genetic interaction 
between both estrogen receptors should be evaluated.
Not observing these genotype effects in men probably suggests that there are 
gender differences on how the ESR2 infl uences fracture risk. It should be considered 
that circulating estrogen levels in elderly men are higher than in postmenopausal 
women (5), which could be an explanation for the gender differences if bioavail-
ability of estrogen plays a role. An effect of the polymorphism was present for the 
occurrence of “other type” of fractures (not hip, pelvis, proximal humerus or wrist) 
with opposing direction to that observed in women, that is, carrying haplotype 4 ex-
erted a protective effect over the occurrence of this type of fractures. Nevertheless, 
the fracture results in men should be interpreted with caution, considering that 
genotype frequencies in males showed deviancy from Hardy-Weinberg equilibrium 
(HWE). Both the deviation in HWE and the protective effect seen over the risk 
of “other type” of non-vertebral fractures appear to be explained by differential 
survival across ESR2 genotypes. Further research is also warranted to elucidate the 
etiology of the early death observed in men.
Our fi ndings with BMD and bone geometry differ from those observed by 
Shearman et al. (17), the only other population-based study reported for the ESR2 
intron 2 polymorphism that we have used in our study. Their cross-sectional study, 
which included relatively younger men and women, displayed a signifi cant associa-
tion with femoral neck BMD in men. The highest BMD was observed in men with 
the TT homozygous (equivalent to non-carriers of haplotype 4 in our study). In ad-
dition, the heterozygous had the lowest BMD compared to both homozygous (sug-
gesting negative heterosis). In women they found no signifi cant association. These 
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confl icting fi ndings could be due to the fact that individuals in the Rotterdam Study 
are much older than the subjects included in the Framingham Study. Similarly, 
in contrast to the exclusively postmenopausal population of the Rotterdam Study, 
Shearman et al. (17) included premenopausal women (~16,7%) in their analyses. 
Replication of our fi ndings on the risk of fracture in the Framingham population 
should be sought to help elucidate these differences between studies.
 
Our study has some limitations. Within the follow-up analyses, individuals were 
selected on the basis of having complete BMD and geometry measurements at 
the fi rst and second follow-up. This might have caused selection bias, due to the 
fact that healthier individuals are most likely to have both BMD-measurements 
performed. As we presented in table 1, individuals in the follow-up analyses were 
younger and had higher BMD at baseline. Individuals without follow-up measure-
ments are probably older, with higher morbidity and probably with lower BMD than 
individuals remaining in the study. Fracture rates in the complete Rotterdam Study 
were not essentially different in the genotyped cohort, making unlikely the effect 
of selection bias in the fracture results. Nevertheless, selection bias may play a role 
in our analyses of vertebral fractures, considering that the screening of vertebral 
fractures was performed on a survival cohort of our population.
As described earlier, software updates, which altered scan image acquisition, 
made follow-up data from the HSA not comparable to baseline. This did not al-
low us to use bone geometry changes in the longest follow-up period of 6.5 years. 
Measurement error could also be an issue as seen in the age-stratifi ed analyses 
of neck width in time  (Figure 2B) where it is suggested that women after age 65 
years are “decreasing” neck width. Since there is no current evidence that normally 
loaded bones contract, this is probably refl ecting no change in neck width in this age 
group. In addition, the age-specifi c effects on bone geometry should be interpreted 
carefully because this analysis could be susceptible to age cohort effects due to its 
cross-sectional nature. Longer follow-up is needed to determine accurate changes 
in bone geometry with aging.
Considering the population-based approach of our study, and the high LD ob-
served across the ESR2 gene, we cannot distinguish whether the genetic variants 
we have considered in this study are responsible for the observed associations or if it 
is in LD with another variant within or in the vicinity if the ESR2 gene. Additional 
research is needed to evaluate the possible functionality of these polymorphisms.
In conclusion, this population-based study showed a signifi cant association, 
between the ESR2 gene and the risk of both fragility and vertebral fractures in 
post-menopausal women.  Differences in vertebral size at the lumbar spine and in 
bone geometry at the femoral neck were in line with these fi ndings; homozygous 
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carriers of the risk haplotype 4 had lower vertebral area, increased femoral neck width, 
decreased cortical thickness and increased buckling ratio (bone instability) as com-
pared to non-carriers. In contrast, male homozygous carriers of haplotype 4 had a 
protective effect for all type of non-vertebral fractures had 0.5 (95% CI 0.3-1.0). In 
line with these fi ndings male homozygous carriers tended to have, thicker cortices, 
less neck width and less bone instability (lower buckling ratios), while in female 
homozygous carriers had thinner cortices, greater neck width and higher instability 
(higher buckling ratios). In men, in homozygous carriers a small but signifi cant 
effect on survival 1.2 (95%CI 1.0-1.4) was seen. The association with fractures 
in males is probably explained by selection on survival. These fi ndings implicate 
the ESR2 gene in the pathogenesis of osteoporotic fracture in post-menopausal 
women. 
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ABSTRACT
Introduction: ESR1, ESR2 and IGF-I gene polymorphisms have been associated 
previously with the risk of  osteoporotic fracture. The aim of  our study was to exam-
ine the joint infl uence of  variants in these genes on the risk of  osteoporotic fracture.
Methods: Participants are part of  the Rotterdam Study, a prospective popula-
tion-based cohort of  Caucasian men and women age 55 and over. Genotypes 
for ESR1 (XbaI, PvuII haplotypes), ESR2 (-10550 intron and  +38 3’UTR hap-
lotypes) and IGF-I (CAn repeat in promoter) were available in 6343 individu-
als. Gene interaction was studied for vertebral fracture (screened in X-ray fi lms 
of  3469 individuals), incident non-vertebral fracture (average follow-up time of  
8.6 years), BMD and bone geometry measured by hip structural analysis (HSA). 
Results: Female homozygote carriers of  the risk haplotypes in the ESR2 gene 
and non-carriers of  the risk haplotype in the ESR1 gene have 3.5 (95%CI 1.4 - 
8.4) and 1.8 (95%CI 1.0 - 3.4) increased risk of  vertebral and fragility (hip, pel-
vis and proximal humerus) fracture, respectively, as compared to non-carriers of  
any of  the risk haplotypes in the estrogen receptor genes (p interaction = 0.06 and 
0.10 for the risk of  vertebral and fragility fracture, respectively). This interaction 
was stronger in women homozygous for the 192-bp allele of  the IGF-I gene pro-
moter polymorphism (p interaction = 0.002 and 0.01 for the risk of  vertebral and 
fragility fracture, respectively). Similar interactions were observed for BMD, bone 
geometry and body height.  In men, no evidence of  interaction was observed. 
Conclusion: Interlocus interaction between ESR1, ESR2 and IGF-I gene poly-
morphisms infl uences the risk of  osteoporotic fracture in postmenopausal women.
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INTRODUCTION
Osteoporosis is a systemic skeletal disease characterized by low bone mineral 
density (BMD) and micro architectural deterioration of bone tissue, with a con-
sequent increase in bone fragility and susceptibility to fracture. From the genetic 
perspective osteoporosis is a multifactorial disease resulting from multiple indepen-
dent gene effects, and gene-gene and gene-environment interactions (1-3). Using 
the so-called candidate gene approach, several gene variants have been shown to 
infl uence independently an individual’s genetic susceptibility to fracture (4) with 
modest, but real effects (5). However, only few studies have addressed the issue of 
gene interaction which probably underlies most of the complexity of multifactorial 
disorders including osteoporosis (1).
Estradiol is a pleitropic sex hormone which regulates many physiological pro-
cesses, including normal cell growth, development, and tissue-specifi c gene regula-
tion in the reproductive tract, the central nervous and skeletal systems (6). The 
estrogen receptors ESR1 (6q25.1) and ESR2 (14q22-24) are obvious candidates to 
study in complex diseases (7). We (8) and others (9-14) have found previously, that 
variants in the ESR1 gene (XbaI, PvuII) lead to increased susceptibility for osteo-
porotic fracture in women, while a large meta-analysis as part of the GENOMOS 
project is currently under way (Ioannidis et al.; unpublished results). In addition, 
we have previously found that variants in this gene may interact with variants in the 
vitamin D receptor in infl uencing the risk of vertebral fracture (15).  The estrogen 
receptor beta (ESR2) has been less often studied in osteoporosis, with only two 
studies performed on its relation with BMD (16,17). Recently, we have found in 
women that variants in this ESR2 gene (-10550 intron  and  +38 3’UTR) are related 
to increased risk of both vertebral and fragility fracture, BMD and bone geometry 
(18). It has been established that there is a complex molecular interplay between both 
estrogen receptors resulting from estrogen-mediated gene regulation which affects 
several biologic processes (19). When both estrogen receptors are co-expressed, 
ESR2 exhibits an inhibitory action on ERS1-mediated gene regulation (20-22). 
Similarly, insulin-like growth factor I (IGF-I) is a ubiquitous polypeptide that 
stimulates osteoblast activity, subsequently leading to bone matrix formation and 
inhibition of bone collagen degradation (23). In the IGF-I gene (12q22-24) we have 
studied a (CA)n microsatellite repeat polymorphism (24) located in the 5’-fl ank-
ing promoter region (25-30), and observed association of the 192-bp (wilt type) 
allele with increased IGF-I serum levels and body height (31), higher BMD levels 
(32), favorable bone geometry (less bone instability) and decreased risk of fragility 
fracture in women (33). 
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Considering that ESR2 modulates ESR1 transcriptional activity (34), and that 
IGF-I and ESR1 have common activation pathways and receptor cross-talk (35), 
biological interaction between variants in these three genes can be expected. We 
therefore explored possible interactions between these genes in relation to the 
occurrence of osteoporotic fracture. Therefore, we have examined the possible 
interaction between genotypes of both estrogen receptors, by themselves, and also 
by genotypes of the IGF-gene, in relation to the risk of osteoporotic fracture and 
bone parameters in the Rotterdam study, a large population-based cohort study in 
elderly men and women.
SUBJECTS AND METHODS
Subjects
The Rotterdam Study is a large prospective population-based cohort study of 
Caucasian men and women aged 55 and over, living in the Ommoord district of the 
city of Rotterdam in The Netherlands. The objective is to study the determinants of 
disease and disability in the elderly, with special focus on neurological, cardiovas-
cular, ophthalmologic and locomotor diseases. The Medical Ethics Committee of 
the Erasmus Medical Centre has approved the Rotterdam Study. Both the rationale 
and the study design have been described previously (36). All 10,275 inhabitants of 
Ommoord, a district in Rotterdam, The Netherlands, were invited to participate. 
Of these, 7983 (4878 women) participated (resulting in a response rate of 78%). 
This study is based on 6343 individuals (3787 women) who had genotypes for the 
three genes available. 
Fracture assessment
Radiographs of the spine (extending from the fourth thoracic to the fi fth lumbar 
vertebrae) were available in 3469 individuals (1971 women) and assessed for the pres-
ence of vertebral fractures at baseline by the McCloskey-Kanis method as described 
previously (37). Information on incident non-vertebral fractures was collected from 
baseline (1990-1993) until December 31st 2001, comprising an average follow-up 
period of 8.6 (SD 3.4) years.  Fracture events were retrieved from computerized 
records of the general practitioners (GP) in the research area (covering 80% of the 
cohort).  Research physicians regularly followed participant information in GP’s 
records outside the research area and made an independent review, encoding of 
all reported events. Subsequently, a medical expert in the fi eld reviewed all coded 
events for fi nal classifi cation. Site-specifi c incidence rates of fracture have been 
reported previously (33,38). In line with the associations observed previously with 
IGF-I (33) and ESR2 (18), we have focused on the occurrence of “fragility” frac-
tures occurring at older age including hip, pelvic and proximal humerus fractures.
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BMD and Bone Geometry Measurements
Bone mineral density measurements (g/cm2) of the proximal femur were 
performed by dual energy X-ray absorptiometry (DXA) using a Lunar DPX-L 
densitometer (Lunar Radiation Corporation, Madison, WI, USA) and analyzed 
with DPX-IQ v.4.7d software. Methods, quality assurance, accuracy and precision 
issues of the DXA measurements have been described previously (39). We have 
used the hip structural analysis (HSA) software developed by Thomas J. Beck (40) 
to measure hip bone geometry from the DXA scans of the narrow-neck (NN) 
region across the narrowest point of the femoral neck. BMD, bone width (outer di-
ameter) and cross-sectional moment of inertia (CSMI) were measured directly from 
mineral mass distributions using algorithms described previously  (41). In addition, 
estimates of cortical thickness and endocortical diameter are obtained modeling the 
NN region as a circular annulus which assumes a proportion of cortical/trabecular 
bone of 60/40. For the current work, calculations of section moduli (Z), an index of 
bending strength, and buckling ratios (BR), index of bone instability, were slightly 
modifi ed from those reported previously (40) to account for shifts in the center-of-
mass. Z was calculated as CSMI /ds, where ds is the maximum distance from the 
center of mass to the medial or lateral surface. Buckling ratios were computed as 
ds divided by estimated mean cortical thickness. In some earlier work (40), ½ the 
outer diameter was used instead of ds in calculations of Z and BR. 
Clinical examination
Height (cm) and weight (kg) were measured in standing position wearing indoor 
clothes and without shoes.  Age at and reason of menopause was assessed as defi ned 
previously (42). 
Genotyping
For ESR1 we determined haplotypes of the PvuII (rs2234693 T>C ) and XbaI 
(rs9340799 A>G) restriction fragment length polymorphisms (RFLP) located in 
intron 1 of the ESR1 gene, 397 bp and 351 bp upstream of exon 2 respectively, 
using direct molecular haplotyping methods as described previously (43). Specifi c 
genotyping methods and quality control procedures have been described earlier 
(8). The alleles were defi ned as haplotypes such as “Px”, capitals denoting absence 
and lower cases letters denoting presence of the restriction site for the PvuII (P/p) 
and XbaI (X/x) enzymes on each of the alleles. The haplotype alleles were coded 
as haplotype numbers 1 through 4 in order of decreasing frequency in the popula-
tion (1 = px, 2 = PX, 3 = Px, and 4 = pX). Based on our previous associations 
we focused our analysis on the presence of the risk haplotype 1 (8), and classifi ed 
individuals in three genotype groups: non-carriers (with frequency of 22%), het-
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erozygotes carriers (with frequency 49%) and homozygote carriers (with frequency 
of 29%) of  haplotype 1 . 
For ESR2 we genotyped initially six SNP’s scattered across the gene. Taqman 
allelic discrimination assay was used, while primer and probe sequences were opti-
mized using the SNP assay-by-design service of Applied Biosystems (Nieuwerkerk 
aan den IJssel, The Netherlands). Specifi c genotyping methods and quality con-
trol procedures have been described earlier (18). Using PHASE (v.2.0) software 
(University of Washington, Seattle, WA) we determined linkage disequilibrium 
(LD) among these six SNP’s, and selected two SNP’s located on intron 2 (rs1256031 
T>C ) and in the 3’UTR regions (rs4986938 C>T ) for the fi nal analysis. Using 
PHASE haplotype alleles were constructed from the two SNP’s  and coded as 
numbers 1 through 4 in order of increasing frequency in the population (1=CintCutr 
2=TintTutr, 3=TintCutr, 4=CintTutr  ). Based on our previous associations (18) we focused 
our analysis on the presence of the risk haplotype 4, and classifi ed individuals in 
three genotype groups: non-carriers (with frequency of 31%), heterozygotes carri-
ers (with frequency of 49%) and homozygote carriers (with frequency of 20%) of 
haplotype 4. 
 
The polymorphic number of (CA)n repeats in the IGF-I gene promoter region 
was determined as described earlier (32). From sequence analysis it is known that 
the 192-bp allele (based on its frequency in our population  referred to as “wild-type” ) 
corresponds to 19 CA-repeats (CA(19)) (44). Based on the relationship between the 
polymorphism and serum IGF-I levels, genotypes were assembled from two allele 
categories as previously described (31): the 192-bp allele and all-other alleles pooled as 
“non-192-bp” alleles. Individuals were classifi ed in three genotypes groups: homo-
zygotes for the 192-bp allele (44% of the population), heterozygotes for the 192-bp 
allele (44%) and non-carriers of the 192-bp allele (12%).
Statistical analysis
We stratifi ed all analyses by gender, and by IGF-I genotypes when we studied 
interaction between the estrogen receptor genotypes in relation to IGF-I genotypes. 
In all analyses we defi ned as reference the group of non-carriers of either risk haplo-
type 1 or 4 in the ESR1 and ESR2 genes, respectively. Nine genotype groups resulted 
from the pair wise combination of estrogen receptor loci with ( /nc denoting non-
carriers of risk haplotype), ( /ht denoting heterozygous carriers of risk haplotype) 
and (/r  denoting homozygous carriers of the risk haplotype): 1) ESR1/nc ESR2/nc 
(reference); 2) ESR1/ht ESR2/nc; 3) ESR1/r ESR2/nc; 4) ESR1/nc ESR2/ht ; 5) 
ESR1/ht ESR2/ht; 6) ESR1/r ESR2/ht; 7) ESR1/nc ESR2/r; 8) ESR1/ht ESR2/r 
; 9) ESR1/r ESR2/r. Relative risks were estimated for the analysis of vertebral 
fracture as Odds Ratios (OR) with 95% confi dence intervals (CI) using multiple 
ESR1, ESR2 and IGF-I Interaction Infl uences Risk of Fracture
143
logistic regression, while risk for incident fragility fractureswas estimated from Cox 
proportional hazards models as hazard ratios (HR) with 95% confi dence intervals 
(CI). Differences in continuous measurements were compared across genotype 
groups using multiple linear regression and analyses of covariance (ANCOVA). All 
estimates were adjusted for age, height and weight (with exception of body height 
and age-at-menopause). Genetic interaction between ESR1 and ESR2 was mod-
eled assuming additive genetic effects (45), with an interaction term obtained from 
the product of main (genotype) effects.  Finally, model assumptions were verifi ed 
and model residuals were checked for goodness-of-fi t. All analyses were performed 
using the SPSS-package V.11 (SPSS Inc. Chicago, IL).  
RESULTS
Table 1 shows the independent effects estimated for each of the studied genes 
in the Rotterdam Study population, of which most have already been previously 
reported. As shown earlier for ESR1, women who are homozygote carriers of haplo-
type 1 have increased risk of vertebral fracture, lower body height and earlier age at 
menopause. Similarly for ESR2, women who are homozygote carriers of haplotype 
4 have increased risk of both vertebral fracture and fragility fracture. In line with 
the latter fi nding, HSA showed that these women have greater periosteal expansion 
and cortical instability of the femoral neck. In contrast for IGF-I, women who do 
not carry the 192-bp or “wild type” allele have increased risk of fragility fracture, 
lower BMD levels at baseline, greater bone instability of the femoral neck and lower 
body height. No associations of these genotypes with osteoporosis genotypes were 
observed in men.
In Table 2 the genotype frequencies of different genotype combinations are 
presented. In general, the absolute and relative number of women in each genotype 
is higher than the number of men. For ease of interpretation, in Table 2 values are 
highlighted for the groups with combinations of homozygous genotypes. These 
specifi c coloring is used in the fi gures below. 
Figure 1 illustrates the risk of both vertebral and fragility fracture (hip, pelvis 
and proximal humerus) in women with the above mentioned combination of 
estrogen receptor genotypes, overall and across IGF- genotypes. In Figure 1A, it 
is seen overall that, homozygous carriers of the risk haplotype in ESR1 but who 
did not carry the risk haplotypes in ESR2 (ESR1/r ESR2/nc) had 2.6 (95%CI 1.1 
- 5.8) increased risk of vertebral fracture. This risk was higher for homozygous 
carriers of the risk haplotype in ESR2 but who did not carry the risk haplotypes 
in ESR1 (ESR1/nc ESR2/r) 3.5 (95%CI 1.4 - 8.4). The risk of vertebral fracture 
was 3.1 (95%CI 1.3 - 7.4) in homozygous carriers of both risk haplotypes in ESR1 
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Figure  1.  Interaction between ESR1and ESR2 genotypes, overall and in IGF-I 
192-bp  homozygotes group for A. the risk of  vertebral fracture and B. the risk of  
fragility fracture. 
ESR1/nc: non carriers haplotype 1,   ESR2/nc: non-carriers haplotype 4   
ESR1/ht: heterozygous haplotype 1 ESR2/ht: heterozygous haplotype 4 
ESR1/r: homozygous haplotype 1     ESR2/r: homozygotous haplotype 4
Data are adjusted for age, height and weight    Signifi cance: * p<0.05  ** p<0.01 
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and ESR2 (ESR1/r ESR2/r) with p interaction =0.06. In the group of individuals 
homozygous for the IGF-I 192-bp allele, a highly signifi cant interaction (p=0.002) 
is seen where the risk of vertebral fracture in individuals ESR1/nc ESR2/r has a 
prominent increase to 9.4 (95%CI 2.3 - 38.2) while it is unexpectedly lower in carriers 
of both risk haplotypes (ESR1/r ESR2/r).  In Figure 1B it is shown that individuals 
with the ESR1/nc ESR2/r combination have 1.8 (95%CI 1.0 - 3.4) increased risk 
of fragility fracture, while no other combination of genotypes showed increased 
risk. A signifi cant gene interaction (p=0.01) with a similar pattern to that observed 
in vertebral fractures, is seen for the risk of fragility fracture, where homozygous 
women for the IGF-I 192-bp allele and with the ESR1/nc ESR2/r combination, the 
risk increases to 3.7 (95%CI 1.4 - 9.8), while no risk is seen for homozygous carriers 
of both risk genotypes (ESR1/r ESR2/r). No relationship between the combination 
of genotypes and the risk of vertebral fracture was seen in males.
As shown in Figure 2, this pattern of interaction, although not signifi cant, is 
also seen in women for lumbar spine and femoral neck BMD in the overall group, 
with individuals with the ESR1/nc ESR2/r combination showing the lowest BMD 
levels. In women who are homozygous for the IGF-I 192-bp allele and carry the 
ESR1/nc ESR2/r combination we observed signifi cantly lower BMD than all the 
other genotype groups, with a signifi cant interaction seen only at the femoral neck 
(p=0.03). No such fi ndings were seen in men.
In Figure 3 the hip structural analysis revealed no signifi cant differences or 
evidence of interaction in neck width, although carriers of any of the risk haplo-
types tend to have wider femoral necks than non-carriers of the risk haplotypes 
(Figure 3A). This pattern is also observed for the endocortical diameter (Figure 
3B). However, in the group of women with the ESR1/nc ESR2/r combination 
these differences reach signifi cance, both overall and in the group of women ho-
mozygous for the IGF-I 192-bp allele. The indexes of bending strength (section 
modulus) and bone instability (buckling ratio) (Figure 3C and 3D respectively) 
show concordantly that, overall, women with the ESR1/nc ESR2/r combination 
have signifi cantly lower bone strength and higher bone instability (interpreted as 
susceptibility to fracture), while this parameters did not differ signifi cantly from the 
reference group in women homozygous for both risk haplotypes (ESR1/r ESR2/r). 
When we analyzed the ESR1 and ESR2 combinations by IGF-I genotypes, evidence 
of interaction is suggested for bone strength and instability (p=0.10 and p=0.06, 
respectively). Again, no such relations were observed in males.
Finally, a similar interaction (p=0.14) is observed for body height (Figure 4A), 
where women with the ESR1/nc ESR2/r combination and who are homozygote 
carriers of the 192-bp allele are approximately 2 cm taller than individuals who don’t 
carry risk haplotypes in any of the two estrogen receptors ESR1/nc ESR2/nc).. 
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Figure  2.  Interaction between ESR1and ESR2 genotypes, overall and in IGF-I 
192-bp  homozygotes group for A. lumbar spine BMD B. Femoral neck BMD.
 
ESR1/nc: non carriers haplotype 1,   ESR2/nc: non-carriers haplotype 4   
ESR1/ht: heterozygous haplotype 1 ESR2/ht: heterozygous haplotype 4 
ESR1/r: homozygous haplotype 1     ESR2/r: homozygotous haplotype 4
Data are adjusted for age, height and weight    Signifi cance: * p<0.05  ** p<0.01 
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Figure  4.  Interaction between ESR1and ESR2 genotypes, overall and in IGF-I 
192-bp  homozygotes group for A. Body height B. Vertebral area and C. Age at 
menopause 
ESR1/nc: non carriers haplotype 1,   ESR2/nc: non-carriers haplotype 4   
ESR1/ht: heterozygous haplotype 1 ESR2/ht: heterozygous haplotype 4 
ESR1/r: homozygous haplotype 1     ESR2/r: homozygotous haplotype 4
Data are adjusted for age, height and weight    Signifi cance: * p<0.05  ** p<0.01 
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Even though there is no evidence of interaction for vertebral area (Figure 4B), 
women with the ESR1/nc ESR2/r combination have signifi cantly lower vertebral 
area, just as seen for women with the ESR1/r ESR2/r combination. These differ-
ences became greater in the group of women who were also homozygous carriers 
of the 192-bp allele of the IGF-I promoter polymorphism. No relation with body 
height or vertebral area was observed in males.
When we examined age at onset of menopause in relation to this genes (Figure 
4C), we also observed evidence of interaction between ESR1 and ESR2 (p=0.07), 
and which was more prominent in women homozygous for the 192-bp allele in the 
IGF-I gene (p=0.01).  Nevertheless, it was women who carried both of the risk hap-
lotypes in the two estrogen receptor genes (ESR1/r ESR2/r) who had signifi cantly 
delayed onset of menopause as compared to the other genotype groups.  
DISCUSSION
This population-based study suggests for the fi rst time interaction between 
ESR1, ESR2 and IGF-I genes in relation to risk of vertebral and fragility fracture 
in Caucasian postmenopausal women. We found that women who are homozygote 
carriers of the risk haplotype 4 in the ESR2 gene and non-carriers of the risk haplotype 
1 in the ESR1 gene (ESR1/nc ESR2/r combination) have 3.5 (95%CI 1.4 - 8.4) and 
1.8 (95%CI 1.0 - 3.4) increased risk of vertebral and fragility fracture, respectively, 
as compared to non-carriers of any of the risk haplotypes in the estrogen receptor 
genes (ESR1/nc ESR2/nc combination). When looking at the interaction between 
estrogen receptor genes across IGF-I genotypes, we found evidence of augmented 
interaction between the same genotypic combination (ESR1/nc ESR2/r) in women 
who were also homozygote for the 192-bp allele of the IGF-I gene (p interaction = 
0.002 and 0.01 for the risk of vertebral and fragility fracture, respectively). This 
gene interaction was also observed for other bone parameters including BMD, 
bone geometry and body height.  
Most association studies in humans focus on effects of single genes and very 
few address the issue of interaction. One of the main reasons for this is that exam-
ining (pair wise) gene interactions usually requires large sample sizes to preserve 
suffi cient power to analyze usually infrequent combination of genotypes and/or 
to control for the occurrence of chance fi ndings. This problem is exacerbated if 
a third or higher number of loci is considered.  This has made the mouse model 
the preferred tool to examine multiple genetic interactions (46), though extrapola-
tion to humans remains an obstacle. One alternative to address this problem is to 
examine the interaction between candidate genes in large population-based studies 
in humans.
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Previously, we have proposed that carriers of the risk haplotype 1 in ESR1 ap-
pear to be less sensitive to estrogen probably due to differential expression of the 
receptor. This has been supported by our previous fi ndings, where body height in 
pre- and postmenopausal women  (47) and estradiol levels in premenopausal women 
decreased, while age at menopause increased (48) with the number of copies of 
haplotype 1 in their genotype. Similarly, we have shown previously that the presence 
of the 192-bp allele in the IGF-I promoter genotype is associated with higher IGF-I 
levels (31) and body height in postmenopausal women (31,33) with evidence for an 
allele-dose effect. Additionally, we have recently shown that IGF-I levels and peak 
body height appear to be related to an “optimum” in the length of repeats in this 
polymorphism, where as, IGF-I levels and body height in individuals decreases 
considerably as alleles in their genotype deviate from the length of the 192-bp (wild-
type) allele (49). The interaction between ESR1 and IGF-I genes is plausible because 
both share common activation pathways and because ESR1 is needed for some 
IGF-I induced responses (35). In addition, it has been demonstrated that ESR1 
can interact in an indirect manner with some promoters by physically associating 
with prebound AP1 or SP1 protein complexes, mechanisms that appears to explain 
how estrogens regulate the cyclin D, c-Myc, and IGF-I promoters (50). Few studies 
in humans have examined the relation between variations in the ESR2 gene and 
estrogen levels. Nevertheless, several studies have demonstrated the regulatory 
action that ESR2 exerts over ESR1 transcriptional activity. The ability of ESR2 
to heterodimerize with and inactivate ESR1, positions ESR2 as the dominant 
regulator of the estrogen signalling (34,51).  So, in this perspective, the ESR1/nc 
ESR2/r combination of genotypes appears to refl ect women with higher (ESR1-
mediated) sensitivity to estrogen (ESR1/nc) while regulatory capacity of ESR2 is 
compromised (ESR2/r). In addition, individuals with the 192/192 genotype in the 
IGF-I promoter polymorphism, appear to have the optimum confi guration for IGF-
I transcription, which is expected to be compromised in homozygote non-carriers 
of the 192-bp allele. 
Results from our current study are in line with this biological framework and may 
explain why the ESR1/nc ESR2/r genotypic combination could be detrimental to 
the bone health of individuals who carry it, and why the possible deleterious effect 
arising from this combination is exacerbated if they are in addition homozygous for 
the 192-allele of the IGF-I promoter polymorphism.     
We have looked at BMD and bone geometry trying to elucidate further the 
underlying mechanisms that could increase the susceptibility to fracture. It has 
been postulated that in long bones, estrogen (via both of its receptors) favours 
endocortical over periosteal apposition (52). The presence of estrogen before 
menopause causes bone formation in the inner border but not on the external bor-
ders of the cortices (limiting the occurrence of bone expansion). This phenomenon 
ESR1, ESR2 and IGF-I Interaction Infl uences Risk of Fracture
153
has important biomechanical implications and is an important sexual dimorphism 
observed in bone (53). It has been suggested that the rapid phase of BMD decline 
observed after menopause is both the result of bone loss (in the form of cortical 
thinning consequence of endocortical expansion) and also, of the increase in bone 
volume (at expense of  periosteal apposition) (54). As bone diameter increases the 
same bending strength (section modulus) can be achieved with progressively less 
material (40). Nevertheless, if the process is carried too far, the section modulus 
no longer governs bending strength, because the cortex and the trabeculae that 
internally support it become unstable and prone to fracture (55).  Considering 
this biomechanical relationship with estrogen and also because IGF-I has been 
implicated in periosteal bone formation (56), we propose a model which integrates 
this fi ndings of our study. 
Our results show that women with the ESR1/nc ESR2/r combination have 
lower femoral neck BMD, which is in line with the fi nding that they also tend to 
have greater increase in endocortical diameter (cortical thinning) and neck width 
(bone volume). This could be the result of enhanced ESR1 mediated bone forma-
tion (ESR1/nc) which is not properly opposed by ESR2 (ESR2/r). If, in addition, 
these women are homozygous for the 192-bp allele in the IGF-I promoter genotype 
(optimized IGF-I response), there would be two driving elements enhancing bone 
formation with inadequate modulation of the response. In line with this, bending 
strength (section modulus) is decreased and cortical instability increased (buckling 
ratios) in women with this combinations. Similarly, this higher cortical instability 
would explain the higher risk of fragility fracture observed in these women. In 
addition, our results also show that homozygous women with both risk haplotypes 
(ESR1/r ESR2/r), instead of having a more deleterious phenotype as would be 
expected, appear to benefi t from this combination and have decreased risk of 
osteoporotic fractures. This could also be explained within the framework of our 
hypothesis. If there is ESR1 mediated bone formation, which is compromised in 
carriers of the risk haplotype (ESR1/r), the improperly modulated opposition on 
bone formation exerted by a compromised ESR2 (ESR2/r) will not result in the 
excessive and consequently harmful response on bone formation. No major dif-
ferences are observed in women homozygous for the 192-bp allele in the IGF-I 
promoter genotype, possibly because ESR1 integrity is needed for optimum IGF-I 
action on bone formation. 
Recently, it has been proposed that such a structural basis of bone fragility 
has some features that could have originated during growth and not only during 
aging (57,58). This concept is supported by the fact that both estrogen receptors are 
highly expressed in the epiphysial plate during different stages of human growth 
(59) and by the observation that estrogens in combination with IGF-I initiate the 
pubertal growth spurt (58).  Our fi nding of increased body height in women with 
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this specifi c genotypic combination (even though they suffered more vertebral 
fractures) is also suggestive of an effect driven by the interaction between ESR1, 
ESR2 and IGF-I during growth. 
No difference in age at menopause was observed for women with the ESR1/nc 
ESR2/r combination. In contrast, women who carried both risk haplotypes of the 
estrogen receptors (ESR1/r ESR2/r combination) appeared to have later age at 
menopause, also in interaction with the 192-bp homozygosis in the IGF-I promoter 
polymorphism. These fi ndings with age at menopause merits further investigation 
that is beyond the scope of this study. 
In concordance with the increased risk of vertebral fractures women with the 
ESR1/nc ESR2/r combination had relatively lower lumbar spine BMD levels, al-
though no interaction was observed. In addition, women with this genotypic combi-
nation had signifi cantly lower vertebral area which is consistent with biomechanical 
theory (60-62), but contrasts with our fi nding of greater height and does not fi t our 
proposed hypothesis. Nevertheless, it should be considered that vertebral bodies 
are mostly trabecular bone where the action of ESR2 is less clear (63).  This could 
suggest that ESR2 may, by itself or in combination with ESR1, exert a distinct type 
of regulation over the maintenance of bone mass at the vertebral bodies and merits 
further investigation.  
An aspect that should be realized is that the polymorphisms which constitute 
the haplotypes of both estrogen receptors genes are most likely anonymous. 
Similarly, the (microsatellite) CA-repeat promoter polymorphism of the IGF1 gene 
has yet to be proved functional. This way, specifi c functional studies are needed 
to determine how these variants (or others in linkage disequilibrium) may interact 
at the molecular level, yet there is some epidemiological evidence to suspect that 
the polymorphisms we studied are functional because of a number of biologically 
consistent observations. 
The absence of interactions in males could be explained by lack of power, con-
sidering the fact that the number of fractures which occur in men is considerably 
lower than in women. On the other hand we can not exclude that gender-differences 
could refl ect truly different biological mechanisms, which should be the target of 
future studies.
Given the high number of statistical interactions that have been tested across the 
multiple genotypic combinations, multiple testing could play a role in our results. 
Nevertheless, the consistency in the occurrence of signifi cant fi ndings (among 
independent parameters) makes it unlikely that our results could be explained by 
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chance alone. Considering this, replication of these genetic interactions in other 
population-based (multicenter) studies is warranted. 
 
In summary, this population-based study in elderly men and women age 55 
and over, has shown interlocus interaction between the ESR1, ESR2 and IGF-I 
genes in relation to the occurrence of bone fracture in postmenopausal women. 
A deleterious genetic combination for bone health may arise from having a risk 
genotype in ESR2, in the presence of higher (ESR1-mediated) estrogen sensitivity 
and enhanced genetically-determined IGF-I activity. These fi ndings provide some 
insight into etiology, but most importantly, they reinforce the complex and poly-
genic character of osteoporosis. 
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The objective of this thesis was to identify genetic determinants of osteoporosis 
using a candidate gene approach framework. Two main aspects of genetic associa-
tion studies were addressed: 
- phenotype defi nition:  which included a comprehensive dissection of the epide-
miological and genetic properties of the traits
- analyses of candidate genes: which included the selection and posterior evalua-
tion of their genetic variants in relation to the targeted traits.
In the previous chapters we have discussed the merits and shortcomings of the 
individual studies. This discussion evaluates the different aspects of the proposed 
framework and provides suggestions for future research.  
7.1 The framework at a glance
Even though the occurrence of fracture is the most important clinical outcome 
in osteoporosis, identifying genetic determinants determining the risk of fracture 
has been diffi cult due to its multifactorial nature and occurrence late in life. 
Intermediate phenotypes which could help explain the risk of fracture have there-
fore attracted the interest of researchers in the fi eld of osteoporosis. Measurements 
of BMD by dual-energy X-ray absorptiometry (DXA) are currently the most 
widespread method to evaluate the risk of fracture, and thus the object of genetic 
studies. However, BMD values are dynamic and ambiguous in nature, considering 
that many biomechanical properties intrinsic to the risk of fracture are not well re-
fl ected by the BMD measurement. Consequently, the fi rst step we took in our quest 
for genetic determinants was a phenotypic dissection of the osteoporosis traits. 
Initially, we evaluated the epidemiological aspects of femoral neck BMD decline 
and of changes in bone geometry in the elderly population of the Rotterdam Study. 
Then, we quantifi ed how much of the variability in BMD and bone geometry is ex-
plained by genetic factors. To do this, we have studied a genetic isolated population 
part of the Erasmus Rucphen Family (ERF) Study, for the analysis of heritability 
and genetic correlation across diverse osteoporosis traits including BMD and bone 
geometry measurements. Based on these analyses, we proposed a theory on how 
the risk of fracture could be heritable and related to biomechanical adaptation. 
After the defi nition of the most heritable osteoporosis traits we would focus on, 
we moved on to a candidate-gene approach to identify specifi c genetic factors. 
The fi rst candidate gene we chose was the insulin-like growth factor I (IGF-I ). 
IGF-I is a ubiquitous polypeptide with a recognized role in bone metabolism and 
an obvious candidate gene to study in osteoporosis. Nevertheless, previous studies 
remained confl icting regarding its possible relationship with BMD while none had 
yet studied its relationship with fracture(1-4). The second candidate gene we chose 
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was the estrogen receptor β (ESR2), far less well-studied in relation to osteoporosis 
than the other estrogen receptor α (ESR1) (5-12) which in fact had been subject 
of previous investigation in our population (5). Only few studies had examined 
the relationship between ESR2 and BMD but none addressed the relationship 
with the occurrence of fracture (13,14). Finally, we analyzed and compared the 
independent gene effects with their patterns of interaction of the different traits of 
osteoporosis.
7.2 Osteoporosis defi ned
Osteoporosis has been defi ned as a systemic skeletal disease characterized by 
low bone mineral density (BMD) and microarchitectural deterioration of bone tis-
sue, with a consequent increase in bone fragility and susceptibility to fracture (15). 
There are many aspects within this defi nition which are of relevance for genetic 
studies. The fi rst is that the most important clinical outcome of osteoporosis is bone 
fracture, even though its occurrence is not needed for the diagnosis. It has been 
proposed that fractures are too uncommon to allow detection of an association 
with genes that regulate structural determinants of bone strength (16). However, 
the studies presented in this thesis and other previous works prove otherwise, 
indicating that genetic studies of osteoporosis should always target the relationship 
with fracture. Furthermore, while low BMD is also a hallmark in the defi nition of 
osteoporosis, even though it has been shown that the majority of fractures occur 
in fact above the risk threshold set for the diagnosis of osteoporosis (17). We have 
therefore also focused on bone geometry, which represents the underlying structural 
properties that determine the way mass is distributed. In addition, bone geometry 
measurements allow evaluating more directly how bone fragility and susceptibility 
to fracture differ between individuals.  
7.3 Epidemiology of  osteoporosis 
7.3.1 Fracture risk
The prevalence and incidence of osteoporotic fractures in the Rotterdam Study 
has been object of detailed research in the past (17,18). It has been shown how 
fractures occurring at different skeletal sites have different risk factors and specifi c 
epidemiological patterns. Considering that osteoporotic fractures are rare events 
and that in a complex disease like osteoporosis the contribution of individual gene 
variants are expected to be modest, one of the questions is if there is justifi cation 
to pool together different types of fractures. Distinct epidemiological patterns sug-
gest that diverse levels of heterogeneity exist between different types of fracture. 
Nevertheless, we have shown in Chapter 2 that even though the heritability of 
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BMD varies across the different sites of measurement, there is also a certain de-
gree of genetic correlation between them. This allows to group different types of 
fractures also based on biomechanical, epidemiological and biostatistical (to gain 
power) aspects. Probably, the most prominent differences exist between vertebral 
and non-vertebral fractures. In contrast to non-vertebral fractures, vertebral frac-
tures usually occur without falling history and are usually asymptomatic (19,20). 
This implies that in a prospective population-based study like the Rotterdam Study, 
vertebral fractures cannot be reliably ascertained from clinical records but need to 
be screened for in the complete population. We should, however, realize that as 
suggested from cross-sectional studies, the prevalence of vertebral fractures also 
increases dramatically (especially in women) with age (21) and they are assessed 
only in those subjects who survived to the second follow-up assessment. In con-
trast, the occurrence of the clinically evident non-vertebral fractures can be reliably 
monitored by accurate registry by general practitioners of the health care system. 
Even though both methodologies are subject to health selection bias, in contrast to 
vertebral fractures, the analysis of non-vertebral fracture does allow consideration 
of time-to-event and age-dependent relationships.
The group considered as “fragility” fractures has traditionally been suggested to 
share common etiological factors ( i.e. to be more related to aspects of bone quality 
and with an increase of their prevalence with old age) (22). They include vertebral, 
hip, pelvic, proximal humerus and distal radius (wrist) fractures. Given the method-
ological differences in ascertainment described above, we have considered vertebral 
fractures separately. Among the rest of non-vertebral fragility fractures, we have 
distinguished also that the prevalence of wrist fractures undergoes a rapid increase 
before 75 years, to level off there after, in contrast to hip, pelvic and proximal 
humerus fractures which only after age 75 years show a substantial increase in their 
prevalence (17). Without disregarding that wrist fractures are also fragility fractures, 
the fact that they occur at a younger age and with specifi c falling patterns made us 
treat them as etiologically distinct phenomena. To reduce etiological heterogeneity 
in the genetic studies of osteoporotic fractures we have focused on the group of 
fragility fractures at older age (hip, pelvic and proximal humerus) rather than on 
all type of fractures.
7.3.2 Longitudinal changes in BMD and bone geometry
When using changes in BMD as an outcome for genetic studies some technical 
considerations need to be taken into account. Even within a large study as the 
Rotterdam Study, the use of standard protocols which guarantee quality control and 
adequate subject positioning, is important to diminish measurement error in serial 
measurements of BMD (23). In contrast to manufacturer’s claims, we and others 
(24) have found that software upgrades do interfere with the use of longitudinal 
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measurements. We therefore had to reanalyze with one uniform version (DPX-IQ) 
all scans whose image acquisition had been done with different software versions 
(DPX-L), and also had to perform additional retrospective calibrations (25) to al-
low comparability between measurements of the same individual in time.
Another important aspect of the longitudinal evaluation of the change of BMD 
measurements in time are the underlying causes for those changes. It would be 
expected that faster rates of decrease in BMD at a moment in time are invariably 
refl ecting increased risk of fracture. Nevertheless, BMD decreases in time due to 
bone loss but also due to bone expansion, with different and opposing biomechani-
cal effects. That is why it is important to also consider changes in bone geometry in 
the interpretation of BMD decline. Comparatively faster or slower rates of decrease 
in BMD across groups should also be interpreted carefully. A group with current 
higher rates of BMD decline could be just going through a phase of decrease in 
BMD that has already happened in another group, which with a lower rate of BMD 
decline may still be having increased risk of fracture. This was well depicted by our 
fi ndings on the patterns of BMD decline (Chapter 2) where higher levels of BMD 
at baseline are associated with higher rates of decline in BMD. In this respect, 
another possibility to explain this is the occurrence of “regression to the mean” 
which could be infl uencing the patterns of change in BMD. Though, this would 
only play a major role after short follow-up intervals and not in a long follow-up like 
we discussed in chapter 3.1. 
7.3.3 Health and survival biases
Other epidemiological aspects to be considered in genetic studies is the infl uence 
of survival and health selection. As described in Chapters 1 and 4 survival plays an 
important role in the determination of fracture risk or patterns of BMD decline in 
time. In chapter 4 we observed how a relation of the ESR2 genotype with survival 
can confound the relation with fracture, generating a spurious association with 
the occurrence of fracture. Similarly, in Chapter 1 we observed how the estima-
tion of change in BMD was done on a relatively healthier cohort that survived 
until follow-up, which does not necessarily refl ect the patterns occurring in the 
population. It should also be noticed that a genetic determinant may be related to 
lower BMD (and risk of fracture) through comorbidity and weight loss without 
infl uencing directly bone health. One fi nal epidemiological aspect is the presence 
of secular trends that may infl uence the relationship between a given genotype and 
osteoporosis or the risk for fracture. Considering the secular trend in body height 
that is seen in our study population (where older generations have considerably 
lower height than younger ones) we have opted to adjust for age, height and weight 
in the vast majority of analyses between genotypes and BMD, bone geometry or the 
risk of fracture, instead of adjusting for age and BMI alone.
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7.4 The osteoporosis phenotype
It has been proposed that progress in the genetics of bone fragility is slow be-
cause the phenotype is poorly defi ned (16). Low trauma fractures are the clinically 
relevant osteoporosis phenotype, however, they are too uncommon and the detec-
tion of an association with genes that regulate a structural determinant of bone 
strength is diffi cult. Alternatively, some genetic studies have focused on surrogate 
traits that assess certain characteristics of bone health. These include the deter-
mination of BMD, quantitative ultrasound and the use of biochemical markers of 
bone metabolism.  BMD measurements are the most widely used method to assess 
the risk of fracture. Nevertheless, BMD is too ambiguous to allow detection of the 
cell- and surface- specifi c genetic determinants of the complex bone traits (16). We 
have therefore refocused the attention away from genes which determine BMD 
and towards the gene loci (their products, the structures formed and the genetic 
regulation) involved with adaptation of bone to changing loads (16).  As we showed 
in Chapter 3, mechanosensitivity indexes of the hip were shown to be heritable and 
may refl ect more in general the predisposition towards bone fragility with aging. 
And unlike BMD, they were genetically independent from size and showed high 
genetic correlation with bone instability, which we propose is the biomechanical 
property that predisposes individuals to fracture. In this perspective we propose 
that the head/skull BMD measurement, which has so far been neglected from stud-
ies in osteoporosis, could be of use in genetic studies of osteoporosis. Not only it is 
one of the most highly heritable traits in the human skeleton (probably due to the 
lack of infl uencing environmental factors especially strains), but also, we showed 
that it can be regarded as a possible indicator of mechanosensitivity. Rather than 
using isolated BMD measurements, future studies should target bone geometrical 
parameters and indexes of mechanosensitivity to further elucidate the underlying 
genetic basis of osteoporosis.  
7.5 Genetics of  osteoporosis
7.5.1 Candidate genes
Bone remodeling makes bone tissue one of the most metabolic active tissues 
in the human body. The complex underlying processes underlying bone remodel-
ing are modulated by mechanical, endocrine, paracrine and autocrine regulation, 
among the most important ones. From this perspective the number of candidate 
genes that could be contemplated for research in osteoporosis is enormous. One of 
the reasons we have focused on this subset of hormones and growth factors is due 
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to the expertise in our group which has evolved towards the study of ligand-recep-
tor functions. With no doubt many other candidates lie within the group of bone 
matrix proteins and mineral metabolism. The known biology of such genes eases 
the choice of them, but also facilitates interpretation of results. This explains why 
the candidate gene approach has been the method of choice used so far to identify 
most of the genes known to infl uence the risk of osteoporotic fracture (26).
As already described in Chapter 1, we have chosen to study the IGF-I and the 
estrogen receptor genes considering that they are ubiquitous and known to share 
common metabolic pathways. This provides a framework to evaluate initially their 
independent effects and to explore their joint action.
7.5.2 Screening for polymorphisms in candidate genes
The CAn microsatellite polymorphism located in the 5’promoter region of 
the IGF-I gene (27) has been studied in relation to diverse outcomes, including 
osteoporosis. Even though no functional studies have been performed to date, its 
location in the 5’regulatory region of the gene made it a very interesting variant to 
be studied. Considering that in our population this polymorphism has been related 
to IGF-I plasma levels and to body height, it is likely that it or another genetic 
variant in LD with this polymorphism, is responsible for differential IGF-I action 
between individuals. 
In contrast, genetic variants in the ESR2 gene are however, much less studied. 
Therefore, we have opted to search for polymorphisms in the gene by consulting 
literature and SNP databases in order to select the most suitable ones for analysis. 
The rationale behind this approach is that LD seems to have a block-like structure in 
genes and that a judiciously chosen subset of SNP’s can identify most of the genetic 
variation in any genomic region through haplotypes (28). A previous study has 
demonstrated that, within LD blocks, more than 90% of the diversity of common 
haplotypes (>5%) may be captured by six to eight common SNPs and that these 
common haplotypes explain the vast majority of genetic variation contributed by 
unmeasured or undiscovered SNP’s (29). In this way, a good representation of the 
polymorphisms in the gene can be tested by choosing a number of polymorphisms 
similarly spaced through out the gene and analyzed in the form of haplotypes (30). 
ESR2 showed a high degree of LD between most of the polymorphisms, a fi nding 
that concurs with another population-based study of ESR2 variants in a Caucasian 
cohort (31). The haplotype analysis we have performed in the ESR2 gene makes it 
likely that the genetic variant(s) responsible for differential effects exerted by the 
ESR2 gene are being picked up by the constructed haplotype. However, more in 
depth analysis of ESR2 variants will be necessary to test this. 
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7.5.3 Genetic effects
It has become clear that there is not one major single gene responsible for the 
risk of osteoporosis (32). Rather, an individual’s susceptibility to develop osteopo-
rosis is determined as in most common diseases, by several common gene variants 
with modest but real genetic effects (33). We have found how the IGF-I promoter 
and ESR2 polymorphisms are related independently to the risk of osteoporotic 
fracture in the general population. In concordance with these fi ndings, we have 
also found them associated in a consistent way to diverse structural parameters 
of bone, suggesting that probably, these are not spurious fi ndings. Nevertheless, 
replication in other large population cohorts is obviously necessary. As expected 
for complex diseases their independent genotype effects are quite modest (33,34). 
Yet, when considered in combination, we have seen that their genetic effects may 
rise beyond the sum of their individual deleterious effects, postulating gene interac-
tion as an important determinant of disease in a subset of individuals (fraction of 
the population with risk alleles) with a specifi c deleterious combination of genetic 
determinants. Nevertheless, an important lesson we have come upon the study 
of gene interactions is that a higher risk for disease will not only arise from the 
combination of risk genotypes, but may also arise from unexpected combinations 
involving non-risk genotypes. 
7.5.4 Population stratifi cation
Spurious associations can result from population stratifi cation either because of 
a recent admixture of a different population or because of inappropriate matching 
of cases and controls (35). This is a growing concern for association studies, espe-
cially in the United States of America where much recent admixture has occurred. 
The occurrence of spurious associations due to population stratifi cation is unlikely 
in our study population, since both cases and non-cases are sampled from the same 
ethnically homogeneous source population, while the population is also stable with 
very little immigration/emigration.
7.6 Future research
Our research has only evaluated a small set of candidate genes that could be 
related to the risk of osteoporosis. Nevertheless, we think we have made some 
progress towards elucidating the genetic basis of osteoporosis when using the 
framework described in this thesis. We have contributed to the understanding of 
how genetic variants of the IGF-I and estrogen receptors could infl uence the occur-
rence of osteoporosis independently or in interaction. The next step is to continue 
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the study of additional candidate genes, which could provide further elucidation of 
these metabolic systems. 
With no doubt, rapid progress in the fi elds of genetics and the availability of DNA 
chips and microarray technology, will lead to the common execution of large-scale 
genome-wide association studies (36). Such association studies involve the evalua-
tion (dependent on linkage disequilibrium) of all existing genes in the genome of 
an individual, using evenly spaced SNP markers with a very dense resolution (5-6 
kb) and in relation to disease status or traits (37,38). Although high throughput 
genotyping is currently possible, some time will pass before it is feasible to apply 
such approximation on population-based studies in thousands of individuals.  
In the immediate future, we will target the study of other polymorphisms 
within the IGF-I gene, but also in other genes of the IGF-I regulatory pathway (i.e. 
IGFBP-3 or IGF-I receptor) and other genes of relevance for estrogen production 
and action. 
Similarly, we will have to develop new analytical strategies to evaluate gene 
interactions, considering the power limitations which arise from these attempts to 
evaluate epistatic effects. Even in a large population-based study like the Rotterdam 
Study (n=7000), the evaluation of a small number of gene interactions already rap-
idly compromises the power needed for robust assessment. It has been proposed 
that alternative statistical modeling may provide the tool necessary to overcome 
such situations (39-44). Replication and validation of such interactions will have 
to be pursued in large scale collaborations between studies, which increase power 
by pooling cohorts. The recently set up European consortium GENOMOS is an 
excellent example of such an effort in osteoporosis research, and has already identi-
fi ed the ESR1 haplotype 1 as a susceptibility allele in osteoporosis (Ioannidis et al. 
JAMA, in press). We have been recently funded with a project to develop genetic 
risk models targeted on the identifi cation of gene interactions that infl uence the 
risk of osteoporosis. In this project we will focus on developing analytical tools 
that will allow the simultaneous evaluation of multiple genetic determinants and 
the identifi cation of genetic risk profi les that could be of use in clinical practice to 
predict the occurrence of multifactorial diseases. 
Additionally, our future research will not only involve a candidate gene approach 
in a population-based setting like the Rotterdam Study. The Family Osteoporosis 
(FAMOS) sample collection and database is an example where family-based studies 
genome scans are pursued to identify genetic determinants of bone mineral density, 
fracture and other osteoporosis-related phenotypes. The FAMOS study group in-
volves in addition to our group in Rotterdam, other leading fi gures in osteoporosis 
research based in Oxford, Cambridge, London, Southampton, Aberdeen, Glasgow 
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and Aarhus. Furthermore, within our group we also have the opportunity to fur-
ther explore the linkage approach methodology in a genetically isolated population 
like the ERF study (already described in this thesis) which possesses well-defi ned 
advantages that favor the identifi cation of genetic determinants in complex diseases 
(45).  Together, these resources provide important research material and opportuni-
ties in our quest for genetic determinants of osteoporosis. 
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Osteoporosis is a systemic skeletal disease characterized by low bone mineral 
density (BMD) and microarchitectural deterioration of bone tissue, with a conse-
quent increase in bone fragility and susceptibility to fracture. It is a condition of 
very high prevalence in the elderly, with associated morbidity and mortality which 
represents enormous costs for health systems. Since the completion of the human 
genome project, the study of the genetic basis of complex diseases and hence oste-
oporosis has gained evolving importance. This etiologic genetic research may result 
in further understanding of the underlying pathophysiology of osteoporosis and 
could lead to the development of specifi c diagnostic, therapeutic and preventive 
strategies. The objective of this thesis was to identify genetic determinants of oste-
oporosis using a candidate gene approach framework. Two main aspects of genetic 
association studies were addressed: (1) a thorough defi nition of osteoporosis phe-
notypes including a comprehensive dissection of the epidemiological and genetic 
properties of the traits, and (2) the analyses of variations in two candidate genes: 
the insulin-like growth factor I (IGF-I ) and the estrogen receptor beta (ESR2).
In Chapter 2 we evaluated in the elderly population of the Rotterdam Study 
the epidemiological aspects of femoral neck BMD decline and of changes in bone 
geometry as assessed by hip structural analysis (HSA) after an average follow-up of 
6.5 years. We found that increasing age (age 75 years or older), BMD and weight loss 
with follow-up are the most signifi cant determinants of bone loss in both genders. 
HSA showed that BMD declines in the elderly due to bone loss (cortical thinning), 
but also due to increase in neck width (periosteal apposition), with both processes 
being more prominent in (postmenopausal) women than in men. Similarly, it was 
found that women had faster progression towards bone instability than men, which 
could explain the higher susceptibility for hip fracture in elderly women.
In Chapter 3 we quantifi ed how much of the variability in BMD and bone 
geometry is explained by genetic factors. To this end, we studied a part of the 
genetically isolated population of the Erasmus Rucphen Family (ERF) Study, for 
the analysis of heritability and genetic correlations across diverse DXA-based 
measurements including BMD and HSA. We found that the heritability of BMD is 
site-specifi c and infl uenced by genes determining height and lean mass. In addition 
we determined that HSA parameters of bone dimensions, strength and instability 
are also heritable. In addition, we studied the mechanosensitivity of individuals 
(defi ned as the relation between skeletal loading and bone strength) and found it 
to be a heritable trait genetically-correlated to bone instability. We propose that 
susceptibility to fragility fracture at older age is heritable partly because they refl ect 
genetically-determined differences in mechanosensitivity.
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In Chapter 4 we applied the candidate gene approach to study a polymorphism 
in the promoter region of the insulin-like growth factor I (IGF-I) gene in relation 
to bone mineral density, bone geometry and the risk of non-vertebral fractures in 
the Rotterdam Study. In Chapter 4.1 we evaluated the relationship with BMD and 
determined that this promoter polymorphism or another functional polymorphism 
in linkage disequilibrium may be a genetic determinant of BMD levels and rate of 
bone loss in postmenopausal women. In Chapter 4.2 we examined the relationship 
with the risk of fracture and found that the absence of the wild-type allele of the 
promoter polymorphism is associated with increased risk of fragility fracture in 
women but not in men. In addition, we analyzed an approximation of hip bone 
geometry (from DXA scans). The results of this analysis suggested the polymorphism 
is associated with bone strength and stability in gender-specifi c ways.
In contrast to estrogen receptor alfa (ESR1), genetic variants in estrogen receptor 
beta (ESR2) have been much less well studied in relation to osteoporosis. In Chapter 
5 we evaluated within the Rotterdam Study variations in ESR2 in relation to bone 
mineral density, and for the fi rst time in relation to bone geometry and the risk of 
osteoporotic fractures. We determined that there is high linkage disequilibrium 
between polymorphisms scattered through the gene and constructed haplotypes for 
analysis. We found that female homozygous carriers of the most frequent haplotype 
have increased risk of vertebral and fragility fractures. In line with these fi ndings, 
hip structural analysis of DXA-scans showed that this group of women have wider 
femoral necks and thinner cortices, and consequently higher bone instability. In 
males, a decreased risk for non-vertebral fracture was seen in homozygous carriers 
of the haplotype, which can possibly be explained by selection on male survival.
In Chapter 6 we studied the interaction between the two estrogen receptors (ESR1 
and ESR2) in relation to the risk of osteoporotic fracture and associated traits 
within the Rotterdam Study. In addition, we evaluated this interaction in relation to 
the IGF-I promoter polymorphism genotypes. We found that as compared to non-
carriers of any of the risk haplotypes in the estrogen receptor genes, women who are 
homozygous carriers of the risk haplotypes in the ESR2 gene and non-carriers of the 
risk haplotype in the ESR1 gene have increased risk of vertebral and fragility (hip, 
pelvis and proximal humerus) fracture. This effect was accentuated in the group 
of individuals who were homozygous for the wild-type allele of the IGF-I promoter 
polymorphism. Similar interactions were observed for BMD, bone geometry and 
body height measurements. No evidence of such interactions was observed in men. 
This way, we conclude that interlocus interaction between ESR1, ESR2 and IGF-I 
gene polymorphisms infl uences the risk of fracture in postmenopausal women and 
reinforces the complex and polygenic character of osteoporosis.
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In the general discussion in Chapter 7 general principles and problems of this 
candidate gene approach framework are discussed. In addition the fi ndings in this 
thesis are placed in perspective of future research and opportunities that arise 
within our quest for genetic determinants of osteoporosis.
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Osteoporose (botontkalking) is een aandoening die wordt gekenmerkt door een 
lage botmassa en een verslechtering  van de microarchitectuur van het botweef-
sel, wat resulteert in een verhoogde botfragiliteit (broosheid van het bot) en een 
verhoogde kans op botbreuken. Het is een aandoening die vooral voorkomt bij 
ouderen en gepaard gaat met een verhoogde kans op ziekte en sterfte, maar ook met 
hoge kosten voor de maatschappij. 
De voltooiing van het in kaart brengen van het menselijk genoom (human 
genome project) heeft het mogelijk gemaakt om de genetische basis van complexe 
ziekten, zoals osteoporose, te bestuderen. Door genetisch onderzoek kan een groter 
begrip van de onderliggende oorzaken van osteoporose ontstaan, hetgeen zou 
kunnen leiden tot de ontwikkeling van specifi eke diagnostische, therapeutische en 
preventieve strategieën. De doelstelling van dit proefschrift is het identifi ceren van 
genetische factoren die een rol spelen bij het ontstaan van osteoporose. Er is hier 
gebruik gemaakt van twee belangrijke aspecten van genetische associatiestudies: 
(1) een grondige defi nitie van de osteoporose fenotypen, met een uitgebreide on-
trafeling van de relevante epidemiologische en genetische eigenschappen en (2) de 
analyse van genetische varianten in het insuline-achtige groeifactor І (IGF-І ) gen en 
in het oestrogeenreceptor beta (ESR2) gen.
In hoofdstuk 2 worden de epidemiologische aspecten van afname van de bot-
mineraaldichtheid (BMD) en veranderingen in de botgeometrie bestudeerd in de 
Rotterdam Studie, over een periode van gemiddeld 6,5 jaar. Bij zowel mannen als 
vrouwen zijn de belangrijkste determinanten van  botverlies een hogere leeftijd 
(75 jaar of ouder), een hogere uitgangs-BMD en gewichtsverlies. Onderzoek van 
de geometrie van het heupbot toonde aan dat afname van de botmassa bij ouderen 
zowel een gevolg is van botverlies (dunner worden van de cortices) als van een 
toename van de wijdte van de dijbeenhals (periosteale botvorming). Beide proces-
sen zijn meer uitgesproken bij vrouwen na de overgang dan bij mannen. In overeen-
stemming hiermee hadden vrouwen een snellere progressie naar bot-instabiliteit, 
hetgeen een verklaring zou kunnen zijn voor de grotere kans op heupfracturen bij 
oudere vrouwen. 
In hoofdstuk 3 onderzochten we in welke mate de variatie in BMD en botgeom-
etrie verklaard kan worden door erfelijke factoren. In een deel van de genetisch 
geïsoleerde populatie uit de Erasmus Rucphen Familie (ERF) studie, bepaalden we 
de erfelijkheid en genetische correlaties van verschillende met DXA (dual energy 
X-ray absorptiometry) gemeten parameters, inclusief BMD en geometrie. Uit de 
analyses van de gegevens bleek dat de mate van erfelijkheid van botmineraaldi-
chtheid afhangt van de plaats in het skelet en dat de erfelijkheid wordt beïnvloed 
door genen die de lichaamslengte en de vetvrije massa bepalen. Ook hebben we 
vastgesteld dat de parameters van botgeometrie zoals botafmetingen, botsterkte 
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en instabiliteit erfelijk zijn. Daarnaast hebben we de relatie tussen de belasting van 
het skelet en sterkte van het bot bestudeerd in de vorm van een index van mecha-
nosensitiviteit. Deze index bleek eveneens erfelijk te zijn en genetisch gecorreleerd 
met botinstabiliteit. Wij zijn van mening dat de erfelijkheid van de gevoeligheid 
voor osteoporotische fracturen (breuken) op hogere leeftijd, de genetisch bepaalde 
verschillen in mechanosensitiviteit weerspiegelen.
 
In hoofdstuk 4 hebben we een polymorfi sme  in het promotor gebied van het 
insuline-achtige groeifactor І (IGF-І ) gen in relatie tot BMD, botgeometrie en 
de kans op fracturen bestudeerd. Dit hebben we gedaan in de Rotterdam Studie. 
In hoofdstuk 4.1 beschrijven we de relatie met BMD. Het door ons bestudeerde 
promoter polymorfi sme of een ander hieraan gekoppeld polymorfi sme lijkt een 
genetisch bepalende factor voor de hoogte van de BMD en de snelheid van bot-
verlies bij postmenopausale vrouwen. In hoofdstuk 4.2 bestudeerden we de risico 
op fracturen en vonden we dat afwezigheid van de meest voorkomende variant 
van het promotor-polymorfi sme (het zogenaamde wild type allel) geassocieerd is 
met een verhoogd risico op osteoporotische fracturen bij vrouwen, maar niet bij 
mannen. Daarnaast analyseerden we ook een benadering van de heupgeometrie. 
De resultaten van deze analyse suggereerden dat het polymorfi sme voor de twee 
geslachten op verschillende wijzen samenhangt met botsterkte en botstabiliteit.
Vergeleken met het oestrogeenreceptor alfa (ESR1) gen is er relatief weinig 
onderzoek gedaan naar de relatie tussen genetische varianten in het oestrogeen-
receptor beta (ESR2) gen en osteroporosis. In hoofdstuk 5 evalueren we in de 
Rotterdam Studie de varianten in het ESR2 gen in relatie tot BMD en voor het eerst 
in relatie tot botgeometrie en de kans op osteoporotische fracturen. We typeerden 
verschillende polymorfi smen verspreid in het ESR2 gen. Omdat er een hoge 
mate van afhankelijkheid was tussen de varianten van de verschillende polymor-
fi smen (linkage disequilibrium) construeerden we haplotypen. Deze haplotypen 
gebruikten wij bij de verdere analyses. Een verhoogd risico op wervel- en andere 
osteoporotische fracturen werd gezien bij vrouwelijke homozygote dragers van 
het meest frequente haplotype. Hiermee samenhangend liet de geometrie-analyse 
zien dat deze vrouwen een wijdere dijbeenhals, een dunnere cortex en een hogere 
botinstabiliteit hadden. Mannelijke homozygote dragers van dit haplotype hadden 
een verlaagd risico op het ontstaan van niet-vertebrale fracturen, hetgeen mogelijk 
te verklaren is door selectie in overleving van mannen.
In hoofdstuk 6 bestudeerden we in de Rotterdam Studie de interactie tussen 
de twee oestrogeenreceptoren (ESR1 en ESR2) en het risico op het ontstaan van 
osteoporotische fracturen en geassocieerde kenmerken. Daarnaast hebben we deze 
interactie bekeken in relatie tot de genotypen van het IGF-Ι promotor polymorf-
isme. In vergelijking met individuen die geen drager zijn van de risicohaplotypen 
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van beide oestrogeengenen, hebben vrouwen die homozygote dragers van het risi-
cohaplotype van het ESR2 gen zijn maar geen drager zijn het risicohaplotype van het 
ESR1 gen, een verhoogd risico op wervel- en andere osteoprotische (heup, bekken 
en bovenarm) fracturen. Eenzelfde interactie zagen we voor BMD, botgeometrie 
en lichaamslengte. Deze interactie was het sterkst in homozygote dragers van het 
wild type variant op het IGF-I gen. Bij mannen vonden we geen aanwijzingen voor 
een dergelijke interactie. Hieruit concluderen we dat er een interactie tussen poly-
morfi smen van het ESR1, ESR2 en IGF-Ι gen bestaat in relatie tot het ontstaan van 
fracturen bij postmenopausale vrouwen. Bovendien benadrukken deze uitkomsten 
het complexe en polygenetische karakter van osteoporose.
In de algemene discussie in hoofdstuk 7 worden algemene principes en 
problemen van deze genetische associatiestudie bediscussieerd. Daarnaast worden 
de bevindingen in dit proefschrift geplaatst in een perspectief van toekomstig 
onderzoek en mogelijkheden die voortkomen uit onze zoektocht naar genetische 
determinanten van osteoporose.
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BIOGRAPHY
Personal view by ANTONIO JOSE RIVADENEIRA VARGAS
English version by ALICIA RAMIREZ DE RIVADENEIRA
Fernando Rivadeneira Ramírez, was born in Bogotá, Colombia, on January 12th, 1971. 
He is the youngest of six siblings born to Antonio José Rivadeneira Vargas and Alicia 
Ramírez Díaz. He attended San Carlos School in Bogotá, which is run by Benedictine 
monks. There, he was known as excellent student, great classmate and sports leader. While 
still a boy, he travelled with his father to the neighbouring country of Venezuela. In the city 
of Güanare, he improvised a public greeting to the former president, Luis Herrera Campins. 
For this reason, a commendable chronic was written in a newspaper in Caracas under the 
title “Interesting People”. In the same column, they also published one of his short stories 
titled “A Desire of Love”. His visit to the Pantheon (in Caracas) grave of Simon Bolívar, 
the Liberator of many Latin-American countries, inspired him another story called “The 
Defeat”. In it, he emphasized his faith in freedom. At the age of 11 years, a third story, “The 
Rose Bush and the Lover” was published in his school newspaper in April 1982. 
In 1989 he graduated from high school with excellent results and started medical 
studies at the Pontifi cia Universidad Javeriana. He had to interrupt his studies to join the 
compulsory military service.  He performed his military task with great duty and he was 
highly valued by his superiors. Nevertheless, he clearly stated to them that he considered 
himself destined by God to save lives and not to take them. As a reward to his conduct 
and his profi ciency in the English language, in March 1990 he joined up the Multinational 
Force & Observers in the Sinai Peninsula, Egypt. During his stay there, he followed an 
intensive course of paramedic aid organized by the American Army and was awarded a 
medal for achieving the fi rst place. He returned to Colombia to continue his medical train-
ing. In 1996, he received his medical degree from the Universidad Javeriana. Thanks to the 
support, stimuli and inspiration from his professor, doctor Jaime Eduardo Bernal Villegas, 
he started his research work in the Human Genetics Institute while he made his Masters in 
Clinical Epidemiology in the same university. 
In the year 2000 he travelled to Rotterdam, The Netherlands to continue his post-
graduate training. He received a Master in Science Degree in Genetic Epidemiology in 
the Netherlands Institute of Health Sciences (NIHES). In 2001, he was appointed by the 
departments of Internal Medicine and Epidemiology & Biostatistics to perform the studies 
described in this thesis. 
Since his childhood, he showed great aptitude for study and research. He is the pride of 
his parents and brothers. His relatives, as well as his professors, colleagues, collaborators 
and friends admire his wonderful human qualities. His great loves are his wife, Maria 
Carolina Pardo and his daughters born in The Netherlands: Gabriëlla, who according to 
his grandfather and author of this biography, combines the delicate essences of the tulip 
and the orchid; and Paulina, who thanks to God only opened her eyes to the world on 
September 26th 2004, after her father had fi nished this thesis.
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SEMBLANZA BIOGRAFICA
Perspectiva personal por ANTONIO JOSE RIVADENEIRA VARGAS
Fernando Rivadeneira Ramírez nació en Bogotá, Colombia, el día 12 de enero de 
1971, es el menor de seis hermanos en el hogar formado por Antonio José Rivadeneira 
Vargas y Alicia Ramírez Díaz. Cursó estudios primarios en el Colegio San Carlos de Bogotá, 
regentado por padres Benedictinos. Allí se distinguió como estudiante sobresaliente, gran 
compañero y líder deportivo. Niño aún, viajo con su padre a la República de Venezuela y en 
la población de Güanare improvisó un saludo al entonces Presidente Luis Herrera Campins. 
Con este motivo se escribió sobre él una elogiosa crónica en un periódico de Caracas bajo 
el título “Gente Interesante”. Allí se reprodujo además uno de sus cuentos titulado “Un 
Deseo de Amor”. Otro escrito titulado “La Derrota” fue inspirado en su visita al Panteón 
de Caracas, donde reposan los restos del Libertador Simón Bolívar. En el destacó la fe que 
siempre tuvo en el triunfo de la libertad. Un tercer cuento suyo, “El Rosal y el Enamorado” 
fue publicado en  el periódico de su colegio en abril de 1982 a la edad de 11 años.
En 1989, una vez terminado el bachillerato en forma sobresaliente, se matriculó en 
la Pontifi cia Universidad Javeriana, en la carrera de Medicina, pero debió interrumpir los 
estudios para prestar el servicio militar obligatorio, donde actuó con pundonor y ganó el 
aprecio de sus superiores a quienes de manera enfática les manifestó que se consideraba 
destinado por Dios para salvar vidas y no para quitarlas. Como premio a su conducta 
y por su dominio del idioma inglés, en marzo de 1990 fue destinado a formar parte de 
la Fuerza Multinacional de Observadores en la Península del Sinaí, Egipto. Allí siguió 
un curso intensivo de paramédico, organizado y dictado por el Ejercito Norteamericano, 
quienes le otorgaron una medalla tras ocupar el primer puesto. De regreso en Colombia 
prosiguió sus estudios de manera que en 1996 la Universidad Javeriana le otorgó el  grado 
de Doctor en Medicina. Gracias al apoyo, estímulo e inspiración que le brindó, su profesor, 
el doctor Jaime Eduardo Bernal Villegas, se vinculó como investigador al Instituto de 
Genética Humana mientras realizaba su Maestría en Epidemiología Clínica en la misma 
Universidad.  
En el año 2000 viajó a Rótterdam, Holanda a continuar sus estudios de postgrado. 
Allí recibió su grado de Maestría en Epidemiología Genética del Netherlands Institute 
of Health Sciences (NIHES). Desde el año 2001 forma parte de los departamentos de 
Medicina Interna y Epidemiología & Bioestadística del Centro Médico Erasmus donde 
realizó los estudios de investigación descritos en esta tesis. 
Desde su infancia ha demostrado particular vocación por el estudio y la investigación, 
es orgullo de sus padres y hermanos y posee una estupenda calidad humana que le ha mere-
cido el cariño de familiares, como también la admiración y el aprecio de sus profesores, 
colegas, colaboradores y amigos. Constituyen el centro de sus afectos su esposa, Maria 
Carolina Pardo y sus hijas nacidas en Holanda: Gabriëlla, de quién su abuelo y autor de esta 
semblanza dijo que reunía en sí las delicadas esencias del tulipán y la orquídea; y Paulina, 
quien gracias a Dios abrió sus ojos al mundo el 26 de septiembre del 2004, sólo después que 
su padre hubiese terminado esta obra.
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